Small molecule inhibitors of mutant KRAS proteins
Small molecule inhibitors are developed to target KRAS-G12C, KRAS-G12D, and KRAS-G12V proteins, addressing the limitations of current treatments by effectively inhibiting these KRAS mutations in cancers.
Patent Information
- Application Number
- JP2024530465
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-24
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-26
AI Technical Summary
Current treatments for KRAS-G12C mutations are limited in efficacy, and there is a need for effective inhibitors targeting other common KRAS mutations such as KRAS-G12D and KRAS-G12V, which lack a reactive cysteine in their active site.
Development of small molecule inhibitors that selectively target KRAS-G12C, KRAS-G12D, and KRAS-G12V proteins, modulating their activity and signaling pathways associated with oncological disorders.
The inhibitors effectively inhibit KRAS-G12C, KRAS-G12D, and KRAS-G12V proteins, providing a therapeutic approach for treating cancers with these mutations, including pancreatic, colorectal, and lung cancers.
Smart Images

Figure 2024543879000001 
Figure 2024543879000002 
Figure 2024543879000003
Abstract
Description
[Technical field]
[0001] cross reference This application claims priority to U.S. Provisional Patent Application No. 63 / 282,878, filed November 24, 2021, the contents of which are incorporated herein by reference in their entirety.
[0002] The present disclosure relates to small molecule inhibitors of Kirsten Rat Sarcoma (KRAS), e.g., that inhibit the G12C, G12D and G12V mutant forms of the KRAS protein, and to pharmaceutical compositions comprising compounds of formula (I) and methods of using such compounds for the treatment of diseases, e.g., cancer. [Background technology]
[0003] RAS is a small, monomeric GTP-binding protein with a molecular weight of about 21 kDa, which acts as an on / off molecular switch. RAS can bind GTP by binding to proteins (e.g., SOS1) that are guanine nucleotide exchange factors (GEFs) that facilitate the release of the bound nucleotide to release GDP. When RAS binds to GTP, it becomes activated (on state) and recruits and activates proteins necessary for the propagation of the signal of other receptors, such as c-Raf and PI 3-kinase. RAS also has an enzymatic activity that cleaves the terminal phosphate group of the GTP nucleotide, converting this nucleotide to GDP. The rate of this conversion is usually slow, but can be dramatically enhanced by proteins classified as GTPase-activating proteins (GAPs), such as RasGAP. When GTP is converted to GDP, RAS becomes inactivated (off state).
[0004] Commonly known members of the RAS subfamily include HRAS, KRAS, and NRAS. Of these, mutations in KRAS have been observed in many malignancies: 86% of pancreatic ductal adenocarcinomas (PDAC), 41% of colorectal cancers (CRC), and 32% of lung adenocarcinomas (LUAD; a subtype of non-small cell lung cancer (NSCLC)). The mutations most often occur at the glycine residue at position 12 ("G12") of KRAS; G12 mutations predominate in 91% (PDAC), 68% (CRC), and 85% (LUAD) of all KRAS mutations, respectively. The distribution of amino acid substitutions at G12 varies among histological types. The most common mutation in LUAD is a cysteine mutation ("G12C") (46%), while the predominant mutation in PDAC (45%) and CRC (45%) is an aspartic acid mutation ("G12D"). A G12 to valine mutation ("G12V") is observed in the majority of G12 mutations in PDAC (35%), CRC (30%) and LUAD (23%). (Nature Reviews Drug Discovery,19,533-552,2020).
[0005] Intense efforts in the development of KRAS-G12C inhibitors are ongoing. Several covalent inhibitors focusing on cysteine residues have been reported, and some, such as AMG510 (NCT03600883), MRTX849 (NCT03785249) and JNJ-74699157 (NCT04006301), are in clinical trials. However, KRAS-G12C mutations account for only a small fraction of all KRAS mutations and are mainly found in LUAD. To effectively inhibit other commonly occurring KRAS mutant proteins, such as KRAS-G12D and KRAS-G12V, a different approach is required because these mutants lack a reactive cysteine in the active site (Nature Reviews Drug Discovery,19,533-552,2020). [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Nature Reviews Drug Discovery,19,533-552,2020 Summary of the Invention
[0007] The present disclosure provides small molecule inhibitors that regulate mutant KRAS, HRAS and / or NRAS proteins and can be useful pharmacoactive compounds for the treatment of cancer. In some embodiments, the compounds of the present disclosure selectively inhibit KRAS-G12C, KRAS-G12D and / or KRAS-G12V proteins. Compounds of formula (I): [ka]
[0008] and its pharmaceutically acceptable salts can regulate the activity of KRAS, HRAS and / or NRAS, thereby affecting the signal transduction pathway that regulates the growth, differentiation and proliferation of cells associated with neoplastic disorders.In some particular embodiments, the compound of formula (I) can inhibit KRAS-G12C, KRAS-G12D and / or KRAS-G12V protein.Furthermore, the present disclosure provides a method for preparing the compound of formula (I), a method for using such compound to treat neoplastic disorders, and a pharmaceutical composition comprising the compound of formula (I). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] Compounds of the Disclosure In one embodiment, the disclosure provides a compound having structural formula (I) as shown above, or a pharma- ceutically acceptable salt thereof: During the ceremony: [ka] part is: [ka] selected from the group consisting of; R for each occurrence B is independently selected from the group consisting of halo, cyano, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl, and C1-C4 cyanoalkyl; Ring X is: (i) a 5-9 membered monocyclic or fused bicyclic or bridged bicyclic heterocycloalkyl, wherein the heterocycloalkyl is saturated and contains, in addition to the depicted N atom, 0-2 heteroatom groups selected from the group consisting of N, S, S(O), S(O)2 and O; and (ii) 8-10 membered spiroheterocycloalkyl, wherein the spiroheterocycloalkyl is saturated and contains, in addition to the depicted N atom, 0-2 heteroatom groups selected from the group consisting of N, S, S(O), S(O)2, and O. selected from the group consisting of; wherein ring X is unsubstituted or independently substituted with 1 to 3 R selected from the group consisting of fluoro, cyano, hydroxy, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C3 hydroxyalkyl, -N(H)C(O)heteroaryl, wherein heteroaryl may be substituted with C1-C3 alkyl. X2 is substituted by a substituent; R X1 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, and C1-C4 cyanoalkyl; Ring Y is: (i) an 8-10 membered bicyclic ring system, wherein the 8-10 membered bicyclic ring system is partially unsaturated or aromatic and the 8-10 membered bicyclic ring system contains 0-3 heteroatoms selected from the group consisting of N, S and O; (ii) a 13-14 membered tricyclic ring system, wherein the 13-14 membered tricyclic ring system is partially unsaturated or aromatic and the 13-14 membered tricyclic ring system contains 0-3 heteroatoms selected from the group consisting of N, S and O; and (iii) phenyl; and (iv) a 6-membered heteroaryl ring containing 1 to 2 N atoms selected from the group consisting of; wherein ring Y is unsubstituted or independently selected from halo, hydroxy, amino, oxo, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 fluoroalkoxy, C2-C3 alkynyl, C2-C3 fluoroalkynyl, C1-C3 fluoroalkyl, C1-C3 cyanoalkyl, C3-C6 cycloalkyl, C3-C6 cyclofluoroalkyl. 、 C3~C6 cycloalkoxy 、 C3-C6 cyclofluoroalkoxy 、 R is selected from the group consisting of C2-C3 alkenyl, C2-C3 fluoroalkenyl, and cyano. Y is substituted by a substituent; Ring Z is: (i) a 5-8 membered monocyclic or bicyclic heterocycloalkyl, wherein the heterocycloalkyl is saturated and contains 1-3 heteroatoms independently selected from the group consisting of N, S and O, and the heterocycloalkyl is unsubstituted or has 1-2 substituents R selected from the group consisting of halo, hydroxy, C1-C3 alkyl, C1-C3 hydroxyalkyl, -C(H)(OH)CF2H, -O-CH2-O-(C1-C3 fluoroalkyl) and methylene(C1-C3 alkyl)(C1-C3 alkyl)carbamate; ZHC has been replaced with; (ii) [ka] wherein M is selected from the group consisting of hydroxy, C1-C3 dialkylamino, and C1-C4 alkylamino, and the cyclopropyl group is unsubstituted or independently substituted with up to two halo groups; (iii) [ka] wherein P is a 5-8 membered monocyclic or fused bicyclic or bridged bicyclic heterocycloalkyl, said heterocycloalkyl being saturated and containing 1-2 heteroatoms selected from the group consisting of N and O, said heterocycloalkyl being unsubstituted or containing one R selected from the group consisting of halo, hydroxy, C1-C3 hydroxyalkyl, C1-C3 cyanoalkyl, carbamoyl, C1-C3 alkoxy, cyano, and -NHC(O)C1-C3 alkyl. P substituted with substituents, wherein the cyclopropyl group is unsubstituted or substituted, independently, with up to two halo groups; and (iv) a 4-8 membered monocyclic or bicyclic cycloalkyl, wherein the cycloalkyl is saturated and the cycloalkyl is unsubstituted or independently selected from the group consisting of halo, hydroxy, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 hydroxyalkyl, C1-C3 hydroxyfluoroalkyl, C3-C4 cycloalkyl, C3-C4 cyclofluoroalkyl, C3-C4 hydroxycycloalkyl and C3-C4 hydroxycyclofluoroalkyl. ZC has been replaced with selected from the group consisting of; The subscript n is 1 or 2; The subscript q is 0, 1, or 2.
[0010] In another embodiment, the disclosure provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof, wherein ring X is a 5-8 membered monocyclic heterocycloalkyl, said heterocycloalkyl being saturated and containing, in addition to the depicted N atom, 0-1 heteroatoms selected from the group consisting of N, S and O.
[0011] In another embodiment, the present disclosure provides: [ka] Based on: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0012] In another embodiment, the present disclosure provides: [ka] Based on: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0013] In another embodiment, the present disclosure provides: [ka] The part [ka] or a pharma- ceutically acceptable salt thereof.
[0014] In another embodiment, the disclosure provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof, wherein ring Y is selected from the group consisting of naphthyl, phenyl, pyridyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, pyridopyrazolyl, and benzothiophenyl.
[0015] In another embodiment, the disclosure provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof, wherein ring Y is selected from the group consisting of naphthyl, phenyl, pyridyl, benzoxazolyl, benzopyrazolyl, and benzothiazolyl.
[0016] In another embodiment, the present disclosure provides that ring Y is: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0017] In another embodiment, the present disclosure provides that ring Y is: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0018] In another embodiment, the present disclosure provides that ring Y is: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0019] In another embodiment, the present disclosure provides a method for providing ring Y that is unsubstituted or is independently selected from the group consisting of halo, hydroxy, amino, oxo, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 fluoroalkoxy, C2-C3 alkynyl, C2-C3 fluoroalkynyl, C1-C3 fluoroalkyl, C1-C3 cyanoalkyl, and cyano. Y The present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof, wherein the compound is substituted by a substituent.
[0020] In another embodiment, the present disclosure provides: [ka] Based on: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0021] In another embodiment, the present disclosure provides: [ka] Based on: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0022] In another embodiment, the present disclosure provides that ring Z is: (i) a 5-8 membered monocyclic or bicyclic heterocycloalkyl, wherein the heterocycloalkyl is saturated and contains one nitrogen heteroatom, the heterocycloalkyl is unsubstituted or is selected from the group consisting of halo, C1-C3 alkyl, C1-C3 hydroxyalkyl, 1 to 2 substituents R selected from the group consisting of -C(H)(OH)CF2H, -O-CH2-O-(C1-C3 fluoroalkyl) and methylene(C1-C3 alkyl)(C1-C3 alkyl)carbamate ZHC has been replaced with; (ii) [ka] where M is selected from the group consisting of hydroxy, C1-C3 dialkylamino, and C1-C4 alkylamino, and the cyclopropyl group is unsubstituted or substituted with up to two halo groups; and (iii) [ka] wherein P is a 5-8 membered monocyclic or fused bicyclic or bridged bicyclic heterocycloalkyl, said heterocycloalkyl being saturated and containing 1-2 heteroatoms selected from the group consisting of N and O, said heterocycloalkyl being unsubstituted or containing one R selected from the group consisting of halo, hydroxy, C1-C3 hydroxyalkyl, C1-C3 cyanoalkyl, carbamoyl, C1-C3 alkoxy, cyano, and -NHC(O)C1-C3 alkyl. P substituted with substituents, and the cyclopropyl group is unsubstituted or substituted with up to two halo groups. The present invention provides a compound of formula (I) selected from the group consisting of:
[0023] In some specific embodiments, the present disclosure provides: Ring Y is: [ka] is selected from the group consisting of Each R Y is independently selected from the group consisting of fluoro, chloro, amino, hydroxy, ethynyl, methyl, trifluoromethyl, and cyano; [ka] but: [ka] is selected from the group consisting of [ka] but: [ka] The present invention provides a compound of formula (I) selected from the group consisting of:
[0024] In specific embodiments, the disclosure provides a compound, or a pharma- ceutically acceptable salt thereof, as set forth in any one of Examples 1-49 as set forth below.
[0025] The present disclosure includes pharma- ceutically acceptable salts of the compounds defined herein, including pharma- ceutically acceptable salts of all structural formulas, embodiments and types defined herein.
[0026] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0027] As used throughout this disclosure, "a compound of formula (I)" is understood to include "a compound of formula (I) or a pharma- ceutically acceptable salt thereof." Similarly, "a compound of formula (I)," "a compound(s) disclosed herein," "a compound(s) described herein," "a compound(s) of the disclosure," and the like are used interchangeably and include both the compound as well as a pharma- ceutically acceptable salt thereof.
[0028] "Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched. Non-limiting examples include ethenyl, propenyl, and butenyl.
[0029] "Alkyl", as well as other groups having the prefix "alk", such as alkoxy, refer to carbon chains containing the indicated number of carbon atoms, which may be linear or branched, or combinations thereof. For example, C1-C6 alkyl refers to alkyl groups having one carbon atom (i.e., methyl) through six carbon atoms (i.e., hexyl). In certain embodiments, linear alkyl groups have from 1 to 6 carbon atoms, and branched alkyl groups have from 3 to 7 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like.
[0030] "Alkoxy" and "alkyl-O-" are used interchangeably and refer to an alkyl group linked to oxygen.
[0031] "Alkynyl" means an aliphatic hydrocarbon group which contains at least one carbon-carbon triple bond and which may be straight or branched. Non-limiting examples include ethynyl, propynyl and butynyl.
[0032] "Aryl" means a monocyclic, bicyclic or tricyclic carbocyclic aromatic ring or ring system containing from 5 to 14 carbon atoms in which at least one ring is aromatic. Non-limiting examples include phenyl and naphthyl.
[0033] "Aminoalkyl" refers to the -alkyl-NH2 group, where alkyl is as defined above. The bond to the parent moiety is through a carbon atom of the alkyl moiety. Non-limiting examples of suitable aminoalkyl groups include aminomethyl and aminoethyl. "Alkylamino" refers to the -NH-alkyl group, where alkyl is as defined above. The bond to the parent moiety is through the nitrogen of the amino moiety.
[0034] A "bicyclic ring system" refers to two rings that are united together. A "tricyclic ring system" refers to three rings that are united together. The rings may be fused, i.e., sharing two adjacent atoms, "spirocyclic", i.e., sharing only a single atom, or "bridged", i.e., sharing three or more atoms, with two bridgehead atoms connected with a bridge moiety containing at least one atom. Similarly, a bicyclic or tricyclic ring may be an aryl ring, a heterocyclic ring, a cycloalkyl ring, and the like.
[0035] "Carbamoyl" refers to the monovalent group HN-C(O)- formed by loss of the -OH group of carbamic acid. The bond to the parent group is through the carbon atom of the carbonyl moiety.
[0036] "Cyanoalkyl" means an -alkyl-CN group, where alkyl is as defined above. The bond to the parent moiety is through a carbon atom of the alkyl portion. Non-limiting examples of suitable cyanoalkyl groups include cyanomethyl and 3-cyanopropyl.
[0037] "Cycloalkyl" refers to a saturated ring hydrocarbon radical. In certain embodiments, a cycloalkyl group has 3-12 carbon atoms forming 1-3 carbocyclic rings, where cyclic systems having 2-3 rings may be fused. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and the like. "Cyclofluoroalkyl" refers to a mono- or multiply-fluoro substituted saturated ring hydrocarbon radical, e.g., doubly fluoro substituted cyclopentyl. "Cycloalkoxy" refers to a cycloalkyl group linked to the parent moiety through an oxygen. "Cyclofluoroalkoxy" refers to a cyclofluoroalkyl group linked to the parent moiety through an oxygen.
[0038] "Dialkylamino" means an alkylamino as defined above where the amino atom is substituted by two alkyl substituents which may be the same or different, e.g., -N(CH3)2 or -N(CH3)(CH2CH3).
[0039] "Fluoroalkyl" includes mono- and multiply fluoro-substituted alkyl groups through to perfluoro-substituted alkyl groups. For example, fluoromethyl, 1,1-difluoroethyl, trifluoromethyl, or 1,1,1,2,2-pentafluorobutyl. "Fluoroalkenyl" includes mono- and multiply fluoro-substituted alkenyl groups. "Fluoroalkynyl" includes mono- and multiply fluoro-substituted alkynyl groups. "Fluoroalkoxy" includes mono- and multiply fluoro-substituted "alkoxy" groups as defined above.
[0040] "Halogen" or "halo" is inclusive of fluorine (fluoro), chlorine (chloro), bromine (bromo) and iodine (iodo), unless otherwise specified. In one embodiment, halo is fluoro (-F) or chloro (-Cl).
[0041] "Heteroaryl" refers to aromatic monocyclic, bicyclic and tricyclic ring systems in which one or more atoms in the ring are heteroatom(s) of an element other than carbon. The heteroatoms are typically O, S or N atoms. Examples of heteroaryl groups include pyrazolyl, oxadiazolonyl, pyridinyl, pyrimidinyl, pyrrolyl, pyridazinyl, isoxazolyl, thiazolyl, oxazolyl, indolyl, benzoxazolyl, benzothiazolyl and imidazolyl.
[0042] "Heterocycloalkyl" or "heterocyclic ring" or "heterocycle" means a non-aromatic monocyclic, bicyclic, tricyclic or bridged ring system containing about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, e.g., nitrogen, oxygen, phosphorus or sulfur, alone or in combination. There are no adjacent oxygen and / or sulfur atoms in the ring system. In some embodiments, a heterocycloalkyl contains about 5 to about 6 ring atoms. The prefix aza, oxa, phospha or thia before the heterocyclyl root name means that at least a nitrogen, oxygen, phosphorus or sulfur atom, respectively, is present as a ring atom. In some embodiments, the nitrogen or sulfur atom of a heterocycloalkyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. For example, in some embodiments, heterocycloalkyl can contain N, S, S(O), S(O)2, and / or O (which are referred to herein as "heteroatom groups"). Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, phosphorinane, phosphinane, 1-oxophosphinan-1-ium, and the like. "Spiroheterocycloalkyl" refers to a fused ring system in which the rings share only one atom and at least one ring is a heterocycloalkyl.
[0043] "Hydroxyalkyl" refers to a HO-alkyl group, where alkyl is as defined above. The bond to the parent moiety is through a carbon atom of the alkyl group. Preferred hydroxyalkyls are those containing lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl. "Hydroxyfluoroalkyl" refers to a HO-fluoroalkyl group, where fluoroalkyl is as defined above. "Hydroxycycloalkyl" refers to a HO-cyclofluoroalkyl group, where cycloalkyl is as defined above. "Hydroxycyclofluoroalkyl" refers to a HO-cyclofluoroalkyl group, where cyclofluoroalkyl is as defined above.
[0044] "Methylene (C1-C3 alkyl) (C1-C3 alkyl) carbamate" is [ka] In other words, the carbamate group has alkyl groups, as defined above, attached to its nitrogen atom, which may be the same or different.
[0045] Any variable part (e.g., R Y When R occurs more than one time in any constituent or in formula (I) or other general formulas herein, its definition at each occurrence is independent of its definition at every other occurrence. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds. In selecting compounds of this disclosure, those of skill in the art will appreciate that various substituents, e.g., R YIt will be recognized that should be selected consistent with well-known principles of connectivity and stability of chemical structures. Unless otherwise specified, substitution with the named substituents is permitted at any atom in the ring (e.g., aryl, heteroaryl or saturated heteroaryl ring), provided that substitution in such ring is chemically feasible and results in a stable compound. A "stable" compound is one that can be prepared and isolated and still maintains its structure and properties, or one that can be made to remain essentially unchanged for a sufficient period of time to be capable of being used for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
[0046] The term "substituted / substituted" shall be deemed to include multiple degrees of substitution with the named substituent. Where multiple substituent moieties are disclosed or claimed, the substituted compound may be independently substituted with one or more of the disclosed or claimed substituent moieties, either singly or multiple. By independently substituted, it is intended that the (two or more) substituents may be the same or different.
[0047] Unless otherwise stated or specified, variables depicted in structural formulae with "fluid" bonds, e.g., R X is allowed on any available carbon atom in the ring to which the variable is attached. When a moiety is described in Formula (I) or any embodiment thereof as being "optionally substituted," this means that Formula (I) or any embodiment thereof encompasses compounds that contain the substituent(s) described on the moiety as well as compounds that do not contain the substituent(s) described on the moiety.
[0048] Wavy line [ka] As used herein, indicates the point of attachment to the remainder of the compound.
[0049] The compounds of formula (I) may contain one or more asymmetric centers and therefore may exist as racemates and racemic mixtures, single enantiomers, diastereoisomeric mixtures and individual diastereoisomers. All asymmetric centers present in the compounds of formula (I) may have, independently of one another, S or R configuration. The compounds of formula (I) encompass all possible enantiomers and diastereomers as well as mixtures of two or more stereoisomers in any ratio, for example mixtures of enantiomers and / or diastereomers. Thus, enantiomers are the subject of the present disclosure in enantiomerically pure form, both as levorotatory and dextrorotatory antipodes, in the form of racemates, and in the form of mixtures of the two enantiomers in any ratio. In the case of cis / trans isomerism, the present disclosure includes both cis and trans forms and mixtures of these forms in any ratio. The present disclosure is intended to encompass all such stereoisomeric forms of the compounds of formula (I). When a structural formula or chemical name specifies a specific configuration at a stereocenter, the enantiomer or stereoisomer of the compound resulting from that specified stereocenter is intended. When the structural formula of a compound of formula (I) shows a straight line at a chiral center, the structural formula encompasses both the S and R stereoisomers associated with that chiral center, as well as mixtures thereof.
[0050] The compounds of formula (I) may be separated into their individual diastereoisomers, for example, by fractional crystallization from suitable solvents, such as methanol or ethyl acetate, or mixtures thereof, or by chiral chromatography using an optically active stationary phase. Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. Absolute stereochemistry may also be determined using vibrational circular dichroism (VCD). Alternatively, any stereoisomer or isomers of the compounds of formula (I) may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known absolute configuration.
[0051] If desired, the racemic mixture of the compound can be separated so that the individual enantiomers are isolated. Separation can be carried out by methods well known in the art, for example, by coupling the racemic mixture of the compound with an enantiomerically pure compound to form a diastereoisomeric mixture, followed by separation of the individual diastereoisomers by standard methods, for example, fractional crystallization or chromatography. The coupling reaction is often the formation of a salt with an enantiomerically pure acid or base. The diasteromeric derivative can then be converted to the pure enantiomer by cleavage of the added chiral residue. The racemic mixture of the compound can also be directly separated by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
[0052] Compounds of formula (I) containing olefinic double bonds, unless otherwise specified, are intended to encompass both E and Z geometric isomers.
[0053] Some of the compounds described herein may exist as tautomers, which differ in the point of attachment of hydrogen with one or more double bond shifts. For example, a ketone and its enol form are keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed by the compounds of formula (I).
[0054] Some of the compounds of formula (I) described herein may exist as atropisomers when the rotational energy barrier around a single bond at a given temperature is high enough to prevent free rotation, and therefore it may be possible to isolate individual conformers with different properties.Individual atropisomers as well as mixtures thereof are encompassed by the compounds of formula (I) of the present disclosure.When resolved, individual atropisomers can be represented according to established rules, such as those established by the International Union of Pure and Applied Chemistry (IUPAC) 2013 Recommendation.
[0055] In the compounds of formula (I), atoms may be present at their natural isotopic abundance, or one or more atoms may be artificially enriched in a particular isotope having the same atomic number but an atomic mass or mass number different from that found predominantly in nature. The present disclosure as described and claimed herein is intended to encompass all suitable isotopic variations of the compounds of formula (I) and embodiments thereof. For example, different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H, also referred to herein as D). Protium is the predominant hydrogen isotope found in nature. Enrichment with deuterium may provide certain therapeutic benefits, such as increased in vivo half-life or reduced dosage requirements, or may provide compounds useful as standards for characterization of biological samples. Isotopically enriched compounds may be prepared without undue experimentation by routine techniques well known to those skilled in the art, or by methods similar to those described in the schemes and examples herein using suitable isotopically enriched reagents and / or intermediates.
[0056] The term "pharmaceutical acceptable salts" refers to salts prepared with pharmaceutical non-toxic bases or acids. When the compound of formula (I) is acidic, its corresponding salts can be easily prepared with pharmaceutical non-toxic bases, such as inorganic and organic bases. Such salts obtained with inorganic bases include aluminum, ammonium, calcium, copper (II and I), ferric, ferrous, lithium, magnesium, manganous (II and I), potassium, sodium, zinc, etc. salts. Preferred are ammonium, calcium, magnesium, potassium and sodium salts. Salts prepared with pharmaceutical non-toxic organic bases include salts of primary, secondary and tertiary amines derived from both naturally occurring and synthetic sources. Pharmaceutically acceptable organic non-toxic bases which can form salts include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
[0057] When the compound of formula (I) is basic, its corresponding salt can be easily prepared with pharma- ceutically acceptable non-toxic inorganic and organic acids. Such acids include, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc. Preferred are citric acid, hydrobromic acid, hydrochloric acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid. When the compound of formula (I) contains both an acidic group and a basic group in the molecule, the present disclosure also includes the inner salt or betaine (zwitterion) in addition to the salt forms described. Salts can be obtained from compounds of formula (I) by conventional methods known to those skilled in the art, for example by combining with organic or inorganic acids or bases in a solvent or dispersant, or by anion or cation exchange with other salts. The present disclosure also encompasses any salts of compounds of formula (I) that are not suitable for direct use in medicines due to poor physiological compatibility, but can be used, for example, as intermediates in chemical reactions or for the preparation of pharmaceutically acceptable salts.
[0058] In addition, the compound of formula (I) may exist in amorphous form and / or one or more crystalline forms, and therefore, the amorphous and crystalline forms of the compound of formula (I) and mixtures thereof, such as the present examples, are all intended to be included within the scope of the present disclosure. Some of the compounds of formula (I) may also form solvates with water (i.e., hydrates) or common organic solvents, such as, but not limited to, ethyl acetate. Such solvates and hydrates of the compounds, particularly pharma- ceutically acceptable solvates and hydrates, are also included within the scope of the present disclosure, along with unsolvated and anhydrous forms.
[0059] Also within the scope of this disclosure are any pharma- ceutically acceptable prodrug modifications of the compounds of formula (I) that, in vivo, become compounds within the scope of this disclosure.
[0060] The term "therapeutically effective (or effective) amount" and similar descriptions, such as "amount effective for treatment" or "effective dose", are intended to mean an amount of a compound of formula (I) that induces a biological or medical response in a tissue, system, animal or human that is sought by a researcher, veterinarian, physician or other clinician. In a preferred embodiment, the term "therapeutically effective amount" refers to an amount of a compound of formula (I) that alleviates at least one clinical symptom in a human patient. The term "prophylactically effective (or effective) amount" and similar descriptions, such as "prophylactically effective amount", are intended to mean an amount of a compound of formula (I) that prevents or reduces the risk of the occurrence of a biological or medical event that is sought to be prevented in a tissue, system, animal or human by a researcher, veterinarian, physician or other clinician.
[0061] Dosage of Compounds of Formula (I) Dosage regimen using the compound of formula (I) is selected according to various factors, such as the type, species, age, weight, sex and medical condition of the patient; the severity of the pathology to be treated; the efficacy of the compound selected for administration; the route of administration; and the renal and hepatic function of the patient.It is well within the scope of the competence of a clinician skilled in the art to consider such factors for the purpose of determining the amount of therapeutically effective dosage or the amount of prophylactically effective dosage required to prevent, counter or stop the progression of a pathology.It will be understood that the amount of a specific daily dosage can be a therapeutically effective amount for the treatment of, for example, a neoplastic pathology, and can be a prophylactically effective amount for the prevention of, for example, a neoplastic pathology.
[0062] While individual needs vary, determination of optimal ranges for effective amounts of the compounds of formula (I) is within the skill of the art. For example, for administration to humans in the curative or prophylactic treatment of the conditions and disorders identified herein, a typical dosage of a compound of formula (I) can be from about 0.05 mg / kg / day to about 50 mg / kg / day, or at least 0.05 mg / kg, or at least 0.08 mg / kg, or at least 0.1 mg / kg, or at least 0.2 mg / kg, or at least 0.3 mg / kg, or at least 0.4 mg / kg, or at least 0.5 mg / kg and any amount therebetween, to about 50 mg / kg or less, or about 40 mg / kg or less, or about 30 mg / kg or less, or about 20 mg / kg or less, or about 10 mg / kg or less and any amount therebetween, which can be, for example, about 2.5 mg / day (0.5 mg / kg x 5 kg) to about 5000 mg / day (50 mg / kg x 100 kg). For example, the dosage of the compound may be from about 0.1 mg / kg / day to about 50 mg / kg / day, or from about 0.05 mg / kg / day to about 10 mg / kg / day, or from about 0.05 mg / kg / day to about 5 mg / kg / day, or from about 0.05 mg / kg / day to about 3 mg / kg / day, or from about 0.07 mg / kg / day to about 3 mg / kg / day, or from about 0.09 mg / kg / day to about 3 mg / kg / day, or from about 0.05 mg / kg / day to about 0.1 mg / kg / day, or or from about 0.1 mg / kg / day to about 1 mg / kg / day, or from about 1 mg / kg / day to about 10 mg / kg / day, or from about 1 mg / kg / day to about 5 mg / kg / day, or from about 1 mg / kg / day to about 3 mg / kg / day, or from about 3 mg / day to about 500 mg / day, or from about 5 mg / day to about 250 mg / day, or from about 10 mg / day to about 100 mg / day, or from about 3 mg / day to about 10 mg / day, or from about 100 mg / day to about 250 mg / day. Such doses may be administered in a single dose or divided into repeated doses.
[0063] Pharmaceutical Compositions The compound of formula (I) and its pharmaceutically acceptable salts can be administered to animals, preferably mammals, particularly humans, as a medicament alone, in a mixture with each other, or in the form of a pharmaceutical composition. The term "subject" or "patient" includes animals, preferably mammals, particularly humans, who use the active agent for the prevention or treatment of a medical condition. The administration of the drug to a subject includes both self-administration and administration to the patient by another person. The subject may be a subject who needs or desires treatment of an existing disease or medical condition, or a subject who needs or desires prophylactic treatment to prevent the occurrence of, or reduce the risk of, said disease or medical condition. As used herein, a subject's "need" to treat or prophylactic treatment of an existing condition includes both the determination of need by a medical professional and the patient's desire for such treatment.
[0064] Therefore, the present disclosure also provides the compound of formula (I) and its pharmaceutically acceptable salts for use as medicine, its use for regulating the activity of mutant KRAS, HRAS and / or NRAS protein, in particular its use in the treatment and prevention of the diseases or disorders described below, and its use for preparing medicaments for such purposes.In some particular embodiments, the compound of formula (I) and its pharmaceutically acceptable salts inhibit KRAS-G12C, KRAS-G12D and / or KRAS-G12V protein.
[0065] The present disclosure further provides pharmaceutical compositions comprising an effective dose of at least one compound of formula (I) and / or a pharma- ceutically acceptable salt thereof as an active ingredient and a conventional pharma- ceutically acceptable carrier, i.e., one or more pharma- ceutically acceptable carrier substances and / or excipients.
[0066] Thus, the present disclosure provides, for example, at least one compound of formula (I) and / or a pharma- ceutically acceptable salt thereof for use as a pharmaceutical composition comprising an effective dose of said compound as an active ingredient and a conventional pharma- ceutically acceptable carrier, as well as the use of said compound and / or a pharma- ceutically acceptable salt thereof in the treatment or prevention of diseases or disorders as described below, such as cancer, and its use for preparing a medicament for such purposes.
[0067] The pharmaceutical compositions according to the present disclosure may be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration may also be parenterally, for example subcutaneously, intramuscularly or intravenously, in the form of solutions for injection or infusion.
[0068] Other suitable administration forms are, for example, transdermal or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or, for example, microcapsules, deposits or rods. The preferred administration form depends, for example, on the disease to be treated and its severity.
[0069] The amount of active compound of the compounds described herein and / or pharma- ceutically acceptable salts thereof in the pharmaceutical composition is usually 0.01-200 mg, or 0.1-200 mg, or 1-200 mg, or may be higher depending on the type of pharmaceutical composition. In some embodiments, the amount of active compound of the compound of formula (I) and / or pharma- ceutically acceptable salts thereof in the pharmaceutical composition is 0.01-10 mg per dose. The pharmaceutical composition usually contains 0.5-90 weight percent of at least one compound of formula (I) and / or pharma- ceutically acceptable salts thereof. The preparation of pharmaceutical compositions can be carried out in a manner known per se. For this purpose, one or more compounds of formula (I) and / or pharma- ceutically acceptable salts thereof are combined with one or more solid or liquid pharmaceutical carrier substances and / or excipients (or auxiliary substances), optionally in combination with other pharma- ceutical active compounds having a therapeutic or prophylactic action, and formed into a suitable administration or dosage form, which can then be used as a medicinal product in human or veterinary medicine.
[0070] For the preparation of pills, tablets, dragees and hard gelatin capsules, it is possible to use, for example, lactose, starch, such as corn starch or starch derivatives, talc, stearic acid or its salts. Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils, etc. Suitable carriers for the preparation of liquids, such as injection solutions, or emulsions or syrups are, for example, water, physiologically acceptable sodium chloride solutions, alcohols, such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils, etc. It is also possible to freeze-dry the compound of formula (I) and its pharma-ceutically acceptable salts, and use the resulting freeze-dried products, for example, to prepare preparations for injection or infusion. Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
[0071] Besides the active compound and the carrier, the pharmaceutical composition may also contain conventional additives, such as fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersing agents, preservatives, sweeteners, colorants, flavorings, fragrances, thickeners, diluents, buffer substances, solvents, solubilizers, agents for obtaining a depot effect, salts for modifying the osmotic pressure, coating agents and / or antioxidants.
[0072] Methods of Use of Compounds of Formula (I) The present application provides a method for inhibiting RAS-mediated cell signaling, comprising contacting a cell with a compound of formula (I) or a pharma- ceutically acceptable salt thereof. Inhibition of RAS-mediated signaling can be assessed and demonstrated by a variety of methods known in the art. Non-limiting examples include: (a) a decrease in the GTPase activity of RAS; (b) a decrease in GTP binding affinity or an increase in GDP binding affinity; (c) an increase in the K off or GDP growth rate off (d) decrease the level of downstream signaling molecules of RAS pathway, such as decrease the level of pMEK, pERK or pAKT; and / or (e) decrease the binding of downstream signaling molecules of RAS complex, such as but not limited to Raf. Kits and commercially available assays can be used to measure one or more of the above.
[0073] The present application also provides methods of using a compound of formula (I) (or a pharma- ceutically acceptable salt thereof) or a pharmaceutical composition comprising such a compound to treat disease states, including but not limited to, conditions involving mutant KRAS, HRAS and / or NRAS proteins (e.g., cancer), in some embodiments KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutations.
[0074] In some embodiments, a method for the treatment of cancer is provided, comprising administering a therapeutically effective amount of a compound of formula (I) (or its pharma- ceutically acceptable salt) or any of the above-mentioned pharmaceutical compositions comprising such a compound to a subject in need of such treatment.In some embodiments, the cancer is mediated by KRAS, HRAS or NRAS mutation, for example KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutation.In various embodiments, the cancer is pancreatic cancer, colorectal cancer or lung cancer.In some embodiments, the cancer is gallbladder cancer, thyroid cancer or cholangiocarcinoma.
[0075] In some embodiments, the disclosure provides a method of treating a disorder in a subject in need thereof, the method comprising determining whether the subject has a KRAS, HRAS or NRAS mutation (e.g., a KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutation), and, if the subject is determined to have a KRAS, HRAS or NRAS mutation, administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof.
[0076] The compounds of the present disclosure inhibit anchorage-independent cell growth and therefore have the potential to inhibit tumor metastasis.Accordingly, another embodiment of the present disclosure provides a method for inhibiting tumor metastasis, comprising administering an effective amount of a compound of formula (I).
[0077] Mutations in KRAS, HRAS or NRAS have also been identified in hematopoietic malignancies (e.g., cancers affecting blood, bone marrow and / or lymph nodes). Thus, some particular embodiments relate to the administration of a compound of formula (I) (e.g., in the form of a pharmaceutical composition) to a subject in need of treatment for hematopoietic malignancies. Such malignancies include, but are not limited to, leukemias and lymphomas. For example, the compounds of the present disclosure can be used for the treatment of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMoL) and / or other leukemias. In other embodiments, the compounds are useful for the treatment of lymphomas, such as Hodgkin's lymphoma or non-Hodgkin's lymphoma. In various embodiments, the compounds are useful in the treatment of malignancies of plasma cells, such as multiple myeloma, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.
[0078] Determining whether tumor or cancer comprises KRAS, HRAS or NRAS mutation (e.g., KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutation) can be performed by assessing the nucleotide sequence encoding KRAS, HRAS or NRAS protein, by assessing the amino acid sequence of KRAS, HRAS or NRAS protein, or by assessing the characteristics of the putative mutant protein of KRAS, HRAS or NRAS.The sequence of wild-type human KRAS, HRAS or NRAS is known in the art.
[0079] Methods for detecting mutations in the nucleotide sequence of KRAS, HRAS or NRAS are also known to those skilled in the art. Such methods include, but are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) assay, real-time PCR assay, PCR sequencing, mutant allele-specific PCR amplification (MASA) assay, direct sequencing, primer extension reaction, electrophoresis, oligonucleotide ligation assay, hybridization assay, TaqMan assay, SNP genotyping assay, high-resolution melting assay and microarray analysis. In some embodiments, samples are evaluated by real-time PCR for mutations of KRAS, HRAS or NRAS (e.g., KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutations). In real-time PCR, a fluorescent probe specific to mutations of KRAS, HRAS or NRAS is used. If mutations exist, the probe binds and fluorescence is detected. In some embodiments, the KRAS, HRAS or NRAS mutation is identified using direct sequencing of specific regions (eg, exon 2 and / or exon 3) within the KRAS, HRAS or NRAS gene.
[0080] The method for detecting the mutation of KRAS, HRAS or NRAS protein (for example, KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutation) is known to those skilled in the art.Such method includes, but is not limited to, detecting the mutant form of KRAS, HRAS or NRAS using the binding agent (for example, antibody) specific to the mutant protein, protein electrophoresis and Western blotting and direct peptide sequencing.
[0081] A number of tissue samples may be assessed to determine whether a tumor or cancer contains a KRAS, HRAS or NRAS mutation (e.g., KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutation). In some embodiments, the sample is taken from a subject with a tumor or cancer. In some embodiments, the sample is a fresh tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a formalin-fixed paraffin-embedded sample. In some embodiments, the sample is a circulating tumor cell (CTC) sample. In some embodiments, the sample is processed into a cell lysate. In some embodiments, the sample is processed into DNA or RNA.
[0082] The present application also provides a method of treating a hyperproliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the method is directed to treating cancer, such as acute myeloid leukemia, adolescent cancer, childhood adrenocortical carcinoma, AIDS-related cancer (e.g., lymphoma and Kaposi's sarcoma), anal cancer, appendix cancer, astrocytoma, atypical teratoid, basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt's lymphoma, carcinoid tumor, atypical teratoid, embryonal tumor, germ cell tumor, primary lymphoma, cervical cancer, childhood cancer, chordoma, cardiac tumor, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myleoproliferative disorder, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic ductal carcinoma in situ, and / or pulmonary arterial cancer. DCIS, embryonal tumors, CNS cancer, endometrial cancer, ependymoma, esophageal cancer, nasal neuroblastoma, Ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), germ cell tumors, gestational trophoblastic tumors, hairy cell leukemia, head and neck cancer, cardiac cancer, liver cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kidney cancer, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic cervical squamous cell carcinoma of unknown primary, carcinoma of the midline nerve bundle, mouth cancer; multiple endocrine neoplasia syndrome , multiple myeloma / plasma cell neoplasms, mycosis fungoides, myelodysplastic syndromes, myelodysplastic / myeloproliferative neoplasms, multiple myeloma, Merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma and osteosarcoma of bone, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oral cavity cancer, cancer of the lip and oral cavity, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, cancer of the paranasal sinuses and nasal cavity, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach (gastric) cancer, small cell lung cancer;The present invention relates to the treatment of subjects suffering from small intestine cancer, soft tissue sarcoma, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumor, rare childhood cancer, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or virus-induced cancer. In some embodiments, the method relates to the treatment of non-cancerous hyperproliferative disorders, such as benign skin thickening (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hyperplasia (BPH));
[0083] In some embodiments, the method for treatment is related to the treatment of lung cancer, and the method comprises administering a therapeutically effective amount of a compound of formula (I) (or a pharmaceutical composition comprising such a compound) to a subject in need thereof.In some particular embodiments, the lung cancer is non-small cell lung cancer (NSCLC), such as adenocarcinoma, squamous cell lung carcinoma or large cell lung carcinoma.In some embodiments, the lung cancer is small cell lung carcinoma.Other lung cancers that can be therapeutically beneficial by the compound of formula (I) include, but are not limited to, ductal tumor, carcinoid tumor and undifferentiated carcinoma.
[0084] The present disclosure also provides a method of modulating the activity of mutant KRAS, HRAS or NRAS proteins (e.g., activity resulting from KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutations) by contacting the protein with an effective amount of a compound of formula (I). Modulation can be inhibition or activation of the activity of the protein. In some embodiments, the present disclosure provides a method of inhibiting the activity of a mutant KRAS, HRAS or NRAS protein (e.g., KRAS-G12C, KRAS-G12D and / or KRAS-G12V mutations) by contacting the mutant KRAS, HRAS or NRAS protein with an effective amount of a compound of formula (I) in solution. In some embodiments, the present disclosure provides a method of inhibiting the activity of a mutant KRAS, HRAS or NRAS protein by contacting a cell, tissue or organ expressing the protein of a subject. In some embodiments, the disclosure provides methods of inhibiting protein activity in a subject, including but not limited to, rodents and mammals (e.g., humans), by administering to the subject an effective amount of a compound of formula (I).
[0085] Combination therapy One or more additional pharmacologically active agents may be administered in combination with the compound of formula (I) (or its pharmaceutically acceptable salt). The additional active agent(s) is intended to mean the pharmaceutically active agent(s) active in the body, such as prodrugs, which are converted into a pharmaceutically active form different from the compound of formula (I) after administration. The additional active agent also includes the free acid, free base and pharmaceutically acceptable salt of the additional active agent. In general, any suitable additional active agent(s), such as chemotherapeutic agents or therapeutic antibodies, can be used in any combination with the compound of formula (I) in a single dosage formulation (e.g., fixed dose combination), or in one or more individual dosage formulations that allow for concurrent or sequential administration of the active agents (co-administration of the individual active agents) to the subject. The compound of formula (I) (or its pharmaceutically acceptable salt) can also be administered in combination with radiation therapy, hormonal therapy, surgery or immunotherapy.
[0086] The present application also provides a method for combination therapy, where the additional active agent is found to regulate other pathways or other components of the same pathway, or even overlapping target enzymes, used in combination with the compound of formula (I) or its pharmaceutically acceptable salt.In one embodiment, such therapy includes, but is not limited to, the combination of one or more compounds of formula (I) with chemotherapeutic agents, immunotherapeutic agents, hormonal and antihormonal agents, targeted therapeutic agents, and antiangiogenic agents, which produces synergistic or additive therapeutic effects.In another embodiment, such therapy includes radiation treatment, which produces synergistic or additive therapeutic effects.
[0087] Examples of additional active agents (i.e., additional anti-cancer agents) include chemotherapeutic agents (e.g., cytotoxic agents), immunotherapeutic agents, hormonal and anti-hormonal agents, targeted therapeutic agents, and anti-angiogenic agents. Many anti-cancer agents can be classified into one or more of these groups. Although some specific anti-cancer agents are categorized herein into specific group(s) or subgroup(s), many of these agents may also be listed in one or more other group(s) or subgroup(s) as may be currently understood in the art. It is understood that the classification of specific agents into specific groups herein is not intended to be limiting. Many anti-cancer agents are currently known in the art and may be used in combination with the compounds of the present disclosure.
[0088] Further, an agent may be an agonist, antagonist, allosteric modulator, toxin, or more generally act to inhibit or stimulate its target (e.g., activation or inhibition of a receptor or enzyme). For example, suitable for use are one or more agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind to a growth factor and inhibit its activity, such as antagonists of hepatocyte growth factor (HGF, also known as scatter factor) and its antibody or antigen binding region that specifically binds to the receptor "c-met".
[0089] In one embodiment, the additional anti-cancer agent is a chemotherapeutic agent, an immunotherapeutic agent, a hormonal agent, an antihormonal agent, a targeted therapy, or an anti-angiogenic agent (or angiogenesis inhibitor). In one embodiment, the additional anti-cancer agent is a chemotherapeutic agent, an antimitotic agent, a plant alkaloid, an alkylating agent, an antimetabolite, a platinum analog, an enzyme, a topoisomerase inhibitor, a retinoid, an aziridine, an antibiotic, a hormonal agent, an antihormonal agent, an antiestrogenic agent, an antiandrogenic agent, an adrenal suppressant, an androgenic agent, a targeted therapy, an immunotherapeutic agent, a biological response modifier, a cytokine inhibitor, a tumor vaccine, a monoclonal antibody, an immune checkpoint inhibitor, an anti-PD-1 agent, an anti-PD-L1 agent, a colony stimulating factor, an immunomodulatory agent ... imide (IMiD), anti-CTLA4 agent, anti-LAGl agent, anti-OX40 agent, GITR agonist, CAR-T cell, BiTE, signal transduction inhibitor, growth factor inhibitor, tyrosine kinase inhibitor, EGFR inhibitor, histone deacetylase (HDAC) inhibitor, proteasome inhibitor, cell cycle inhibitor, anti-angiogenic agent, matrix metalloproteinase (MMP) inhibitor, hepatocyte growth factor inhibitor, TOR inhibitor, KDR inhibitor, VEGF inhibitor, HIF-1α inhibitor, HIF-2α inhibitor, fibroblast growth factor (FGF) inhibitor, RAF inhibitor, MEK inhibitor, ERK inhibitor, PI3K inhibitor, AKT inhibitor, MCL-1 inhibitor, BCL-2 inhibitor, SHP2 inhibitor, HER-2 inhibitor, BRAF-inhibitor, gene expression regulator, autophagy inhibitor, apoptosis inducer, antiproliferative agent and glycolysis inhibitor.
[0090] In one embodiment, the additional anticancer agent(s) is a chemotherapeutic agent. Non-limiting examples of chemotherapeutic agents include mitotic inhibitors and plant alkaloids, alkylating agents, antimetabolites, platinum analogs, enzymes, topoisomerase inhibitors, retinoids, aziridines, and antibiotics.
[0091] Non-limiting examples of mitotic inhibitors and plant alkaloids include taxanes such as cabazitaxel, docetaxel, larotaxel, ortataxel, paclitaxel, and tesetaxel; demecolcine; epothilones; eribulin; etoposide (VP-16); etoposide phosphate; navelbine; noscapine; teniposide; thaliblastine; vinblastine; vincristine; vindesine; vinflunine; and vinorelbine.
[0092] Non-limiting examples of alkylating agents include nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, cytophosphane, estramustine, ifosfamide, mannomustine, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichine, phenesterine, prednimustine, tris(2-chloroethyl)amine, trofosfamide, and uracil mustard; alkylsulfonates, such as busulfan, improsulfan, and piposulfan; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, These include methylamelamines such as altretamine, ranimustine, streptozotocin, and TA-07; ethyleneimines and methylamelamines such as altretamine, thiotepa, triethylenemelamine, triethylenethiophosphaoramide, trietylenephosphoramide, and trimethylolomelamine; ambamustine; bendamustine; dacarbazine; etoglucide; irofulven; mafosfamide; mitobronitol; mitolactol; pipobroman; procarbazine; temozolomide; treosulfan; and triaziquone.
[0093] Non-limiting examples of antimetabolites include folic acid analogs such as aminopterin, denopterin, edatrexate, methotrexate, pteropterin, raltitrexed, and trimetrexate; purine analogs such as 6-mercaptopurine, 6-thioguanine, fludarabine, forodesine, thiamiprine, and thioguanine; pyrimidine analogs such as 5-fluorouracil (5-FU), 6-azauridine, ancitabine, azacitidine, capecitabine, carmofur, cytarabine, These include decitabine, dideoxyuridine, doxifiuridine, doxifluridine, enocitabine, floxuridine, galocitabine, gemcitabine, and sapacitabine; 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; broxuridine; cladribine; cyclophosphamide; cytarabine; emitefur; hydroxyurea; mercaptopurine; nelarabine; pemetrexed; pentostatin; tegafur; and troxacitabine.
[0094] Non-limiting examples of platinum analogs include carboplatin, cisplatin, dicycloplatin, heptaplatin, lobaplatin, nedaplatin, oxaliplatin, satraplatin and triplatin tetranitrate.
[0095] Non-limiting examples of enzymes include asparaginase and pegaspargase.
[0096] Non-limiting examples of topoisomerase inhibitors include acridine carboxamide, amonafide, amsacrine, belotecan, elliptinium acetate, exatecan, indolocarbazole, irinotecan, lurtotecan, mitoxantrone, razoxane, rubitecan, SN-38, sobuzoxane, and topotecan.
[0097] Non-limiting examples of retinoids include alitretinoin, bexarotene, fenretinide, isotretinoin, liarozole, RII retinamide, and tretinoin.
[0098] Non-limiting examples of aziridines include benzodopa, carboquone, metuledopa and uredopa.
[0099] Non-limiting examples of antibiotics include intercalating antibiotics; anthracenediones; anthracycline antibiotics such as aclarubicin, amrubicin, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, nogalamycin, pirarubicin, and valrubicin; 6-diazo-5-oxo-L-norleucine; aclacinomycin; actinomycin; authramicin; azaserine; bleomycin; cactinomycin; calicheamicin; carabicin; carminomycin; carzinophilin; chromo Mycobacterium purpuratum; dactinomycin; detorubicin; esorubicin; esperamicin; geldanamycin; marcellomycin; mitomycin; mitomycin C; mycophenolic acid; olivomycin; novantrone; peplomycin; porfiromycin; potfiromycin; puromycin; chelamycin; rebeccamycin; rodorubicin; streptonigrin; streptozocin; tanespimycin; tubercidin; ubenimex; zinostatin; zinostatin stimalamer; and zorubicin.
[0100] In one embodiment, the additional anti-cancer agent(s) is / are hormonal and / or anti-hormonal (i.e., hormonal therapy).Non-limiting examples of hormonal and anti-hormonal agents include anti-androgens, such as abiraterone, apalutamide, bicalutamide, darolutamide, enzalutamide, flutamide, goserelin, leuprolide and nilutamide; anti-estrogens, such as 4-hydroxytamoxifen, aromatase inhibitor 4(5)-imidazole, EM-800, fosfestrol, fulvestrant, keoxifene, LY 117018, onapristone, raloxifene, tamoxifen, toremifene and trioxyphene; adrenal suppressants such as aminoglutethimide, dexaminoglutethimide, mitotane and trilostane; androgenic drugs such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane and testolactone; abarelix; anastrozole; cetrorelix; deslorelin; exemestane; fadrozole; finasteride; formestane; histrelin (RL 0903); human chorionic gonadotropin; lanreotide; LDI 200 (Milkhaus); letrozole; leuprorelin; mifepristone; nafarelin; nafoxidine; osaterone; prednisone; thyrotropin alfa; and triptorelin.
[0101] In one embodiment, the additional anti-cancer agent(s) is an immunotherapeutic agent (i.e., an immunotherapeutic drug). Non-limiting examples of immunotherapeutic agents include biological response modifiers, cytokine inhibitors, tumor vaccines, monoclonal antibodies, immune checkpoint inhibitors, colony stimulating factors, and immunomodulators.
[0102] Non-limiting examples of biological response modifiers, e.g., cytokine inhibitors (cytokines), e.g., interferons and interleukins, include interferon alfa / alpha, e.g., interferon alpha-2, interferon alpha-2a, interferon alpha-2b, interferon alpha-nl, interferon alpha-n3, interferon alfacon-1, pegylated interferon alpha-2a, pegylated interferon alpha-2b and leukocyte alpha interferon; interferon beta, e.g., interferon beta-1a and interferon beta-1b; interferon gamma, e.g., natural interferon gamma-1a and interferon gamma-1b; aldesleukin; interleukin-1 beta; interleukin-2; oprelvekin; sonermin; tasonermin; and virulizin.
[0103] Non-limiting examples of tumor vaccines include APC 8015, AVICINE, bladder cancer vaccine, cancer vaccine (Biomira), gastrin 17 immunogen, Maruyama vaccine, melanoma lysate vaccine, melanoma oncolysate vaccine (New York Medical College), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering Institute), TICE® BCG (bacille Calmette-Guerin) and melanoma cell lysate virus-based vaccine (Royal Newcastle Hospital).
[0104] Non-limiting examples of monoclonal antibodies include abagovomab, adecatumumab, aflibercept, alemtuzumab, blinatumomab, brentuximab vedotin, CA 125 MAb (Biomira), MAb for cancer (Japan Pharmaceutical Development), daclizumab, daratumumab, denosumab, edrecolomab, gemtuzumab zogamicin, HER-2 and Fc MAb (Medarex), ibritumomab tiuxetan, idiotypic 105AD7 MAb (CRC Technology), idiotypic CEA MAb (Trilex), ipilimumab, lintuzumab, LYM-1-iodine 131 MAb (Techni clone), mitumomab, moxetumomab, ofatumumab, polymorphic epithelial cell mucin-yttrium 90 Examples of MAb (Antisoma) include ranibizumab, rituximab and trastuzumab.
[0105] Non-limiting examples of immune checkpoint inhibitors include anti-PD-1 agents or antibodies, such as cemiplimab, nivolumab, and pembrolizumab; anti-PD-L1 agents or antibodies, such as atezolizumab, avelumab, and durvalumab; anti-CTLA-4 agents or antibodies, such as ipilumumab; anti-LAG1 agents; and anti-OX40 agents.
[0106] Non-limiting examples of colony stimulating factors include darbepoetin alfa, epoetin alfa, epoetin beta, filgrastim, granulocyte-macrophage colony stimulating factor, lenograstim, religistim, millimostim, molgramostim, nartograstim, pegfilgrastim, and sargramostim.
[0107] Non-limiting examples of additional immunotherapeutic agents include BiTEs, CAR-T cells, GITR agonists, imiquimod, immunomodulatory imides (IMiDs), mismatched double-stranded RNA (Ampligen), resiquimod, SRL 172, and thymalfasin.
[0108] In one embodiment, the additional anticancer agent(s) is a targeted therapy (i.e., targeted therapy drug).Targeted therapy agents include, for example, monoclonal antibodies and small molecule drugs.Non-limiting examples of targeted therapy agents include signal transduction inhibitors, growth factor inhibitors, tyrosine kinase inhibitors, EGFR inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, cell cycle inhibitors, angiogenesis inhibitors, matrix metalloproteinase (MMP) inhibitors, hepatocyte growth factor inhibitors, TOR inhibitors, KDR inhibitors, VEGF inhibitors, fibroblast growth factor (FGF) inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, AKT inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, HER-2 inhibitors, BRAF-inhibitors, gene expression regulators, autophagy inhibitors, apoptosis inducers, antiproliferative agents and glycolysis inhibitors.
[0109] Non-limiting examples of signal transduction inhibitors include tyrosine kinase inhibitors, multikinase inhibitors, anlotinib, avapritinib, axitinib, dasatinib, dovitinib, imatinib, lenvatinib, lonidamine, nilotinib, nintedanib, pazopanib, pegvisomant, ponatinib, vandetanib, and EGFR inhibitors.
[0110] Non-limiting examples of EGFR inhibitory agents include small molecule antagonists of EGFR, such as afatinib, brigatinib, erlotinib, gefitinib, lapatinib and osimertinib; and antibody-based EGFR inhibitors, such as any anti-EGFR antibody or antibody fragment that can partially or completely block activation of EGFR by natural ligands. Antibody-based EGFR inhibitors include, for example, those described in Modjtahedi, H., et al., 1993, Br. J. Cancer 67:247-253; Teramoto, T., et al., 1996, Cancer 77:639-645; Goldstein et al., 1995, Clin. Cancer Res. 1:1311-1318; Huang, SM, et al., 1999, Cancer Res. 15:59(8):1935-40; and Yang, X., et al., 1999, Cancer Res. 59:1236-1243; the monoclonal antibody Mab E7.6.3 (Yang, 1999 supra); Mab C225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having the binding specificity thereof; specific antisense nucleotides or siRNA; afatinib, cetuximab; matuzumab; necitumumab; nimotuzumab; panitumumab; and zalutumumab.
[0111] Non-limiting examples of histone deacetylase (HDAC) inhibitors include belinostat, panobinostat, romidepsin, and vorinostat.
[0112] Non-limiting examples of proteasome inhibitors include bortezomib, carfilzomib, ixazomib, marizomib (salinosporamide a) and oprozomib.
[0113] Non-limiting examples of cell cycle inhibitors, e.g., CDK inhibitors, include abemaciclib, alvocidib, palbociclib, and ribociclib.
[0114] In one embodiment, the further anti-cancer agent(s) are anti-angiogenic agents (or angiogenesis inhibitors), including but not limited to matrix metalloproteinase (MMP) inhibitors; VEGF inhibitors; EGFR inhibitors; TOR inhibitors, such as everolimus and temsirolimus; PDGFR kinase inhibitory agents, such as crenolanib; HIF-lα inhibitors, such as PX 478; HIF-2α inhibitors, such as velzutifan and the HIF-2α inhibitors described in WO2015 / 035223; fibroblast growth factor (FGF) or FGFR inhibitory agents, such as B-FGF and RG 13577; hepatocyte growth factor inhibitors; KDR inhibitors; anti-Ang1 and anti-Ang2 agents; anti-Tie2 kinase inhibitors; Tek antagonists (US2003 / 0162712; US6,413,932); anti-TWEAK agents (US6,727,225); ADAM distintegrin domains that antagonize the binding of integrins to their ligands (US2002 / 0042368); anti-eph receptor and / or anti-ephrin antibodies or antigen binding regions (US5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; and 6,057,124); and antibodies or antigen binding regions that specifically bind to PDGF-BB ligands as well as anti-PDGF-BB antagonists.
[0115] Non-limiting examples of matrix metalloproteinase (MMP) inhibitors include MMP-2 (matrix metalloproteinase 2) inhibitors, MMP-9 (matrix metalloproteinase 9) inhibitors, prinomastat, RO 32-3555, and RS 13-0830. Examples of useful matrix metalloproteinase inhibitors are described, for example, in WO96 / 33172, WO96 / 27583, EP1004578, WO98 / 07697, WO98 / 03516, WO98 / 34918, WO98 / 34915, WO98 / 33768, WO98 / 30566, EP0606046, EP09 31788, WO90 / 05719, WO99 / 52910, WO99 / 52889, WO99 / 29667, WO1999 / 007675, EP1786785, EP1181017, US2009 / 0012085, US5,863,949, US5,861,510 and EP0780386. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred are those that selectively inhibit MMP-2 and / or MMP-9 relative to other matrix metalloproteinases (i.e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12 and MMP-13).
[0116] Non-limiting examples of VEGF inhibitors and VEGFR inhibitors include bevacizumab, cediranib, CEP 7055, CP 547632, KRN 633, orantinib, pazopanib, pegaptanib, pegaptanib octasodium, semaxanib, sorafenib, sunitinib, VEGF antagonist (Borean, Denmark) and VEGF-TRAP™.
[0117] The additional anti-cancer agent(s) may also be another anti-angiogenic agent, such as, but not limited to, 2-methoxyestradiol, AE 941, alemtuzumab, alpha-D148 Mab (Amgen, US), alphastatin, anecortave acetate, angiocidin, angiogenesis inhibitor, (SUGEN, US), angiostatin, anti-Vn Mab (Crucell, Netherlands), atiprimod, axitinib, AZD 9935, BAY RES 2690 (Bayer, Germany, BC 1 (Genoa Institute of Cancer Research, Italy), beloranib, benefin (Lane Labs, US), cabozantinib, CDP 791 (Celltech Group, UK), chondroitinase AC, cilengitide, combretastatin A4 prodrug, CP 564959 (OSI, US), CV247, CYC 381 (Harvard University, US), E 7820, EHT 0101, endostatin, enzastaurin hydrochloride, ER-68203-00 (IVAX, US), fibrinogen-E fragment, Flk-1 (ImClone Systems, US), forms of FLT 1 (VEGFR 1), FR-111142, GCS-100, GW 2286 (GlaxoSmithKline, UK), IL-8, Ilomastat, IM-862, irsogladine, KM-2550 (Kyowa Hakko, Japan), lenalidomide, lenvatinib, MAb alpha5beta3 integrin, second generation (Applied Molecular Evolution, USA and MedImmune, US), MAb VEGF (Xenova, UK), marimastat, maspin (Sosei, Japan), metastatin, motuporamine C, M-PGA, ombrabulin, OXI4503, PI 88, platelet factor 4, PPI 2458, ramucirumab, rBPI 21 and BPI-derived antiangiogenic drugs (XOMA, US), regorafenib, SC-236, SD-7784 (Pfizer, US), SDX 103 (University of California, San Diego, US), SG292 (Telios, US), SU-0879 (Pfizer, US), TAN-1120, TBC-1635, tecevatinib, tetrathiomolybdate, thalidomide, thrombospondin 1 inhibitors, Tie-2 ligand (Regeneron, US), tissue factor pathway inhibitor (EntreMed, US), tumor necrosis factor-alpha inhibitors, tumstatin, TZ 93, urokinase-type plasminogen activator inhibitors, vadimezan, vandetanib, vasostatin, vatalanib, VE-cadherin-2 antagonists, xanthrizol, XL 784 (Exelixis, US), dib-aflibercept, and ZD 6126.
[0118] In some embodiments, the additional anti-cancer agent(s) is an additional active agent that disrupts or inhibits the RAS-RAF-ERK or PI3K-AKT-TOR signaling pathway, or is a PD-1 antagonist and / or a PD-L1 antagonist. In some embodiments, the additional anti-cancer agent(s) is a RAF inhibitor, an EGFR inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, an AKT inhibitor, a TOR inhibitor, an MCL-1 inhibitor, a BCL-2 inhibitor, an SHP2 inhibitor, a proteasome inhibitor, or an immunotherapeutic agent, such as a monoclonal antibody, an immunomodulatory imide (IMiD), an anti-PD-1 agent, an anti-PDL-1 agent, an anti-CTLA4 agent, an anti-LAG1 agent, and an anti-OX40 agent, a GITR agonist, a CAR-T cell, and a BiTE.
[0119] Non-limiting examples of RAF inhibitors include dabrafenib, encorafenib, regorafenib, sorafenib, and vemurafenib.
[0120] Non-limiting examples of MEK inhibitors include binimetinib, CI-1040, cobimetinib, PD318088, PD325901, PD334581, PD98059, refametinib, selumetinib, and trametinib.
[0121] Non-limiting examples of ERK inhibitors include LY3214996, LTT462, MK-8353, SCH772984, ravoxertinib, ulixertinib, and ERKi's such as those described in WO2017 / 068412.
[0122] Non-limiting examples of PI3K inhibitors include 17-hydroxywortmannin analogs (e.g., WO06 / 044453); AEZS-136; alpelisib; AS-252424; lisiblisib; CAL263; copanlisib; CUDC-907; dactolisib (WO06 / 122806); demethoxyviridin; duvelisib; GNE-477; GSK1059615; IC87114; idelalisib; INK1117; LY294002; palomido 529; paxalisib; perifosine; PI-103; PI-103 hydrochloride; pictilisib (e.g., WO09 / 036,082; WO09 / 055,730); PIK 90; PWT33597; SF1126; sonolisib; TGI 00-115; TGX-221; XL147; XL-765; wortmannin; and ZSTK474.
[0123] Non-limiting examples of AKT inhibitors include Akt-1-1 (inhibits Aktl) (Barnett et al. (2005) Biochem. J., 385(Pt. 2), 399-408); Akt-1-1,2 (Barnett et al. (2005) Biochem. J. 385(Pt. 2), 399-408); API-59CJ-Ome (e.g., Jin et al. (2004) Br. J. Cancer 91, 1808-12); lH-imidazo[4,5-c]pyridinyl compounds (e.g., WO05011700); indole-3-carbinol and its derivatives (e.g., U.S. Pat. No. 6,656,963; Sarkar and Li (2004) J Nutr. 134(12) Suppl), 3493S-3498S); perifosine, Dasmahapatra et al. (2004) Clin. Cancer Res. 10(15), 5242-52, 2004); phosphatidylinositol ether lipid analogs (e.g., Gills and Dennis (2004) Expert. Opin. Investig. Drugs 13, 787-97); triciribine (Yang et al. (2004) Cancer Res. 64, 4394-9); imidazooxazone compounds such as trans-3-amino-1-methyl-3-[4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl]-cyclobutanol hydrochloride (WO2012 / 137870); afuresertib; capivasertib; MK2206; patasertib and those disclosed in WO2011 / 082270 and WO2012 / 177844.
[0124] Non-limiting examples of TOR inhibitors include deforolimus; ATP-competitive TORC1 / TORC2 inhibitors such as PI-103, PP242, PP30 and torin1; TOR inhibitors of the FKBP12 enhancer, rapamycin and its derivatives such as temsirolimus, everolimus, WO9409010; rapalogs such as those disclosed in WO98 / 02441 and WO01 / 14387, such as AP23573, AP23464 or AP23841; 40-(2-hydroxyethyl)rapamycin, 40-[3-hydroxy(hydroxymethyl)propanoate methyl]-rapamycin; 40-epi-(tetrazolyl)-rapamycin (also referred to as ABT578); 32-deoxolamycin; 16-pentynyloxy-32(S)-dihydrorapanycin and other derivatives disclosed in WO05 / 005434; US5,258,389, WO94 / 090101, WO92 / 05179, US5,118,677, US5,118,678, US5,100,883, US5,151,413, US5,1 20,842, WO93 / 111130, WO94 / 02136, WO94 / 02485, WO95 / 14023, WO94 / 02136, WO95 / 16691, WO96 / 41807, WO96 / 41807 and US 5,256,790; and phosphorus-containing rapamycin derivatives (e.g., WO05 / 016252).
[0125] Non-limiting examples of MCL-1 inhibitors include AMG-176, MIK665 and S63845.
[0126] Non-limiting examples of SHP2 inhibitors include those described in WO2019 / 167000 and WO2020 / 022323.
[0127] Further non-limiting examples of anti-cancer agents suitable for use include 2-ethylhydrazide, 2,2',2"-trichlorotriethylamine, ABVD, aceglatone, acemannan, aldophosphamide glycoside, alpharadin, amifostine, aminolevulinic acid, anagrelide, ANCER, ancestim, anti-CD22 immunotoxin, antitumorigenic herbs, apaziquone, aruglavin, arsenic trioxide, azathioprine, BAM 002 (Novelos), bcl-2 (Genta), bestrabucil, biricodar, bisantrene, bromocriptine, brostallicin, bryostatin, buthionine sulfoximine, calyculin, cell cycle non-specific anti-neoplastic agents, celmoleukin, clodronate, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A), defofamine, denileukin diftitox, dexrazoxane, diaziquone, dichloroacetic acid, dilazep, discodermolide, docosanol, doxercalciferol, edelfosine, eflornithine, EL532 (Elan), elfomithine, elsamitrucin, eniluracil, etanidazole, exisulind, ferruginol, folic acid supplements, e.g. fluorin (frolinic) acid, gacytosine, gallium nitrate, gimeracil / oteracil / tegafur combination (S-1), glycopine, histamine dihydrochloride, HIT diclofenac, HLA-B7 gene therapy drug (Vical), human fetal alpha-fetoprotein, ibandronate, ibandronic acid, ICE chemotherapy regimen, imexon, iobenguane, IT-101 (CRLX101), laniquidar, LC 9018 (Yakult), leflunomide, lentinan, levamisole + fluorouracil, lovastatin, lucantone, masoprocol, melarsoprol, metoclopramide, miltefosine, miproxifene, mitoguazone, mitozolomide, mopidamol, motexafin gadolinium, MX6 (Galderma), naloxone + pentazocine, nitracrine, nolatrexed, NSC631570 Octreotide (Ukrain), Olaparib, P-30 protein, PAC-1, Palifermin, Pamidronate, Pamidronic acid, Pentosan polysulfate sodium, Fenamet, Picibanil, Pixantrone, Platinum preparations, Podophyllic acid, Porfimer sodium, PSK (Polysaccharide-K), Rabbit antithymocyte polyclonal antibody, Rasburiembodiment, Retinoic acid, Rhenium Re 186 Etidronate, Romurtide, Samarium (153 Sm) lexidronam, sizofiran, sodium phenylacetate, sparfosic acid, spirogermanium, strontium-89 chloride, suramin, swainsonine, talaporfin, tariquidar, tazarotene, tegafur-uracil, temoporfin, tenuazonic acid, tetrachlorodecaoxide, thrombopoietin, ethyl etiopurpurin tin, tirapazamine, TLC ELL-12, tositumomab-iodine 131, trifluridine and tipiracil combination, troponin I (Harvard University, US), urethane, valspodar, verteporfin, zoledronic acid and zosuquidar.
[0128] Furthermore, the present disclosure provides the method of using the compound of formula (I) or pharmaceutical composition provided herein in combination with radiation therapy to treat cancer.The method of administering radiation therapy is known in the art, and such method can be used in the combination therapy described herein.The administration of the compound of formula (I) in this combination therapy can be determined as described herein.
[0129] Radiation therapy can be administered by one of several methods or a combination of methods, including but not limited to external beam therapy, internal radiation therapy, interstitial irradiation, stereotactic radiosurgery, total body radiation therapy, radiation therapy, and permanent or temporary interstitial brachytherapy. The term "brachytherapy" as used herein refers to radiation therapy performed by spatially confined radioactive material inserted at or near the site of a tumor or other proliferative tissue disease in the body. The term is intended to encompass, but is not limited to, exposure to radioisotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioisotopes of Lu). Suitable radiation sources for use as cell conditioners of the present disclosure include both solids and liquids. As a non-limiting example, the radiation source can be a radionuclide, such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays. The radioactive material can also be a fluid made from any solution of radionuclide(s), such as a solution of I-125 or I-131, or a radioactive fluid can be made using a slurry of a suitable fluid containing small particles of solid radionuclide, such as Au-198, Y-90. Furthermore, the radionuclide(s) can be embodied in a gel or radioactive microspheres.
[0130] The present disclosure also provides a method for combination therapy, where the additional active agent is found to regulate other pathways or other components of the same pathway, or even overlapping target enzymes, used in combination with the compound of formula (I) or its pharmaceutically acceptable salt.In one embodiment, such therapy includes, but is not limited to, the combination of one or more compounds of formula (I) with chemotherapeutic agents, immunotherapeutic agents, hormonal therapy agents, therapeutic antibodies, targeted therapy agents and radiation treatment, which results in synergistic or additive therapeutic effects.
[0131] The compounds of the present disclosure may be used in combination with the drugs disclosed herein or other suitable drugs depending on the condition being treated. Thus, in some embodiments, one or more compounds of the present disclosure are co-administered with other drugs as described above. When used in combination therapy, the compounds described herein are administered simultaneously with the second drug or separately. The administration in combination may include simultaneous administration of the two drugs in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, the compound of formula (I) and any of the above drugs may be formulated together in the same dosage form and administered simultaneously. Alternatively, the compound of formula (I) and any of the above drugs may be administered simultaneously, but both drugs are in separate formulations. In another alternative, the compound of formula (I) may be administered immediately after any of the above drugs, or vice versa. In some embodiments of the separate administration protocol, the compound of formula (I) and any of the above drugs are administered minutes apart, hours apart, or days apart.
[0132] In one aspect of the present disclosure, since the treatment of a disease / condition with a combination of pharmacoactive compounds that can be administered separately is envisioned, the present disclosure further relates to assembling separate pharmaceutical compositions into a kit form. The kit comprises two separate pharmaceutical compositions: a compound of formula (I) and a second pharmaceutical compound. The kit comprises a container for containing the separate compositions, such as a individually packaged bottle or an individually packaged foil packet. Further examples of containers include syringes, boxes and bags. In some embodiments, the kit comprises instructions for use of the separate components. The kit form is particularly convenient when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), administered for different dosing periods, or when titration of the individual components of the combination is desired by the prescribing medical practitioner.
[0133] The disclosure also provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in therapy, or the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in therapy. The disclosure also provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in the treatment of cancer, or the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof for treating cancer. The disclosure also provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for the preparation of a medicament for the treatment of cancer, or the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof for the preparation of a medicament for the treatment of cancer. The disclosure also provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof and an additional anti-cancer agent for use in the treatment of cancer, or the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof and an additional anti-cancer agent for treating cancer. The present disclosure also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof and an additional anti-cancer agent for the preparation of a medicament for the treatment of cancer, or a use of a compound of formula (I) or a pharmaceutically acceptable salt thereof and the additional anti-cancer agent for the preparation of a medicament for the treatment of cancer. The present disclosure also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, or a use of the pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating cancer. The present disclosure also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and an additional anti-cancer agent for use in the treatment of cancer, or a use of the pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating cancer.
[0134] Methods for Preparing the Compounds of the Disclosure The compounds described herein can be prepared using appropriate materials according to the procedures of the following schemes and examples, and are further illustrated by the following specific examples. However, the compounds illustrated in the examples should not be construed as constituting the only class considered in the present disclosure. The examples further illustrate the details for preparing the compounds of the present disclosure. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparation procedures can be used to prepare such compounds. For example, in some cases, the order of steps in the reaction schemes may be changed to facilitate the reaction or to avoid unwanted reaction products. These examples are presented for the purpose of further illustration only and are not intended to be limitations on the present disclosure. Any intermediates described below may be referred to herein by indicating "Int-" before the number.
[0135] Throughout the synthetic schemes and examples, the following abbreviations and acronyms may be used, unless otherwise indicated: anhydr. = anhydrous; aq. = aqueous; atm = atmosphere; Bodipy-GDP = ((2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3-(((2-(3-(5,5-difluoro-7,9-dimethyl-5H-414,514-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborin-3-yl)propanamido)ethyl)carbamoyl)oxy)-4-hydroxytetrahydrofuran-2-yl)methyl hydrogen diphosphate and ((2R,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purine 1-9-yl)-4-(((2-(3-(5,5-difluoro-7,9-dimethyl-5H-414,514-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborin-3-yl)propanamido)ethyl)carbamoyl)oxy)-3-hydroxytetrahydrofuran-2-yl)methyl hydrogen diphosphate mixture (Invitrogen™, catalog number G22360); Boc2O = di-tert-butyl dicarbonate; BOP = benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate; B2pin2 = bis(pinacolato)diboron; br s = broad singlet; Bu = butyl; t-Bu = tert-butyl; cataCxium® C = trans-di(μ-acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II); CDCl3 = deuterated chloroform; Cbz = carbobenzyl; CDI = 1,1'-carbonyldiimidazole; CELITE = diatomaceous earth; CF3 = trifluoromethyl; cGMP = cyclic guanosine monophosphate; CH3NO2 = nitromethane; conc. = concentrated; DAST = (diethylamino)sulfur trifluoride; DBU = 1,8-diazabicyclo[5.4.0]Undec-7-ene;DCM=dichloromethane;DCE=dichloroethane;DHP=3,4-dihydropyran;DIAD=diisopropyl azodicarboxylate;DIEA / DIPEA=N,N-diisopropylethylamine;DMAP=dimethylaminopyridine;DME=dimethoxyethane;DMEA=N,N-dimethylethanamine;DMF=N,N-dimethylformamide;DMP=Dess-Martin periodinane;DMS=dimethylsulfide; DMSO = dimethylsulfoxide; DPPF or dppf = 1,1'-bis(diphenylphosphino)ferrocene; EDTA = ethylenediaminetetraacetic acid; equiv, eq. = equivalents; Et = ethyl; Et3N = triethylamine; EtOAc = ethyl acetate; EtOH = ethanol; Grubbs' catalyst = (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)l guanosine;GTP=guanosine triphosphate;h=hours;HATU=1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate;HEPES=4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;HMDS=hexamethydisilazane;HPLC=high performance liquid chromatography;Int=intermediate;iPr=isopropyl;IP=inflection point i-PrOH = isopropanol; KHMDS = potassium bis(trimethylsilyl)amide; LAH = lithium aluminum hydride; LCMS, LC / MS = liquid chromatography-mass spectrometry; min, min. = minutes; LDA = lithium diisopropylamide; M = molar concentration; m-CPBA or mCPBA = 3-chlorobenzoperoxoic acid; Me = methyl; MeCN, ACN = acetonitrile; MeOH = methanol; mp, mp= melting point; mpk = milligrams per kilogram; MsCl = methanesulfonyl chloride; MOM = methoxymethyl; MTBE = methyl tert-butyl ether; N = normal; NaOMe = sodium methoxide; NaHMDS = sodium hexamethyldisilazide; NBS = N-bromosuccinimide; NCS = N-chlorosuccinimide; NMO = 4-methylmorpholine N-oxide; NMR = nuclear magnetic resonance; ND = not determined; PDA = photodiode array; Pet.ether = petroleum ether; Pd-C = palladium on carbon; Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(0); Ph = phenyl; Pr = propyl; psi = pounds per square inch gauge; POCl3 = phosphorus(V) oxide chloride; PPTS = pyridinium p-toluenesulfonate; PTLC, prep TLC = preparative thin layer chromatography; pTsOH = p-toluenesulfonic acid; rac = racemic; RT = retention time; RP-HPLC = reversed-phase HPLC; rt = room temperature; sat. = saturated; SFC = supercritical fluid chromatography; SOS = son of sevenless; TBAF = tetra-n-butylammonium fluoride; TBSCl = tert-butyldimethylsilyl chloride; TBDPS-Cl = tert-butyl(chloro)diphenylsilane; TEA = triethylamine; TEMPO = 2,2,6,6-tetramethylpiperidine 1-oxyl; Tf2O = triflic acid Anhydride; TFA = trifluoroacetic acid; TFAA = trifluoroacetic anhydride; THP = tetrahydropyran; TLC = thin layer chromatography; THF = tetrahydrofuran; TMEDA = N,N,N',N'-tetramethylethylenediamine; TMS = trimethylsilyl; TWEEN = polyoxyethylene(20) sorbitan monolaurate; VCD = vibrational circular dichroism; v, v / v = volume, volume to volume; w, w / w = weight, weight to weight, XPhos = 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl; μm = micrometer.
[0136] [Example] Concentration refers to removal of volatile components under reduced pressure (e.g., by rotary evaporation) unless otherwise noted. All temperatures are in degrees Celsius unless otherwise noted. Mass spectra (MS) were measured by electrospray ionization-mass spectrometry (ESI) in positive ion detection mode and m / z is [M+H] unless otherwise noted. + ions are shown. 1 H NMR spectra were recorded at 400-600 MHz at ambient temperature unless otherwise noted. Protons reported as 0.5H are due to rotamer signals. RP-HPLC indicates reversed-phase HPLC on a C18-loaded preparative or semi-preparative column with gradient elution using acetonitrile and water modified with trifluoroacetic acid or ammonium hydroxide as eluents, and fractions were lyophilized or concentrated by rotary evaporation unless otherwise noted. Purification by column chromatography on silica gel was performed using a flash chromatography system (e.g., ISCO® or Biotage®) and commercially available prepacked silica gel columns with elution with the solvent system indicated. Compounds described herein were synthesized as racemates in the Experimental Procedures and Compounds Tables unless otherwise noted. Some specific products / intermediates in the Examples include the designation "Peak 1" and / or "Peak 2" which indicates the elution order of the indicated product / intermediate from the chromatographic column (e.g., SFC column) used to isolate the compound under the conditions specifically indicated. Thus, for example, peak 1 represents the first eluting compound, eg, the first eluting stereoisomer, under the conditions specified.
[0137] The SFC columns used in the chiral resolution of stereoisomers are summarized in the following table: [Table 1]
[0138] Synthesis of intermediates: Intermediate 1: 2-Methyl-8-azabicyclo[3.2.1]octan-2-ol (Int-1) [ka]
[0139] Step A: Benzyl 2-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate (Int-1-A) To a solution of 8-azabicyclo[3.2.1]octan-2-ol, HCl (600 mg, 3.67 mmol) in DCM (18 ml) was added N-ethyl-N-isopropylpropan-2-amine (948 mg, 7.33 mmol) followed by N,N-dimethylpyridin-4-amine (45 mg, 0.37 mmol). Benzyl carbonochloridate (1.00 g, 5.87 mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at ambient temperature for 5 hours. The mixture was diluted with DCM, washed with saturated sodium bicarbonate solution, saturated brine solution and concentrated under reduced pressure. The racemic mixture was purified by flash silica gel chromatography (eluting with a gradient of 0 to 25% methanol in dichloromethane) to give the title compound. MS (ESI): m / z (M+H) + 262.
[0140] Step B: 2-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate benzyl (Int-1-B) To a solution of benzyl 2-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate (Int-1-A) (800 mg, 3.06 mmol) in DCM (28 mL) was added Dess-Martin periodinane (1.17 g, 2.76 mmol). The reaction mixture was stirred at ambient conditions for 5 h. The mixture was diluted with DCM, washed with saturated sodium bicarbonate solution, saturated brine solution, and concentrated under reduced pressure. The product was purified by flash silica gel chromatography (elution with a gradient of 0 to 45% ethyl acetate in hexanes) to give the title compound. MS (ESI): m / z (M+H) + 260.
[0141] Step C: 2-Hydroxy-2-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate benzyl (Int-1-C) To a solution of benzyl 2-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (Int-1-B) (540 mg, 2.1 mmol) in THF (19 ml) under nitrogen was added methylmagnesium bromide (1.4 ml, 4.2 mmol, 3M in Et2O) at 0°C. The mixture was slowly brought to ambient temperature and stirred for 45 min. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (2 x 10 mL). The combined extracts were washed with saturated brine solution and concentrated under reduced pressure. The product was purified by flash silica gel column chromatography (eluted with a gradient of 0 to 40% ethyl acetate in hexane) to give the title compound as a mixture of stereoisomers. MS (ESI): m / z (M+H) + 276. This mixture of stereoisomers was resolved by SFC (column A; 15% MeOH with 0.1% NH4OH). Fractions were concentrated under reduced pressure to give the title compounds Int-1-C-1, Int-1-C-2, Int-1-C-3 and Int-1-C-4 as isolated stereoisomers (numbered in order of elution).
[0142] Step D: 2-Methyl-8-azabicyclo[3.2.1]octan-2-ol (Int-1) An 8 ml vial was charged with palladium hydroxide on carbon (19.18 mg, 0.068 mmol) to which (1R,5S)-2-hydroxy-2-methyl-8-azabicyclo[3.2.1]octane-8-benzyl carboxylate (Int-1-C-4) in MeOH (3 ml) was added under nitrogen. The flask was evacuated and back-filled with nitrogen (3 times). It was then evacuated and back-filled with a hydrogen balloon. After stirring at ambient temperature for 1.5 h, the reaction mixture was evacuated and back-filled with nitrogen. The reaction was filtered and washed with methanol. The filtrate was concentrated to give the title compound (Int-1). MS (ESI): m / z (M+H) + 142.
[0143] Intermediate 2: 3-(difluoromethyl)piperidin-3-ol (Int-2) [ka]
[0144] Step A: Benzyl 3-(difluoromethyl)-3-hydroxypiperidine-1-carboxylate (Int-2-A) To a solution of 3-(difluoromethyl)piperidin-3-ol, HCl (1.5 g, 8.0 mmol) in DCM (30 ml) was added N-ethyl-N-isopropylpropan-2-amine (2.85 ml, 16.0 mmol) and N,N-diisopropylethylamine (0.098 g, 0.80 mmol). To this mixture was added benzyl carbonochloridate (2.28 ml, 16.0 mmol) dropwise. The mixture was stirred at ambient temperature overnight. The mixture was diluted with DCM, washed with saturated sodium bicarbonate solution, saturated brine and concentrated under reduced pressure. The racemic mixture was purified by flash silica gel chromatography (eluted with a gradient of 0 to 25% EtOAc in hexanes). The products were resolved by chiral SFC column B; 25% MeOH containing 0.1% NH4OH to give the title compounds as isolated stereoisomers (Int-2-A-1, peak 1) MS (ESI): m / z (M+H) + 286 and (Int-2-A-2, peak 2) MS (ESI): m / z (M+H) + Obtained as 286.
[0145] Step B: 3-(Difluoromethyl)piperidin-3-ol (Int-2) An 8 mL vial was charged with palladium hydroxide on carbon (39.4 mg, 0.140 mmol) to which was added benzyl 3-(difluoromethyl)-3-hydroxypiperidine-1-carboxylate (Int-2-A-2) (100 mg, 0.351 mmol) in MeOH (3 mL) under nitrogen. The flask was evacuated and back-filled with nitrogen (3 times). It was then evacuated and back-filled with a hydrogen balloon. After stirring at ambient temperature for 3 hours, the reaction mixture was evacuated and back-filled with nitrogen. The reaction was filtered and concentrated to give the title compound. 1H NMR(499MHz,DMSO-d6)δ 5.79(t,J=55.9Hz,1H),5.07(s,1H),2.73(dd,J=12.8,3.9Hz,1H),2.64-2.54(m,2H),2.44(d d,J=15.8,6.7Hz,1H),1.59(d,J=9.7Hz,1H),1.57-1.50(m,2H),1.38(dd,J=11.6,4.2Hz,1H).
[0146] Intermediate 3: 4,4-Difluoro-3-methylpiperidin-3-ol (Int-3) [ka]
[0147] Step A: tert-Butyl 4,4-difluoro-3-hydroxy-3-methylpiperidine-1-carboxylate (Int-3-A) tert-Butyl 4,4-difluoro-3-oxopiperidine-1-carboxylate (200 mg, 0.921 mmol) in THF (2367 μl) was treated with methylmagnesium bromide (1630 μl, 4.89 mmol, 3M in diethyl ether) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 4 h, and the reaction mixture was carried on to the next step.
[0148] Step B: 4,4-Difluoro-3-methylpiperidin-3-ol (Int-3-B) HCl (in dioxane) (1183 μl, 4.73 mmol, 4 M) was added (dropwise) to the reaction mixture of step A at 0° C. The reaction mixture was allowed to warm to room temperature and stirred overnight. It was neutralized with sodium bicarbonate (sat. aq. solution). The product was extracted with DCM (3×20 mL) and concentrated under reduced pressure. The crude residue was used in the next step without further purification.
[0149] Step C: Benzyl 4,4-difluoro-3-hydroxy-3-methylpiperidine-1-carboxylate (Int-3-C) The crude mixture of 4,4-difluoro-3-methylpiperidin-3-ol obtained in step B was dissolved in methylene chloride (2.4 mL) and treated with Hunig's base (2000 μl, 11.45 mmol) and DMAP (11.57 mg, 0.095 mmol) followed by benzyl chloroformate (270 μl, 1.893 mmol) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was concentrated in vacuo and redissolved in DMSO (3 mL). The product was isolated directly from the solution by Prep-HPLC (C18, 0-100% MeCN / water, with 0.1% TFA modifier). The product-containing fractions were concentrated under reduced pressure to give the title compound as a mixture of epimers. LCMS (ESI): m / z (M+H) + 286.
[0150] Step D: 4,4-Difluoro-3-methylpiperidin-3-ol (Int-3) Benzyl 4,4-difluoro-3-hydroxy-3-methylpiperidine-1-carboxylate (11 mg, 0.039 mmol) (Int-3-C) in MeOH (1000 μL) was added to palladium on carbon (14 mg, 0.013 mmol, 10% wt) in a sealed vial under argon. Hydrogen was introduced via a balloon and an attached outlet needle, and hydrogen was bubbled below the solvent level for 1 min. The hydrogen inlet was raised above the solvent level and the outlet was removed. The reaction was stirred under hydrogen for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to give the title compound. LCMS (ESI): m / z (M+H) + 152.
[0151] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Int-3, with appropriate substitutions of starting materials, intermediates and / or reagents, and optionally completing the indicated steps using the conditions indicated, resolving stereoisomers and carrying forward the indicated peak(s). The appropriate substitutions are commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 2]
[0152] Intermediate 8: ((2R,7aS)-2-Fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) [ka]
[0153] Step A: Ethyl 2-(2-(chloromethyl)allyl)-5-oxopyrrolidine-2-carboxylate (Int-8-A) LiHMDS (1.00M, 2.55L) was added dropwise to a solution of ethyl 5-oxopyrrolidine-2-carboxylate (200g, 1.27mol) and 3-chloro-2-(chloromethyl)prop-1-ene (255g, 2.04mol, 236mL) in THF (2.00L) at -40°C under N2. The mixture was stirred at 20°C for 20h. The reaction mixture was poured into saturated NH4Cl solution (1.00L) and the pH of the mixture was adjusted to 6-7 with 1N HCl. The biphasic solution was extracted with EtOAc (500mL x 3). The organic layers were combined, washed with brine (600mL) and concentrated under reduced pressure to give the crude residue. The crude material was purified by silica gel column chromatography (eluent: petroleum ether:ethyl acetate=gradient from 50:1 to 1:1) to give ethyl 2-(2-(chloromethyl)allyl)-5-oxopyrrolidine-2-carboxylate (Int-8-A). 1 H NMR(400MHz,CDCl3)δ 5.06(br d,J=17Hz,2H),4.14-4.38(m,3H),3.73(br d,J=16Hz,1H),3.06(br d,J=16Hz,1H),2.70-2.85(m,1H),2.53-2.66(m,1H),2.36-2.50(m,2H),2.09-2.21(m,1H),1.23-1.31(m,3H).
[0154] Step B: Ethyl 2-methylene-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-B) A solution of ethyl 2-(2-(chloromethyl)allyl)-5-oxopyrrolidine-2-carboxylate (Int-8-A) (500.g, 2.03 mol) in THF (500 mL) was added dropwise to a mixture of sodium hydride (97.7 g, 2.44 mol, 60.0% wt%) and THF (3.00 L) at 0° C. under nitrogen. The reaction mixture was stirred at 70° C. for 12 h under nitrogen. The reaction mixture was cooled and poured into saturated ammonium chloride solution (2.00 L) and stirred at 5° C. for 1 h. The biphasic mixture was extracted with EtOAc (600 mL×3). The combined organic layers were washed with brine (500 mL×2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (eluent: petroleum ether:ethyl acetate=50:1 to 1:1) to give ethyl 2-methylene-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-B). 1 H NMR(400MHz,CDCl3)δ 4.96-5.13(m,2H),4.27(br d,J=16Hz,1H),4.19(q,J=7Hz,2H),3.71(br d,J=16Hz,1H),3.04(d,J=16Hz,1H),2.69-2.83(m,1H),2.59(ddd,J=2,9,13Hz,1H),2.40-2.52(m,2H),1.96-2.22(m,1H),1.26(t,J=7Hz,3H).
[0155] Step C: Ethyl 2,5-dioxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-C) Ozone (239 mmol) (0.5-1 m 3 / hr) was bubbled into a solution of ethyl 2-methylene-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-B) (160 g, 765 mmol) in DCM (1.60 L) / MeOH (160 mL) at -70 °C for 9 h. Nitrogen was bubbled into the reaction mixture to purge excess ozone. Dimethyl sulfide (76.0 g, 1.22 mol) was then added to the mixture at -70 °C. The reaction mixture was stirred at 20 °C for 14 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 50:1 to 1:1) to give ethyl 2,5-dioxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-C). 1 H NMR(400MHz,CDCl3)δ 4.22(q,J=7Hz,2H),4.07-4.12(m,1H),3.54(dd,J=1,18Hz,1H),2.92-3.03(m,2 H),2.74-2.88(m,1H),2.42-2.51(m,2H),2.12-2.23(m,1H),1.27(t,J=7Hz,3H).
[0156] Step D: Ethyl 2-hydroxy-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-D) To a solution of ethyl 2,5-dioxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-C) (200 g, 947 mmol) in EtOH (2.00 L) under N2 at 0°C was added NaBH4 (10.8 g, 284 mmol). The reaction mixture was stirred at 0°C for 10 min. The reaction mixture was quenched at 5°C by addition of saturated NH4Cl (50.0 mL) and the mixture was stirred at 5°C for 0.5 h. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 50:1 to 1:1) to give ethyl 2-hydroxy-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-D). 1H NMR(400MHz,CDCl3)δ 4.54-4.70(m,1H),4.16-4.31(m,2H),3.93(dd,J=6,13Hz,1H),3.09(d,J=13Hz,1H),2.75-2. 90(m,1H),2.39-2.63(m,4H),2.01-2.13(m,1H),1.83(dd,J=6,14Hz,1H),1.29(t,J=7Hz,3H).
[0157] Step E: (2R,7aS)-2-Fluoro-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate ethyl (Int-8-E-2) To a solution of ethyl 2-hydroxy-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-D) (100 g, 468 mmol) in DCM (1 L) was added DAST (113 g, 703 mmol, 93 mL) dropwise at -70 °C under N2. The reaction mixture was warmed to 20 °C and stirred for 16 h. The reaction was quenched at 10 °C by addition of EtOH (50.0 mL), then diluted with water (300 mL) and extracted with DCM (200 mL x 2). The combined organic layers were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude products of six identical reactions were combined and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 50:1 to 1:1). This material was further purified by preparative HPLC (C18, 0-100% MeCN / water, containing 0.05% HCl). The racemic mixture was resolved using chiral SFC (column E; EtOH containing 0.1% NH4OH) to give ethyl (2R,7aS)-2-fluoro-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-E-2, peak 2). 1 H NMR(400MHz,CDCl3):δ 5.16-5.43(m,1H),4.14-4.27(m,3H),3.06-3.26(m,1H),2.57-2.85(m,3H),2.38-2.50(m,1H),2.07-2.30(m,2H),1.28(t,J=7Hz,3H).
[0158] Step F: ((2R,7aS)-2-Fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) A solution of (2R,7aS)-ethyl 2-fluoro-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-8-E-2) (82.0 g, 381 mmol) in THF (300 mL) was added to a mixture of LAH (21.7 g, 571 mmol) and THF (520 mL) at 0 °C under nitrogen. The reaction mixture was warmed to 70 °C and stirred for 3 h. The reaction mixture was cooled to 0 °C and quenched by the addition of Na2SO4·10H2O at 0 °C under nitrogen. The reaction mixture was stirred at 20 °C for 0.5 h and then filtered. The filter cake was washed with EtOAc (600 mL × 5) and the filtrate was dried over anhydrous Mg2SO4. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The crude residue was purified by silica gel column chromatography (SiO2, DCM:methanol=100:1 to 10:1) to give the title compound. 1 H NMR (400MHz, CDCl3): δ 5.06-5.34(m,1H),3.25(s,2H),3.08-3.23(m,3H),2.85-3.08(m,2H),2.00-2.12(m,2H),1.74-1.93(m,4H).
[0159] Intermediate 9: ((3S,7aS)-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-9) [ka]
[0160] Step A: 2-(but-3-en-1-yl)pyrrolidine-1,2-dicarboxylate 1-benzyl 2-methyl (Int-9-A) To a stirred solution of (S)-pyrrolidine-1,2-dicarboxylate 1-benzyl 2-methyl (38 g, 144 mmol) in THF (200 mL) was added LiHMDS (216 mL, 216 mmol) at -78 °C under nitrogen and the reaction was stirred at -78 °C for 1 h under N2 atmosphere. 4-Bromobut-1-ene (39.0 g, 289 mmol) was then added at -78 °C and the reaction was stirred at 25 °C for 2 h under nitrogen atmosphere. The mixture was quenched with aqueous saturated NH4Cl (300 mL), extracted with EtOAc (200 mL x 3), and the organic layer was washed with NaCl (aqueous saturated, 200 mL), dried over Na2SO4, and concentrated under vacuum. The residue was purified by flash silica gel chromatography (eluted with a gradient of 0 to 30% ethyl acetate in hexanes) to give the title compound. MS (ESI) [M+H] + m / z 318.
[0161] Step B: 2-(2-(oxiran-2-yl)ethyl)pyrrolidine-1,2-dicarboxylate 1-benzyl 2-methyl (Int-9-B) To a solution of 1-benzyl 2-methyl 2-(but-3-en-1-yl)pyrrolidine-1,2-dicarboxylate (Int-9-A) (27 g, 85 mmol) in DCM (500 mL) was added m-CPBA (45.9 g, 213 mmol) (80%) and the resulting mixture was stirred at 20 °C for 2 h. The reaction was filtered and the filtrate was washed with Na2SO3 (aqueous saturated, 100 mL) and brine (aqueous saturated, 100 mL). The organic layer was dried over Na2SO4, filtered, and the filtrate was purified by flash silica gel chromatography (eluting with a gradient of 0 to 20% ethyl acetate in hexanes) to give the title compound. MS (ESI) m / z 334.
[0162] Step C: Methyl 3-(hydroxymethyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-9-C) To a solution of 1-benzyl 2-methyl 2-(2-(oxiran-2-yl)ethyl)pyrrolidine-1,2-dicarboxylate (Int-9-B) (24 g, 72.0 mmol) in MeOH (500 mL) was added Pd-C (3.83 g, 3.60 mmol, 10% wt) and the resulting mixture was stirred at 20° C. for 3 h. The reaction was filtered, washed with MeOH (200 mL) and the filtrate was concentrated under reduced pressure to give the title compound, which was used directly in the next step. MS (ESI) [M+H] + : m / z 200.
[0163] Step D: Methyl trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-9-D-2) To a solution of methyl 3-(hydroxymethyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-9-C) (14 g, 70.3 mmol) in DCM (30 mL) was added imidazole (9.57 g, 141 mmol) and TBDPS-Cl (21.7 mL, 84 mmol), and the resulting mixture was stirred at 20° C. for 1 h. The reaction was filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with ethyl acetate / hexanes) to give the title compound (Int-9-D-2, second eluting isomer, trans). MS (ESI) [M+H] + : m / z 438.
[0164] Step E: (3S,7aS)-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate methyl (Int-9-E-2) A mixture of methyl trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (Int-9-D-2) (11.5 g, 26.3 mmol) was separated by preparative SFC (column F; 20% EtOH containing 0.1% NH4OH) to give the title compound (Int-9-E-2, second eluting isomer). MS(ESI)[M+H] + : m / z 438.
[0165] Step F: ((3S,7aS)-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-9) To a solution of (3S,7aS)-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (4.2 g, 9.6 mmol, Int-9-E-2) in THF (60 mL) was added LiAlH4 (0.546 g, 14.39 mmol) in portions at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched with Na2SO4·10H2O (10 g) and diluted with EtOAc (50 mL). The reaction mixture was filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (eluting with 10% isocratic methanol in DCM) to give ((3S,7aS)-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-9). MS(ESI)[M+H] + m / z:410.
[0166] Intermediate 10: (R)-(1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methanol hydrochloride (Int-10) [ka]
[0167] Step A: 2-[(acetyloxy)methyl]prop-2-en-1-yl acetate (Int-10-A) A 5 L 4-neck round bottom flask was charged with 3-chloro-2-(chloromethyl)prop-1-ene (600.g, 4.80 mol), triethylamine (1.46 kg, 14.4 mol) and acetic acid (721 g, 12.0 mol). The resulting solution was stirred overnight at 70° C. The reaction mixture was cooled to room temperature and quenched by the addition of 3 L of water. The resulting solution was extracted with ethyl acetate (3×1 L) and the combined organic layers were washed with brine (2×1 L). The organic layer was dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column with ethyl acetate / petroleum ether (1:6) to give 2-[(acetyloxy)methyl]prop-2-en-1-yl acetate (Int-10-A).
[0168] Step B: [1-[(acetyloxy)methyl]-2,2-difluorocyclopropyl]methyl acetate (Int-10-B) In a 20 L 4-neck round bottom flask, a solution of 2-[(acetyloxy)methyl]prop-2-en-1-yl acetate (Int-10-A) (600.g, 3.48 mol) in diglyme (5 L) was placed under an inert atmosphere of nitrogen. Then, a solution of ClCF2CO2Na (2.65 kg, 17.4 mol) in diglyme (5 L) was added dropwise with stirring at 180° C. over 5 hours. The resulting solution was stirred at 180° C. for 1 hour. The reaction mixture was cooled to room temperature and quenched by the addition of H2O (5 L). The resulting solution was extracted with petroleum ether (4×2 L) and the organic layers were combined. The combined organic layers were washed with water (3×2 L) and dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was concentrated to dryness to give [1-[(acetyloxy)methyl]-2,2-difluorocyclopropyl]methyl acetate (Int-10-B), which was used directly in the next step without further purification.
[0169] Step C: [2,2-Difluoro-1-(hydroxymethyl)cyclopropyl]methanol (Int-10-C) In a 20 L 4-neck round bottom flask was placed [1-[(acetyloxy)methyl]-2,2-difluorocyclopropyl]methyl acetate (Int-10-B) (800 g, 3.60 mol), MeOH (10 L) and K2CO3 (995 g, 7.20 mol). The resulting solution was stirred overnight at room temperature. The solids were filtered off. The filtrate was concentrated. The resulting mixture was then diluted by addition of water (2 L). The resulting solution was extracted with ethyl acetate (5 x 1 L). The organic layers were combined and dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography using ethyl acetate / petroleum ether (1:1) to give [2,2-difluoro-1-(hydroxymethyl)cyclopropyl]methanol (Int-10-C). 1 H NMR(300MHz,DMSO-d6)δ 1.30(t,J=9Hz,2H),3.52(m,4H),4.79(t,J=5.6Hz,2H).
[0170] Step D: (1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-D) A 500 mL single-neck round-bottom flask fitted with a nitrogen inlet adapter was purged with nitrogen and then charged with sodium hydride (4.52 g, 113 mmol) and N,N-dimethylformamide (100 mL). The suspension was cooled to 0° C. Solid [2,2-difluoro-1-(hydroxymethyl)cyclopropyl]methanol (Int-10-C) (12.0 g, 87 mmol) was added in portions. The mixture was allowed to warm to room temperature with stirring for 1 h. The resulting reaction mixture was cooled to 0° C. and treated with a solution of benzyl bromide (10.3 mL, 87 mmol) in N,N-dimethylformamide (10 mL). The mixture was stirred at room temperature for 1 h and then treated with aqueous saturated ammonium chloride (10 mL) and water (10 mL). The mixture was partitioned between ethyl acetate (75 mL) and water (75 mL). The organic layer was washed with 1 wt% aqueous LiCl (30 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Purification by column chromatography on silica gel (EtOAc in hexanes, gradient from 0 to 40%) gave (1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-D). 1H NMR (499 MHz, methanol-d4) δ 7.39-7.32 (m, 4H), 7.32-7.26 (m, 1H), 4.62-4.49 (m, 2H), 3.79-3.64 (m, 3H), 3.60 (dd, J = 10.4, 2.1 Hz, 1H), 1.35 (dddd, J = 29.1, 12.5, 8.0, 4.5 Hz, 2H).
[0171] Step E: (R)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-E-1) and (S)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-E-2) Racemic (1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-D) was resolved using SFC chiral chromatography (column B; containing 5% MeOH, 0.1% NH4OH and 5% HO) to give (R)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-E-1, peak 1) and (S)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-E-2, peak 2). (Int-10-E-1, peak 1) 1 H NMR (499MHz, methanol-d4) δ 7.39-7.26 (m, 5H), 4.58-4.51 (m, 2H), 3.78-3.67 (m, 3H), 3.60 (dd, J = 10.4, 2.0Hz, 1H), 1.35 (dddd, J = 28.4, 12.5, 8.0, 4.5Hz, 2H). (Int-10-E-2 peak 2) 1 H NMR(400MHz,CDCl3)δ 7.42-7.29(m,5H),4.63-4.51(m,2H),3.87-3.76(m,2H),3.69(d,J=2.0Hz,2H),2.40(t ,J=6.1Hz,1H),1.39(ddd,J=4.5,8.0,12.5Hz,1H),1.28(ddd,J=4.3,7.9,12.4Hz,1H).
[0172] Step F: (S)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methyl methanesulfonate (Int-10-F-1) (R)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-10-E-1) (3.25 g, 14.24 mmol) in DCM (30 mL) was cooled to 0° C. and treated with triethylamine (7.94 mL, 57.0 mmol) followed by a solution of methanesulfonyl chloride (2.22 mL, 28.5 mmol) in DCM (2.2 mL). The reaction mixture was allowed to warm to room temperature with stirring over 3 h. The reaction mixture was purified by column chromatography on silica gel (eluting with a gradient of ethyl acetate in hexanes, 0 to 100%) to give (S)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methyl methanesulfonate (Int-10-F-1). MS (ESI): m / z (M+Na) + 329.
[0173] Step G: (R)-1-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)-N,N-dimethylmethanamine (Int-10-G-1) (S)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methyl methanesulfonate (Int-10-F-1) (4.10 g, 13.4 mmol) and dimethylamine (2M in THF) (33.5 mL, 66.9 mmol) were treated with potassium carbonate (3.70 g, 26.8 mmol). The flask was capped and heated at 50° C. for 24 h. The reaction mixture was cooled to room temperature, diluted with water (20 mL) and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated. The crude residue was purified by column chromatography on silica gel (eluting with a gradient of 0 to 100% EtOH / EtOAc in hexanes (1:3)) to give (R)-1-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)-N,N-dimethylmethanamine (Int-10-G-1). MS(ESI):m / z(M+H) + 256.
[0174] Step H: (R)-(1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methanol hydrochloride (Int-10) (R)-1-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)-N,N-dimethylmethanamine (Int-10-G-1) (2.96 g, 11.6 mmol) and Pd / C (10 wt%, wet loaded) (0.618 g, 0.580 mmol) in 2,2,2-trifluoroethanol (20.0 mL) were placed in a 100 mL eggplant flask and stirred at room temperature under hydrogen gas (1 atm, balloon) for 20 h. The mixture was filtered through a Celite™ pad and the pad was rinsed with methanol (3×10 mL). The combined filtrate and washings were treated with 3 M HCl in methanol (12 mL, 36.0 mmol) and then concentrated under reduced pressure to give a clear, colorless, viscous syrup. Diethyl ether (10 mL) was added and the mixture was swirled to initiate precipitation. The mixture was concentrated in vacuo, then treated with diethyl ether (10 mL) and sonicated for 1 min. The diethyl ether was decanted. The solid was dried under vacuum to give the title compound (Int-10). MS (ESI): m / z (M+H) + 166.
[0175] Intermediate 11: 2,4-dichloro-6,8-difluoroquinazoline (Int-11) [ka]
[0176] Step A: 6,8-Difluoroquinazoline-2,4(1H,3H)-dione (Int-11-A) Sodium hydroxide (67.9 g, 1.70 mol) was dissolved in H2O (2.10 L) in a 5 L 3-neck round bottom flask at 20 °C. To this mixture was added 2-amino-3,5-difluorobenzoic acid (210 g, 1.21 mol) at 20 °C. The resulting mixture was stirred at 35 °C for 1 h. To this mixture was added sodium isocyanate (173 g, 2.67 mol) at 35 °C and the mixture was stirred until the solids were completely dissolved. The resulting mixture was stirred at 35 °C for 1 h. To this mixture was added HCl (6 M, 1.01 L, 6.06 mol) dropwise at 30-35 °C for 1 h to maintain the pH at 6-7. NaOH (146 g, 3.64 mol) was then added at 25 °C for 1 h. The resulting mixture was stirred at 25 °C for 9 h. To this mixture was added HCl (12N) dropwise at 20-25°C to maintain the pH at about 1-2. Acetone (1.2 L) was added to this mixture and the mixture was stirred at 25°C for 1 hour. The precipitate was removed by filtration and the filter cake was washed with acetone (500 mL). Methanol (1.2 L) was added to the filtrate and the mixture was stirred at 25°C for 1 hour. The product was obtained by collecting the precipitate to give 6,8-difluoroquinazoline-2,4(1H,3H)-dione (Int-11-A). 1 H NMR(400MHz DMSO-d6)δ 11.54(s,1H),11.34(s,1H),7.71-7.72(m,1H),7.46-7.49(m,1H).
[0177] Step B: 2,4-Dichloro-6,8-difluoroquinazoline (Int-11) A 5 L 3-neck round bottom flask was charged with 6,8-difluoroquinazoline-2,4(1H,3H)-dione (Int-11-A) (166 g, 838 mmol) and POCl3 (1.03 kg, 6.70 mol) at 20° C. The resulting mixture was cooled to 10° C. and DIPEA (324 g, 2.51 mol) was added. The reaction mixture was stirred at 100° C. for 3 h. The reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in EtOAc (1 L) and washed with saturated NaHCO3 (1 L). The organic layer was washed with brine (300 mL×2), dried over Na2SO4, and filtered. The filtrate was concentrated to dryness in vacuo. The residue was triturated with MTBE (300 mL) at 25° C. for 30 min. The mixture was filtered and the solid was collected to give 2,4-dichloro-6,8-difluoroquinazoline (Int-11). 1 H NMR(400MHz DMSO-d6)δ 8.24-8.29(m,1H),7.97-7.99(m,1H).
[0178] Intermediate 12: 4-Bromo-6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazole (Int-12) [ka]
[0179] Step A: 1-Bromo-5-fluoro-2-iodo-3-methylbenzene (Int-12-A) 2-Bromo-4-fluoro-6-methylaniline (200.g, 0.983mol) was dissolved in MeCN (800mL). The resulting mixture was cooled to 0°C. Concentrated HCl (12M, 245mL) was added into the reaction mixture while maintaining the reaction temperature at 0°C. A solution of NaNO2 (81.1g, 1.18mol equiv) in water (400mL) was added dropwise into the reaction mixture while maintaining the reaction temperature at 0°C. The resulting mixture was stirred for 0.5h at 0°C. Then a solution of KI (195g, 1.18mol) in water (400mL) was added dropwise into the reaction mixture at 0°C. The resulting mixture was allowed to warm to room temperature and stirred for 12h at 20°C. The resulting mixture was adjusted to pH 8-9 by aqueous NaOH and the aqueous layer was extracted with EtOAc (2.00L x 2). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (EtOAc in hexanes, gradient from 0 to 100%) to give 1-bromo-5-fluoro-2-iodo-3-methylbenzene (Int-12-A). 1 H NMR(400MHz,CDCl3)δ 7.27-7.22(m,1H),6.95(dd,J=2.4,8.8Hz,1H),2.56(s,3H).
[0180] Step B: 1-Bromo-5-fluoro-3-methyl-2-(trifluoromethyl)benzene (Int-12-B) 1-Bromo-5-fluoro-2-iodo-3-methylbenzene (Int-12-A) (100 g, 0.317 mol) was dissolved in DMF (1.50 L). To this mixture was added CuI (514 g, 2.70 mol) and 2,2-difluoro-2-(fluorosulfonyl)methyl acetate (518 g, 2.70 mol) at 25° C. The reaction mixture was heated and stirred at 60° C. for 12 h. The reaction was repeated using the above conditions in three more batches. The four reaction batches were combined and quenched with water (24.0 L). The mixture was extracted with petroleum ether (8.00 L×2). The combined organic layers were washed with brine (4.00 L×2) and dried over Na2SO4. The dried solution was filtered and the filtrate was concentrated in vacuo to give the crude material containing 1-bromo-5-fluoro-3-methyl-2-(trifluoromethyl)benzene (Int-12-B).
[0181] Step C: 2-Bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde (Int-12-C) 1-Bromo-5-fluoro-3-methyl-2-(trifluoromethyl)benzene (Int-12-B) (100 g, 0.382 mol) was dissolved in 2-MeTHF (500 mL). The reaction mixture was cooled to -65 °C. A 2M solution of LDA (213 mL, 426 mmol) was added to the mixture at -65 °C. The reaction mixture was stirred for 0.5 h at -65 °C. DMF (31.2 g, 0.420 mol) was added dropwise to the mixture at -65 °C. The reaction mixture was stirred for 2 h at -65 °C. The pH of the reaction mixture was adjusted to 3-4 by using 1 M HCl, and the aqueous layer was extracted with 2-MeTHF (500 mL x 2). The organic layer was dried over Na2SO4, filtered and concentrated to give 2-bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde (Int-12-C).
[0182] Step D: 4-Bromo-6-methyl-5-(trifluoromethyl)-1H-indazole (Int-12-D) 2-Bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde (Int-12-C) (100 g, 0.351 mol) was dissolved in THF (800 mL). To this mixture was added N2H4·H2O (53.7 g, 1.05 mol) at 25° C. The mixture was heated and stirred at 60° C. for 2 h. The resulting mixture was quenched with water (400 mL) and extracted with EtOAc (200 mL×2). The combined organic layers were washed with brine (200 mL) and dried over Na2SO4. The dried solution was filtered and the filtrate was concentrated in vacuo to give a residue. The resulting residue was triturated with DCM (100 mL) at 15° C. for 2 h. The solid was collected by filtration to give 4-bromo-6-methyl-5-(trifluoromethyl)-1H-indazole (Int-12-D). 1 H NMR(400MHz,CDCl3)δ 10.61-10.20(m,1H),8.20(d,J=0.8Hz,1H),7.34(d,J=0.6Hz,1H),2.67-2.63(m,3H).
[0183] Step E: 4-Bromo-6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazole (Int-12) 4-Bromo-6-methyl-5-(trifluoromethyl)-1H-indazole (Int-12-D) (60.0 g, 0.215 mol) was dissolved in DCM (240 mL) / MeCN (240 mL). To this mixture was added DHP (21.7 g, 0.258 mol) and TsOH·H2O (8.18 g, 0.043 mol) at 20°C. The reaction mixture was stirred for 12 h at 20°C. To the resulting mixture was added water (200 mL). The resulting mixture was extracted with DCM (200 mL x 2). The combined organic layers were washed with brine (200 mL) and dried over Na2SO4. The dried solution was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=1:0 to 0:1) to give 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazole (Int-12). 1H NMR(400MHz,CDCl3-d)δ 8.12(s,1H),7.44(s,1H),5.69(dd,J=3,9Hz,1H),4.09-3.94(m,1H),3.81-3.69(m,1H),2.69-2.63(m ,3H),2.56-2.43(m,1H),2.19-2.14(m,1H),2.12-2.04(m,1H),1.87-1.73(m,2H),1.71-1.63(m,1H).
[0184] Intermediate 13: ((2-Fluoro-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (Int-13) [ka]
[0185] Step A: 7-Fluoronaphthalen-1-ol (Int-13-A) To a stirred solution of 7-fluoro-3,4-dihydronaphthalen-1(2H)-one (5.00 g, 30.5 mmol) in AcOH (100 mL) / HBr (0.375 mL, 2.279 mmol, 33% in AcOH) was added Br2 (1.726 mL, 33.5 mmol) in AcOH (3 mL) at 0 °C. The mixture was stirred at 25 °C for 3 h. Upon completion, the reaction mixture was diluted with DCM (300 mL) and washed with water (30 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in DMF (100 mL) and lithium carbonate (3.83 g, 51.8 mmol) and lithium bromide (4.50 g, 51.8 mmol) were added to the solvent. The resulting mixture was stirred at 165 °C for 3 h. The reaction mixture was diluted with EtOAc (300 mL) and washed with brine (aqueous saturated, 50 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluted with a gradient of 0 to 100% ethyl acetate in hexanes) to give 7-fluoronaphthalen-1-ol (Int-13-A). 1H NMR(400MHz,CDCl3)δ 7.86-7.71(m,2H),7.42(d,J=8.3Hz,1H),7.26-7.22(m,2H),6.82(d,J=7.6Hz,1H).
[0186] Step B: 7-Fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-ol (Int-13-B) To a solution of 7-fluoronaphthalen-1-ol (Int-13-A) (7.00 g, 43 mmol) in DCE (70 mL) was added (bromoethynyl)triisopropylsilane (13.5 g, 51.8 mmol), potassium carbonate (5.97 g, 43.2 mmol), sodium acetate (0.708 g, 8.63 mmol) and dichloro(p-cymene)ruthenium(II) dimer (3.97 g, 6.47 mmol) at 25° C. under N2 atmosphere and the mixture was stirred at 40° C. for 16 h. The reaction mixture was diluted with DCM (100 mL) and the resulting mixture was filtered. The filtrate was concentrated in vacuo and the residue was purified by flash silica gel chromatography (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to give 7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-ol (Int-13-B). 1 H NMR(400MHz,CDCl3)δ 9.07(s,1H),7.76(dd,J=5.9,9.0Hz,1H),7.39-7.28(m,2H),7.20(t,J=8.8Hz,1H),7.07-6.96(m,1H),1.20-1.13(m,21H).
[0187] Step C: 7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl trifluoromethanesulfonate (Int-13-C) To a solution of 7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-ol (Int-13-B) (10.6 g, 30.9 mmol) in DCM (100 mL) was added DIEA (16.2 mL, 93 mmol) and TfO (7.84 mL, 46.4 mmol) at −40° C., and the mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated in vacuo, and the residue was purified by flash silica gel chromatography (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to give 7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl trifluoromethanesulfonate (Int-13-C). 1 H NMR(400MHz,CDCl3)δ 7.96-7.83(m,2H),7.58(br d,J=7.6Hz,1H),7.54-7.45(m,1H),7.45-7.35(m,1H),1.31-1.16(m,21H).
[0188] Step D: ((2-Fluoro-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (Int-13) To a solution of 7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl trifluoromethanesulfonate (Int-13-C) (4.6 g, 9.69 mmol) and bis(pinacolato)diboron (3.69 g, 14.5 mmol) in dioxane (50 mL) was added potassium acetate (1.903 g, 19.4 mmol) and PdCl2(dppf)-CHCl2 adduct (0.792 g, 0.969 mmol) at 25 °C, and the solution was stirred at 110 °C for 15 h under N2 atmosphere. The reaction mixture was diluted with EtOAc (50 mL) and the resulting mixture was filtered. The filtrate was concentrated in vacuo and the residue was purified by flash silica gel chromatography (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to give ((2-fluoro-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (Int-13). 1H NMR(400MHz,CDCl3)δ 7.84-7.72(m,3H),7.40(t,J=7.5Hz,1H),7.26-7.20(m,1H),1.42(s,12H),1.15(s,21H).
[0189] Intermediate 14: 2-(8-chloro-7-fluoronaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Int-14) [ka]
[0190] Step A: 8-chloro-7-fluoronaphthalen-1-ol (Int-14-A) To a solution of 1-bromo-3-chloro-2,4-difluorobenzene (5.00 g, 22.0 mmol) and furan (3.20 mL, 44.0 mmol) in toluene (100 mL) was added n-BuLi (16.1 mL, 26.4 mmol, 1.64 M in hexanes) at 20 °C. After the mixture was stirred at 20 °C to room temperature overnight, the reaction was quenched by addition of H2O, filtered, and concentrated in vacuo. The residue was dissolved in EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash silica gel chromatography (gradient of 0 to 60% EtOAc in hexanes) to give 5-chloro-6-fluoro-1,4-dihydro-1,4-epoxynaphthalene, which was redissolved in EtOH (40 mL). HCl (25.0 mL, 300 mmol, 12 M in water) was added. After stirring the mixture at 80° C. for 3 hours, the reaction mixture was cooled to room temperature and concentrated in vacuo The residue was purified by flash silica gel chromatography (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to give 8-chloro-7-fluoronaphthalen-1-ol (Int-14-A). 1 H NMR(500MHz,CDCl3)δ ppm 7.09(d,J=7Hz,1 H)7.25-7.32(m,1 H)7.36-7.44(m,2 H)7.75(dd,J=9,6Hz,1 H)7.92(s,1 H).
[0191] Step B: 8-chloro-7-fluoronaphthalen-1-yl trifluoromethanesulfonate (Int-14-B) To a solution of 8-chloro-7-fluoronaphthalen-1-ol (Int-14-A) (2.36 g, 12.0 mmol) in dichloromethane (20 mL) was added pyridine (2.13 mL, 26.4 mmol) and trifluoromethylsulfonic anhydride (2.62 mL, 15.6 mmol) at 0° C. After the mixture was stirred at 0° C. for 2 h, the reaction was quenched by the addition of water. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluted with a gradient of 0 to 100% ethyl acetate in hexanes) to give 8-chloro-7-fluoronaphthalen-1-yl trifluoromethanesulfonate (Int-14-B). 1 H NMR(500MHz,CDCl3)δ ppm 7.41-7.48(m,1 H)7.49-7.55(m,1 H)7.59(br d,J=8Hz,1 H)7.82-7.88(m,1 H)7.90(br d,J=8Hz,1 H).
[0192] Step C: 2-(8-chloro-7-fluoronaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Int-14) A mixture of 8-chloro-7-fluoronaphthalen-1-yl trifluoromethanesulfonate (Int-14-B) (200 mg, 0.609 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (309 mg, 0.122 mmol), KOAc (299 mg, 3.04 mmol) and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (49.7 mg, 0.0609 mmol) in DMF (2.0 mL) was stirred at 80° C. for 2 h. The reaction was quenched by the addition of water, and the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to give 2-(8-chloro-7-fluoronaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Int-14). 1 H NMR(400MHz,CDCl3)δ 7.85(dd,J=8.4,1.2Hz,1H),7.76(dd,J=9.2,5.6Hz,1H),7.70(d,J=6.8Hz, 1H),7.48(dd,J=8.0,8.0Hz,1H),7.33(dd,J=8.8,8.4Hz,1H),1.45(s,12H).
[0193] Intermediate 15: tert-Butyl (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinane-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15) [ka]
[0194] Step A: (6-Bromo-2,3-difluorophenyl)methanol (Int-15-A) To a solution of 6-bromo-2,3-difluorobenzaldehyde (5.00 g, 22.6 mmol) in MeOH (100 mL) was added sodium borohydride (5.00 g, 22.0 mmol) at 0° C. After the mixture was stirred at room temperature for 1 h, the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give (6-bromo-2,3-difluorophenyl)methanol (Int-15-A). 1 H NMR(400MHz,CDCl3)δ 7.37-7.31(m,1H),7.09-7.02(m,1H),4.86(dd,J=6.8,2.4Hz,2H),2.11(t,J=6.8Hz,1H).
[0195] Step B: 2-(6-bromo-2,3-difluorophenyl)acetonitrile (Int-15-B) To a solution of (6-bromo-2,3-difluorophenyl)methanol (Int-15-A) (3.00 g, 13.5 mmol) in THF (30 mL) was added N,N-diisopropylethylamine (2.81 mL, 16.1 mmol) and methanesulfonyl chloride (1.15 mL, 14.8 mmol) at 0 °C. After the mixture was stirred at room temperature for 15 h, the reaction mixture was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the benzyl chloride derivative, which was not further purified. To a solution of the benzyl chloride derivative in EtOH (30 mL) / H2O (6 mL) was added potassium cyanide (818 mg, 12.6 mmol). After the mixture was stirred at 80 °C for 1 h, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluted with a gradient of 0 to 100% ethyl acetate in hexanes) to give 2-(6-bromo-2,3-difluorophenyl)acetonitrile (Int-15-B). 1H NMR(400MHz,CDCl3)δ 7.43-7.38(m,1H),7.17-7.09(m,1H),4.89(d,J=2.0Hz,2H).
[0196] Step C: Ethyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15-C) To a solution of 2-(6-bromo-2,3-difluorophenyl)acetonitrile (Int-15-B) (2.00 g, 8.62 mmol) in DMF (20 mL) was added potassium tert-butoxide (1.02 g, 9.05 mmol) at 0° C. After the mixture was stirred at 0° C. for 10 min, ethoxycarbonyl isothiocyanate (1.07 mL, 9.05 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 1 h and then heated at 100° C. for 30 min. The mixture was then cooled to 0° C. and HO was added slowly with stirring. The resulting precipitate was collected by filtration, rinsed with HO and hexanes, and dried in vacuum to give ethyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15-C). ESI-MS m / z[MH] - 341, 343.
[0197] Step D: tert-Butyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15-D) To a solution of ethyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15-C) (2.51 g, 7.31 mmol) in DMSO (10 mL) was added a 5.0 M aqueous solution of NaOH (8.00 mL, 40.0 mmol). After stirring the mixture at 100° C. for 13 h, the mixture was then cooled to room temperature and H2O was added slowly with stirring. The resulting precipitate was collected by filtration, rinsed with H2O and hexanes, and dried in vacuum. The residue was redissolved in THF (40 mL) and treated with N,N-diisopropylethylamine (1.54 mL, 8.85 mmol), DMAP (36.0 mg, 0.295 mmol), and di-tert-butyl dicarbonate (1.42 g, 6.49 mmol). After the mixture was stirred at room temperature for 13 hours, HO was added to EtOAc, and the resulting precipitate was then collected by filtration, rinsed with HO and hexanes, and dried in vacuo to give tert-butyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate. The filtrate layer was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 0 to 10% MeOH in EtOAc) to give tert-butyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15-D). 1 H NMR(400MHz,CDCl3)δ 7.96(s,1H),7.54-7.49(m,1H),6.94-6.88(m,1H),1.59(s,9H).
[0198] Step E: tert-Butyl (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinane-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15) To a solution of tert-butyl (4-bromo-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15-D) (1.00 g, 2.69 mmol) and bis(neopentylglycolato)diboron (1.83 g, 8.08 mmol) in 1,4-dioxane (15 mL) was added potassium acetate (793 mg, 8.08 mmol). After the mixture was stirred at room temperature for 1 h, dichlorobis(diphenylphosphinophenyl)etherpalladium(II) (193 mg, 0.269 mmol) was added to the mixture, and the mixture was then heated at 100° C. for 2 h. The reaction mixture was cooled to room temperature and H2O was added. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 0 to 30% EtOAc in hexanes) to give tert-butyl (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (Int-15). 1 H NMR(400MHz,DMSO-d6)δ 11.6(s,1H),7.61-7.56(m,1H),7.22-7.15(m,1H),3.77(s,4H),1.52(s,9H),1.02(s,6H).
[0199] Intermediate 16: 4-Bromo-5-chloro-1-fluoro-2-(methoxymethoxy)naphthalene (Int-16) [ka]
[0200] Step A: 4-Bromo-5-chloro-1-fluoronaphthalen-2-ol (Int-16-A) To a solution of 1-bromo-8-chloro-3-(methoxymethoxy)naphthalene (200 mg, 0.663 mmol) in MeCN (2.0 mL) was added 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (470 mg, 1.33 mmol). After stirring the mixture at 60° C. for 2 h, the reaction was quenched by the addition of aqueous saturated NaHCO3. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give the fluorinated compound.
[0201] To a solution of the fluorinated compound in MeOH (2.2 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.428 mL, 3.32 mmol) and sodium tetrahydroborate (125 mg, 3.32 mmol) at 0° C. After the mixture was stirred at 50° C. for 30 min, the reaction was quenched by the addition of aqueous saturated NH4Cl. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient from 0 to 20% EtOAc in hexanes) to give 4-bromo-5-chloro-1-fluoronaphthalen-2-ol (Int-16-A). 1 H NMR(400MHz,CDCl3)δ7.95(ddd,J=8.4,1.2,1.2Hz,1H),7.71(d,J=8.6Hz,1H),7.56(d,J=7.5Hz,1H),7.39(dd,J=8.0,7.9Hz,1H),5.54(d,J=3.8Hz,1H).
[0202] Step B: 4-Bromo-5-chloro-1-fluoro-2-(methoxymethoxy)naphthalene (Int-16) To a solution of 4-bromo-5-chloro-1-fluoronaphthalen-2-ol (Int-16-A) (158 mg, 0.573 mmol) in dichloromethane (3.0 mL) was added N,N-diisopropylethylamine (2.96 mL, 17.0 mmol) and chloromethyl methyl ether (0.0871 mL, 1.15 mmol). After the mixture was stirred at room temperature for 15 min, the reaction was quenched by the addition of aqueous saturated NaHCO3. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 0 to 20% EtOAc in hexanes) to give 4-bromo-5-chloro-1-fluoro-2-(methoxymethoxy)naphthalene (Int-16). 1 H NMR(400MHz,CDCl3)δ 8.05(ddd,J=8.5,1.2,1.2Hz,1H),7.88(d,J=8.1Hz,1H),7.60(d,J=7.4Hz,1H),7.40(dd,J=8.2,7.8Hz,1H),5.30(s,2H),3.57(s,3H).
[0203] Intermediate 17: (R)-1-(7-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17) [ka]
[0204] Step A: 2-Chloro-3-fluoro-5-iodopyridin-4-amine (Int-17-A) To a solution of 2-chloro-3-fluoro-pyridin-4-amine (13.6 g, 92.8 mmol) and N-iodosuccinimide (25.1 g, 111 mmol) in acetonitrile (67 mL) was added p-toluenesulfonic acid monohydrate (883 mg, 4.64 mmol). The mixture was stirred at 70° C. for 17 h. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The organic layer was washed with saturated Na2CO3 solution, saturated Na2SO3 solution and brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was dried under reduced pressure for 4 h to give 2-chloro-3-fluoro-5-iodo-pyridin-4-amine (Int-17-A). ESI-MS m / z[M+H] + 273. 1 H NMR (400 MHz, methanol-d4) δ 8.08 (d, J = 0.8 Hz, 1H).
[0205] Step B: Ethyl 4-amino-6-chloro-5-fluoronicotinate (Int-17-B) To a solution of 2-chloro-3-fluoro-5-iodo-pyridin-4-amine (Int-17-A) (24.6 g, 90.3 mmol) and Pd(PPh3)2Cl2 (6.34 g, 9.03 mmol) in ethanol (492 ml) was added Et3N (45.4 ml, 326 mmol) under nitrogen atmosphere. The suspension was degassed under reduced pressure and purged with carbon monoxide several times. The mixture was stirred at 80° C. for 15 h under carbon monoxide atmosphere. The reaction mixture was cooled to room temperature, filtered, the filtrate was concentrated in vacuo to remove 70% of the ethanol, and the residue was filtered. The filter cake was dried under reduced pressure for 4 h to give ethyl 4-amino-6-chloro-5-fluoronicotinate (Int-17-B). ESI-MS m / z [M+H] + 219,221. 1 H NMR(400MHz,DMSO-d6)δ 8.38(s,1H),7.59(br s,2H),4.32(q,2H,J=7.0Hz),1.32(t,3H,J=7.1Hz). Step C: Ethyl 6-chloro-5-fluoro-4-(3-(2,2,2-trichloroacetyl)ureido)nicotinate (Int-17-C) To a solution of ethyl 4-amino-6-chloro-5-fluoronicotinate (Int-17-B) (8.44 g, 38.6 mmol) in THF (25 ml) was added 2,2,2-trichloroacetyl isocyanate (6.86 ml, 57.9 mmol) at 25° C. The mixture was stirred at room temperature for 10 min under nitrogen atmosphere. The reaction mixture was concentrated in vacuo. The residue was dried under reduced pressure for 4 h to give ethyl 6-chloro-5-fluoro-4-(3-(2,2,2-trichloroacetyl)ureido)nicotinate (Int-17-C). ESI-MS m / z[M+H] + 406. 1 H NMR(400MHz,DMSO-d6)δ 11.96(br s,1H),10.48(s,1H),8.64(s,1H),4.31(q,2H,J=7.1Hz),1.29(t,J=7.1Hz,3H).
[0206] Step D: 7-Chloro-8-fluoropyrido[4,3-d]pyrimidine-2,4(1H,3H)-dione (Int-17-D) To a solution of ethyl 6-chloro-5-fluoro-4-(3-(2,2,2-trichloroacetyl)ureido)nicotinate (Int-17-C) (15.7 g, 38.6 mmol) in methanol (157 ml) was added 7 M ammonia in methanol (16.5 ml, 116 mmol) at 25° C. The mixture was stirred at 25° C. for 1 h under nitrogen atmosphere. The reaction mixture was concentrated in vacuo. The residue was dried under reduced pressure for 4 h to give 7-chloro-8-fluoropyrido[4,3-d]pyrimidine-2,4(1H,3H)-dione (Int-17-D). ESI-MS m / z[M+H] + 216. 1 H NMR(400MHz,DMSO-d6)δ 8.32(s,1H).
[0207] Step E: 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (Int-17-E) To a solution of 7-chloro-8-fluoropyrido[4,3-d]pyrimidine-2,4(1H,3H)-dione (Int-17-D) (6.0 g, 27.8 mmol) in POCl3 (59.1 ml) was added diisopropylethylamine (38.1 ml, 223 mmol) at 25° C. The mixture was stirred at 100° C. for 1 h under nitrogen atmosphere. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was azeotroped with toluene and dried under reduced pressure for 4 h to give 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (Int-17-E). ESI-MS m / z[M+H] + 252.
[0208] Step F: (R)-1-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17-F) To a solution of 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (Int-17-E) (3.5 g, 13.9 mmol) in N,N-dimethylacetamide (35 ml) was added (3R)-3-methylpiperidin-3-ol (1.89 g, 12.5 mmol) and diisopropylethylamine (24.1 ml, 139 mmol) at -20°C. The mixture was stirred at -20°C for 0.5 h under nitrogen atmosphere. The reaction mixture was diluted with water and ethyl acetate. The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash silica chromatography (eluent 12 to 100% EtOAc in hexanes) to give (R)-1-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17-F). ESI-MS m / z [M+H] + 331. 1 H NMR(400MHz,DMSO-d6)δ 9.19(s,1H),4.74(br s,1H),4.47(br d,1H,J=12.5Hz),4.12(d,1H,J=13.4Hz),3.58(d,J=13.4Hz,1H),3.26-3.29(m,1H),1.90-2.03(m,1H),1.60-1.73(m,3H),1.16(s,3H).
[0209] Step G: (R)-1-(7-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17) To a solution of (R)-1-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17-F) (300 mg, 0.91 mmol) and (1-((dimethylamino)methyl)cyclopropyl)methanol (234 mg, 1.81 mmol) in 1,4-dioxane (4.5 ml) was added diisopropylethylamine (473 μl, 2.72 mmol) at room temperature. The mixture was stirred at 80° C. for 6 hours under nitrogen atmosphere. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash NH-silica chromatography (eluent, 12 to 100% EtOAc in hexanes) and reverse-phase HPLC (MeCN / water with 0.1% formic acid) to give (R)-1-(7-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17). ESI-MS m / z[M+H]+424. 1 H NMR(400MHz,CDCl3)δ 8.88(s,1H),4.33-4.42(m,4H),3.36-3.43(m,1H),3.25(d,1H,J=13.5Hz),2.77(br s,1H),2.29-2.38(m,2H),2.25(s,6 H),1.97-2.09(m,1H),1.86-1.90(m,1H),1.62-1.75(m,2H),1.33(s,3H),0.64-0.74(m,2H),0.42-0.52(m,2H).
[0210] Intermediate 18: (R)-1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18) [ka]
[0211] Step A: (R)-1-(7-bromo-2-chloro-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18-A) To a solution of 7-bromo-2,4-dichloro-8-fluoroquinazoline (200 mg, 0.676 mmol) and (R)-3-methylpiperidin-3-ol hydrochloride (108 mg, 0.676 mmol) in DMF (3.0 mL) was added N,N-diisopropylethylamine (0.471 mL, 2.70 mmol) at room temperature. After the mixture was stirred at room temperature for 30 min, the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give (R)-1-(7-bromo-2-chloro-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18-A). ESI-MS m / z[M+H] + 374,376,378.
[0212] Step B: (R)-1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18) To a solution of (R)-1-(7-bromo-2-chloro-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18-A) (190 mg, 0.507 mmol) and (1-((dimethylamino)methyl)cyclopropyl)methanol (112 mg, 0.867 mmol) in DMF (5.0 mL) was added cesium carbonate (496 mg, 1.52 mmol) and 1,4-diazabicyclo[2.2.2]octane (11.4 mg, 0.101 mmol) at room temperature. After the mixture was stirred at room temperature for 13 h, the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash NH-silica gel chromatography (gradient of 20 to 50% EtOAc in hexanes) to give (R)-1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18). ESI-MS m / z[M+H] + 467,469.
[0213] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Int-18, making appropriate substitutions of starting materials, intermediates and / or reagents, where the appropriate replacement materials are either commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 3]
[0214] Intermediate 22: 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline (Int-22) [ka]
[0215] Step A: 2-Amino-4-bromo-5-chloro-3-fluorobenzoic acid (Int-22-A) In a 10 L 4-neck round bottom flask were added 2-amino-4-bromo-3-fluorobenzoic acid (700 g, 2.99 mol), THF (7.0 L) and DMSO (93.5 g, 1.20 mol). NCS (799 g, 5.98 mol) was then added in several batches at 25° C. The resulting solution was stirred overnight at room temperature. The reaction was then quenched by the addition of 7 L of saturated NaCl (aq). The resulting solution was extracted with ethyl acetate (2×2 L), the organic layer was washed with water (3×1 L) and dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The resulting residue was triturated in petroleum ether:ethyl acetate=10:1 (5 L) for 1 hour. The solid was collected by filtration to give 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid (Int-22-A), which was used directly in the next step without further purification.
[0216] Step B: 7-Bromo-6-chloro-8-fluoroquinazoline-2,4(1H,3H)-dione (Int-22-B) A 2 L 4-neck round bottom flask was charged with 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid (Int-22-A) (100 g, 372 mmol) and urea (112 g, 1.86 mol). The resulting solution was stirred at 200° C. for 2 hours. The reaction mixture was cooled to 25° C., and the reaction solidified. This reaction was repeated with six more batches using the above conditions. The seven reaction batches were combined and the solid mass was crushed to give a crude mixture of 7-bromo-6-chloro-8-fluoroquinazoline-2,4(1H,3H)-dione (Int-22-B), which was used directly in the next step without further purification.
[0217] Step C: 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline (Int-22) A 3 L 4-neck round bottom flask was charged with 7-bromo-6-chloro-8-fluoroquinazoline-2,4(1H,3H)-dione (Int-22-B) (290 g, 0.980 mol) and POCl3 (1.51 kg, 9.86 mol). DIEA (382 g, 2.96 mol) was then added dropwise with stirring at 25° C. The resulting solution was stirred at 100° C. for 2 h. The reaction was repeated in two more batches using the above conditions. The three reaction batches were combined and concentrated. The residue was purified by silica gel column eluted with petroleum ether:ethyl acetate=10:1. The crude product was slurried in petroleum ether:ethyl acetate=5:1 (1 L). The solid was collected by filtration to give 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (Int-22). 1 H NMR(300MHz,CDCl3,ppm):δ 8.227(s,1H).
[0218] Intermediate 23: (R)-1-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23) [ka]
[0219] Step A: (R)-1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23-A) To a solution of 2,4-dichloro-6,8-difluoroquinazoline (Int-11) (350 mg, 1.49 mmol) in 1,4-dioxane (8.00 ml) was added (R)-3-methylpiperidin-3-ol (226 mg, 1.49 mmol) followed by N-ethyl-N-isopropylpropan-2-amine (1.04 ml, 5.96 mmol). The reaction mixture was stirred at room temperature for 25 minutes. The reaction was then cooled to room temperature and diluted with DCM and water. The organic layer was shaken and then separated. The organic layer was concentrated. The resulting residue was purified by silica gel column chromatography (gradient of 0 to 10% ethyl acetate in hexanes) to give (R)-1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23-A). MS (ESI): m / z (M+H) + 314.
[0220] Step B: (R)-1-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23) To a solution of (R)-1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23-A) (315 mg, 1.00 mmol) in 1,4-dioxane (6.00 ml) was added ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) (176 mg, 1.10 mmol), cesium carbonate (818 mg, 2.51 mmol) and RuPhos Pd G2 (78 mg, 0.100 mmol). The reaction mixture was stirred at 80° C. for 3 hours. It was then cooled to room temperature, quenched with water and extracted with EtOAc. The combined extracts were washed with saturated brine and concentrated. The product was purified by silica gel column chromatography using 100% EtOAc in hexanes to give (R)-1-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23). MS (ESI): m / z (M+H) + 437.
[0221] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Int-23, making appropriate substitutions of starting materials, intermediates and / or reagents, where the appropriate replacements are either commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 4]
[0222] Intermediate 25: (R)-1-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-25) [ka]
[0223] A solution of (R)-1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23-A) (1000 mg, 3.19 mmol) in tetrahydrofuran (15.0 ml) was cooled to −78° C. under nitrogen bubbler and treated with LDA (2M in THF / heptane / ethylbenzene, 4.8 ml, 9.6 mmol). The mixture was stirred at −78° C. for 30 minutes to give a red solution. This mixture was treated at −78° C. with a solution of 1,2-dibromotetrafluoroethane (1.14 ml, 9.56 mmol) in tetrahydrofuran (2.00 ml). The mixture was stirred at −78° C. for 30 minutes and then quenched at −78° C. with aqueous saturated ammonium chloride (1 ml). The mixture was allowed to warm to room temperature, diluted with water (1 ml) and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Purification by column chromatography on silica gel (gradient of 0 to 100% EtOAc in hexanes) afforded the title compound (Int-25). MS (ESI): m / z (M+H) + 392,394 1 H NMR(500MHz,acetone-d6)δ 8.07(d,J=9.6Hz,1H),4.42(d,J=13.2Hz,1H),4.19(d,J=13.5Hz,1H),3.96(s,1H),3.50(d,J=13.5H z,1H),3.34-3.24(m,1H),2.25-2.14(m,1H),1.85(t,J=9.8Hz,1H),1.80-1.70(m,2H),1.28(s,3H).
[0224] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Int-25, making appropriate substitutions of starting materials, intermediates and / or reagents, where the appropriate replacement materials are either commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 5]
[0225] Intermediate 27: 7-(5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-ol (Int-27) [ka]
[0226] Step A: 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-27-A) A solution of 2,4-dichloro-6,8-difluoroquinazoline (Int-11) (2.00 g, 8.51 mmol) in anhydrous THF (42 mL) was cooled in an ice bath under nitrogen. Sodium tert-butoxide (4.7 mL of a 2.0 M solution in THF, 9.4 mmol) was then added. After stirring in the ice bath for 72 min, additional sodium tert-butoxide (0.63 mL of a 2.0 M solution in THF, 1.26 mmol) was added. After stirring for an additional 18 min, the mixture was concentrated by rotary evaporation. The residue was extracted with DCM (20 mL), filtered, and concentrated by rotary evaporation. The residue was extracted with DCM (8 mL), filtered, and the filtrate was purified by silica gel column chromatography (90% hexanes and 10% DCM, gradient to 100% DCM) to give 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-27-A). MS (ESI): m / z (M+H-tBu). + 217.1. 1 H NMR(500MHz,CDCl3)δ 7.53-7.47(m,1H),7.32(td,J=9.5,2.7Hz,1H),1.75(s,9H).
[0227] Step B: (R)-4-(tert-butoxy)-6,8-difluoro-2-((1-((3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (Int-27-B) To a suspension of 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-27-A) (14.17 g, 52.0 mmol) in anhydrous 1,4-dioxane (139 mL) was added a solution of (R)-(1-((3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methanol (6.0 g, 35 mmol) in anhydrous 1,4-dioxane (14 mL) along with additional anhydrous 1,4-dioxane (20 mL). To this mixed suspension was added lithium 2-methylpropan-2-olate (38 mL, 1.0 M solution in THF, 38 mmol). The mixture was stirred at 100° C. under nitrogen atmosphere for 3 h 42 min and then left at 4° C. for 20.5 h. The mixture was diluted with EtOAc (170 mL) and washed with aqueous saturated NaHCO3 (170 mL). The separated aqueous layer was extracted twice with EtOAc / MeOH (50 mL / 1 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (0 to 10% EtOAc in hexanes, both phases containing 0.5% triethylamine) and then again by silica gel column chromatography (1.5% triethylamine in hexanes) to give (R)-4-(tert-butoxy)-6,8-difluoro-2-((1-((3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (Int-27-B). MS (ESI): m / z (M+H) + 410.2.
[0228] Step C: 4-(tert-butoxy)-7-(5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (Int-27-C) To (R)-4-(tert-butoxy)-6,8-difluoro-2-((1-((3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (Int-27-B) (1.75 g, 4.27 mmol) was added bis(2,2,6,6-tetramethylpiperidin-1-yl)zinc, complex with MgCl2 and LiCl (0.13 M solution in THF / toluene, Aldrich catalogue no. 748188-100ML, 36 mL, 4.7 mmol). The solution was heated with stirring for 1 hour 21 minutes at 40° C. and then stirred at room temperature for 37 minutes. Anhydrous 1,4-dioxane (43 mL) was then added and the mixture was stirred at room temperature for 15 minutes. Then 4-bromo-5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.65 g, 8.55 mmol) was added followed by Pd(CPhos)G3 (515 mg, 0.639 mmol). The mixture was heated at 80° C. for 36 min with stirring under nitrogen and then cooled to room temperature. The mixture was diluted with EtOAc (80 mL) and water (40 mL). The mixture was filtered and the filtered residue was extracted with EtOAc (200 mL). The combined filtrate was concentrated by rotary evaporation and the residue was suspended in EtOAc (80 mL) / water (40 mL). After mixing, the layers were separated and the aqueous layer was extracted with EtOAc (30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated.The residue was purified by silica gel column chromatography (30-40% DCM in hexanes, both phases containing 1.5% triethylamine), then by silica gel column chromatography (10-15% DCM in hexanes, both phases containing 1.5% triethylamine), and again by silica gel column chromatography (20% DCM in hexanes, both phases containing 1.5% triethylamine) to give 4-(tert-butoxy)-7-(5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (atropisomer mixture), which was purified by SFC (column A, 40% IPA containing 0.1% NH4OH), which was resolved into four peaks. The first two eluting peaks from the SFC purification were combined to give 4-(tert-butoxy)-7-(5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (Int-27-C). MS (ESI): m / z (M+H). + 638.3
[0229] Step D: 7-(5,6-Dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-ol (Int-27) To 4-(tert-butoxy)-7-(5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazoline (Int-27-C) (500 mg, 0.784 mmol) was added a solution of MeCN / water / trifluoroacetic acid (4:1:0.05, v / v / v) (19 mL). The solution was stirred at room temperature for 1 h 20 min; then aqueous sodium carbonate (2 M solution, 1.53 mL) was added. The mixture was concentrated and the residue was dissolved in DCM / water. The aqueous layer was extracted four times with DCM, then the combined organic layers were dried over sodium sulfate, filtered and concentrated to give 7-(5,6-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6,8-difluoro-2-((1-(((R)-3-fluoropyrrolidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-ol (Int-27). MS (ESI): m / z (M+H) + 582.3.
[0230] Intermediate 28: 6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)quinazolin-4-ol (Int-28) [ka]
[0231] Step A: 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)quinazoline (Int-28-A) To 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (hereinafter Int-34-B) (1.8 g, 4.55 mmol) was added (TMP)2Zn·2MgCl2·2LiCl (41.4 mL, 13.66 mmol) (0.33 M in THF) at 25° C. under N2 atmosphere and the mixture was stirred at 50° C. for 2 h. The reaction mixture was monitored by LCMS-1, which showed that the exchange was complete (quenched with I2 (dissolved in THF)). To the reaction mixture was then added a solution of 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazole (2.480 g, 6.83 mmol) and CPhos Pd G3 (0.367 g, 0.455 mmol) in 1,4-dioxane (30 mL) at 25° C. The reaction was stirred at 50° C. for 40 h. The reaction mixture was diluted with EtOAc (60 mL) and aqueous saturated NaHCO3 solution (50 mL) was added to the mixture. The mixture was filtered, the filtrate was dried over Na2SO4, and the solvent was then evaporated under reduced pressure to give the crude product. The crude product was purified by flash silica gel chromatography (elution with ethyl acetate / hexanes) to give 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)quinazoline (Int-28-A). MS(ESI)[M+H] + : m / z 678.3.
[0232] Step B: 6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)quinazolin-4-ol (Int-28-B) To a solution of TFA (9 mL, 117 mmol) in DCM (30 mL) was added 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)quinazoline (Int-28-A) (4 g, 5.90 mmol) at 25° C. The reaction was stirred at 25° C. for 6 h. The solvent was evaporated under reduced pressure to give the crude product, which was washed with aqueous saturated NaHCO3 (3×20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give 6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)quinazolin-4-ol (Int-28-B). MS(ESI)[M+H] + : m / z 538.2. Step C: 6,8-Difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)quinazolin-4-ol (Int-28) Racemic 6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)quinazolin-4-ol (Int-28-B) (3.10 g, 5.77 mmol) was separated by preparative SFC (column G; 0.1% NH4OH, 60% EtOH) to give 6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)quinazolin-4-ol (Int-28, second eluting isomer by SFC). MS(ESI)[M+H] + : m / z 538.2. 1H NMR(400MHz,MeOD)δ 7.78-7.70(m,1H),7.68(s,1H),7.59(s,1H),5.52-5.25(m,1H),4.50-4.36(m,2H),3.63-3.40(m,3H),3.16(dt,J=5.9,9.8Hz,1H),2.70(br d,J=1.5Hz,3H),2.47-2.28(m,2H),2.25-2.16(m,1H),2.15-2.04(m,2H),2.02-1.90(m,1H).
[0233] Intermediate 29: (3R)-1-(2-chloro-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-29-1, Int-29-2) [ka]
[0234] A mixture of (R)-1-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-25) (775 mg, 1.97 mmol) and 2-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (826 mg, 2.37 mmol) in tetrahydrofuran (10.0 ml) was treated at room temperature with potassium phosphate, tribasic acid (1257 mg, 5.92 mmol), (S)-BI-DIME (130 mg, 0.395 mmol), (R)-BI-DIME (130 mg, 0.395 mmol) and palladium(II) acetate (89 mg, 0.395 mmol). The mixture was sparged under the surface with a stream of nitrogen for 1 min. The vial was capped and the mixture was heated at 85° C. for 20 h. The mixture was cooled to room temperature, diluted with ethyl acetate, and filtered through a layered pad of Florisil on Celite. The pad was rinsed with ethyl acetate, and the combined filtrates were concentrated. The residue was purified by column chromatography on silica gel (eluting with a gradient of 0 to 100% EtOAc in hexanes) to give the title compound as a mixture of atropisomers. The atropisomers were resolved by chiral SFC (column H, 20% MeOH with 0.1% NH4OH) to give atropisomer 1 and atropisomer 2.
[0235] Atropisomer 1 (Int-29-1): MS(ESI): m / z(M+H)+534,536. 1H NMR (500MHz, acetone-d6)δ 8.01-7.97(m,1H),7.95(d,J=10.1Hz,1H),7.75(s,1H),7.55-7.49(m,2H ),7.39(s,1H),5.43(s,2H),4.42(d,J=13.2Hz,1H),4.23(d,J=13.4Hz,1H ),3.99(s,1H),3.54(d,J=13.4Hz,1H),3.52(s,3H),3.36(t,J=11.2Hz,1 H),2.29-2.18(m,1H),1.91-1.84(m,1H),1.83-1.74(m,2H),1.30(s,3H).
[0236] Atropisomer 2 (Int-29-2): MS(ESI): m / z(M+H)+534,536. 1H NMR (500MHz, acetone-d6)δ 8.02-7.97(m,2H),7.75(s,1H),7.53-7.48(m,2H),7.38(s,1H),5.42(s,2H),4.40(d,J=13.2Hz,1H),4.23(d,J=13.4Hz,1H),4.06(s,1 H),3.52(s,3H),3.48(d,J=13.4Hz,1H),3.36(t,J=11.8Hz,1H),2.27-2.16(m,1H),1.92-1.85(m,1H),1.83-1.74(m,2H),1.32(s,3H).
[0237] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Int-29, with appropriate substitutions of starting materials, intermediates and / or reagents, and optionally, after completion of the indicated step using the indicated conditions, stereoisomers were resolved and the indicated peak was carried forward. The appropriate substitutions are commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 6]
[0238] Intermediate 31: (3S)-1-(7-(8-chloronaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-31) [ka]
[0239] A microwave vial was charged with (R)-1-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23) (178 mg, 0.408 mmol). It was then degassed three times using a vacuum line and nitrogen and flushed three times with argon. To this was added THF (4100 ml) followed by TMP2ZnMgCl2LiCl (5.44 ml, 0.816 mmol in THF / toluene). The solution was purged with argon for 5 minutes and stirred at room temperature for 45 minutes. An aliquot was quenched in a mixture of iodine and THF. A mixture of 1-bromo-8-chloronaphthalene (197 mg, 0.816 mmol) and CPHOS PD G4 (50.3 mg, 0.061 mmol) was dissolved in 1,4-dioxane (4100 ml) and sonicated to a clear solution. The mixture was added to a microwave vial and stirred at room temperature for 45 minutes. The mixture was diluted with ethyl acetate and aqueous saturated ammonium chloride. The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting mixture was purified by silica gel column chromatography using 100% EtOAc in hexane to give (3S)-1-(7-(8-chloronaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-31). MS(ESI):m / z(M+H) + 597.
[0240] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Int-31, making appropriate substitutions of starting materials, intermediates and / or reagents, where the appropriate replacement materials are either commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 7]
[0241] Intermediate 33: 1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-(hydroxymethyl)piperidin-3-ol (Int-33) [ka]
[0242] Step A: (rac) 3-(hydroxymethyl)piperidin-3-ol (Int-33-A) To a solution of (rac) tert-butyl 3-hydroxy-3-(hydroxymethyl)piperidine-1-carboxylate (1.00 g, 4.32 mmol) in dioxane (14 ml) was added HCl (16 ml, 65 mmol, 4M in dioxane) and the reaction was stirred at room temperature for 5 h. The organic solvent was removed under reduced pressure and ethyl ether was added to the residue and coevaporated to give the title compound (Int-33-A).
[0243] Step B: (rac) 1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-(hydroxymethyl)piperidin-3-ol (Int-33-B) To a solution of 2,4-dichloro-6,8-difluoroquinazoline (Int-11) (1.2 g, 5.0 mmol) in dioxane (14 ml) / DIPEA (3.8 ml, 22 mmol) was added Int-33-A and the resulting mixture was stirred at room temperature for 2.5 h. The reaction was quenched with cold water and the resulting mixture was diluted with ethyl acetate. The organic layer was separated, washed with brine, dried over MgSO4, filtered and excess solvent was removed under reduced pressure. The product was purified by column chromatography on silica gel (MeOH in DCM, gradient from 0 to 15%). Product-containing fractions were pooled together and excess solvent was removed under reduced pressure to give the title compound (Int-33-B). MS (ESI): m / z (M+H) + 330.1.
[0244] Step C: 7-(2-chloro-6,8-difluoroquinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-C-1) To a solution of (rac) 1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-(hydroxymethyl)piperidin-3-ol (Int-33-B) (1.2 g, 3.8 mmol) in DMF (20 ml) / 2,2-dimethoxypropane (0.93 ml, 7.5 mmol) was added pTsOH (716 mg, 3.77 mmol) and the resulting mixture was stirred at room temperature. The reaction was quenched with cold water and the resulting mixture was diluted with ethyl acetate. The organic layer was separated, washed with brine, dried over MgSO4, filtered and excess solvent was removed under reduced pressure. The product was purified by column chromatography on silica gel (MeOH in DCM, gradient from 0 to 15%). Fractions containing the desired product were pooled together and excess solvent was removed under reduced pressure, then dried under vacuum to give a yellow solid. The resulting solid was separated by SFC (column H, 10% MeOH containing 0.1% NH4OH) to give the two enantiomers. Int-33-C-1 (eluted first), 7-(2-chloro-6,8-difluoroquinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane, was a yellow solid MS(ESI): m / z(M+H) + Int-33-C-2 (second elution), 7-(2-chloro-6,8-difluoroquinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane, obtained as 370.1, was a yellow foam MS (ESI): m / z (M+H) + The result was 370.1.
[0245] Step D: 7-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-D) To a solution of 7-(2-chloro-6,8-difluoroquinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-C-1) (200 mg, 0.541 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) (172 mg, 1.082 mmol) in DMSO (1.00 ml) was added cesium fluoride (329 mg, 2.16 mmol) and the resulting mixture was stirred at 100° C. for 3 h. The reaction mixture was cooled to room temperature and diluted with water. It was partitioned between ethyl acetate and water. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, washed with brine, dried over MgSO4, filtered and excess solvent was removed under reduced pressure. The product was purified by column chromatography on silica gel (MeOH in DCM, gradient from 0 to 15%). The product-containing fractions were pooled together and excess solvent was removed under reduced pressure, which was then dried in vacuum to give the title compound (Int-33-D). MS (ESI): m / z (M+H). + 493.3.
[0246] Step E: 7-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-E) To a vial that had been thoroughly purged with N2 was added TMP2Z-MgClLiCl (1.096 mL, 0.164 mmol) in THF / toluene. To this was added a solution of 7-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-D) (123.0 mg, 0.250 mmol) in THF (1 mL) and the reaction mixture was stirred at room temperature for 1 h. A solution of 1-bromo-8-chloro-3-(methoxymethoxy)naphthalene (136 mg, 0.450 mmol) and CPHOS PD G4 (22 mg, 0.027 mmol) in dioxane (1.00 ml) was added to the above reaction mixture and stirred for 2 h in a preheated oil bath at 100° C. for 2.5 h. The reaction was cooled in ice and quenched with water. Excess solvent was removed in vacuo and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted twice with ethyl acetate, the organic layers were pooled together, excess solvent was removed under reduced pressure and the residue was purified on a silica gel column (eluted with a gradient of 0 to 15% MeOH in DCM). Fractions containing the desired product were pooled together, excess solvent removed under reduced pressure, and the residue dried in vacuo to give 7-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-E). MS (ESI): m / z (M+H). + 713.2.
[0247] Step F: 1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-(hydroxymethyl)piperidin-3-ol (Int-33) To a solution of 7-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-2,2-dimethyl-1,3-dioxa-7-azaspiro[4.5]decane (Int-33-E) (158 mg, 0.222 mmol) in isopropanol (1.00 ml) was added HCl (1.1 ml, 4.4 mmol) and the reaction mixture was stirred at 45° C. for 4 h. Excess solvent was removed under reduced pressure. The residue was dissolved in MeOH and directly purified by reverse phase HPLC (C18, ACN-water with 0.5% TFA, gradient from 0 to 100%). Fractions containing the desired product were pooled together and lyophilized. 1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-(hydroxymethyl)piperidin-3-ol was obtained as a yellow oil as a mixture of atropisomers (Int-33). MS (ESI): m / z (M+H) + 629.2.
[0248] Intermediate 34: 7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-34) [ka]
[0249] Step A: 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-27-A) To a solution of 2,4-dichloro-6,8-difluoroquinazoline (Int-11) (10 g, 42.6 mmol) in THF (100 mL) was added sodium tert-butoxide (21.28 mL, 42.6 mmol, 2.0 M in THF) at 0° C. under N2 atmosphere. The mixture was stirred at 25° C. for 2 h. The mixture was diluted with EtOAc (200 mL), washed with H2O (30 mL), dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by flash silica gel chromatography (eluted with a gradient of 0 to 100% ethyl acetate in petroleum ether) to give 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-27-A). 1 H NMR(400MHz,CDCl3)δ 7.52-7.44(m,1H),7.35-7.27(m,1H),1.74(s,9H).
[0250] Step B: 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-B) To a solution of 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-34-A) (4 g, 14.67 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) (3.50 g, 22.00 mmol) in dioxane (60 mL) was added Cs2CO3 (9.56 g, 29.3 mmol) and RuPhos Pd G2 (1.139 g, 1.467 mmol) in a glove box and the reaction mixture was stirred at 80 °C for 15 h under N2 atmosphere. The reaction mixture was quenched with water (20 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (elution with a gradient of 0 to 100% EtOAc in hexanes) to give 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-B). MS(ESI)[M+H] + m / z 396.
[0251] Step C: 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-C) To a solution of (TMP)2Zn·2MgCl2·2LiCl (90 mL, 29.6 mmol, 0.33 M in THF) was added 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-B) (3.9 g, 9.86 mmol) at 25 °C in a glove box, and the mixture was stirred at 50 °C for 3 h. 1-Bromo-8-chloro-3-(methoxymethoxy)naphthalene (3.57 g, 11.84 mmol) and CPhos Pd G3 (0.795 g, 0.986 mmol) in THF (24 mL) were added to the reaction solution at 25 °C in a glove box; then the reaction mixture was stirred at 50 °C for 15 h. LCMS showed starting material was consumed and desired MS was observed. The mixture was diluted with EtOAc (300 mL) and saturated NaHCO3 solution (30 mL) was added to the mixture. The mixture was filtered and separated. The organic layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by flash silica gel chromatography (elution with a gradient of 0 to 100% ethyl acetate in hexanes) to give 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-C). MS(ESI)[M+H] + : m / z 616.
[0252] Step D: 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-D-2) A mixture of 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-C) (3.8 g, 6.17 mmol) was separated by preparative SFC (column G, 30% EtOH with 0.1% NH3HO) to give 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (second eluting isomer) (Int-34-D-2). MS(ESI)[M+H] + : m / z 616.
[0253] Step E: 7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-34) A mixture of 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-34-D-2) (1.5 g, 2.435 mmol) and MeCN (16 mL) / water (4 mL) / TFA (0.4 mL) was stirred at 25° C. for 1.5 hours. The reaction was concentrated to remove MeCN and the mixture was purified by preparative HPLC (C18, ACN in water with 0.1% TFA) to give 7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol as the TFA salt (Int-34). MS(ESI)[M+H] + : m / z 560.
[0254] Intermediate 35: 7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-(((R)-2,2-difluoro-1-(hydroxymethyl)cyclopropyl)methoxy)-6,8-difluoroquinazolin-4-ol (Int-35) [ka]
[0255] Step A: (R)-2-((1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methoxy)-4-(tert-butoxy)-6,8-difluoroquinazoline (Int-35-A) To a mixture of chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (1.85 g, 2.38 mmol), cesium carbonate (23.3 g, 72 mmol) and 4-(tert-butoxy)-2-chloro-6,8-difluoroquinazoline (Int-27-A) (6.5 g, 24 mmol) was added a solution of (S)-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methanol (8.16 g, 35.8 mmol) in dioxane (100 ml) under argon. The reaction mixture was stirred at 100° C. under argon overnight. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (300 mL), filtered (Celite), and washed with sodium bicarbonate (aqueous saturated 3×100 mL). The organics were retained and concentrated under reduced pressure. The resulting mixture was purified by silica gel column chromatography (gradient of ethyl acetate in hexanes) to afford the title compound (Int-35-A). MS (ESI): m / z (M+H-tBu). + 409.
[0256] Step B: (R)-(1-(((4-(tert-butoxy)-6,8-difluoroquinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-35-B) (R)-2-((1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methoxy)-4-(tert-butoxy)-6,8-difluoroquinazoline (Int-35-A) (4 g, 9 mmol) in THF (43 mL) was added to a flask containing palladium hydroxide (0.61 g, 0.86 mmol) under inert atmosphere. Hydrogen was bubbled into the reaction mixture, which was then sealed with a hydrogen balloon. The reaction mixture was stirred for 6 h at room temperature. Argon was bubbled into the reaction mixture, which was then filtered through Celite under argon. The filtrate was concentrated in vacuo. The resulting mixture was purified by silica gel column chromatography (gradient of ethyl acetate in hexanes) to give the title compound. MS(ESI):m / z(M+H-tBu)+319.1H NMR(499MHz, methanol-d4)δ 7.55-7.45(m,2H),4.69(d,J=12Hz,1H),4.60(d,J=12Hz,1H),3.85(d,J=12Hz ,1H),3.79(d,J=12Hz,1H),1.79(s,9H),1.68-1.57(m,1H),1.55-1.45(m,1H).
[0257] Step C: (S)-4-(tert-butoxy)-2-((1-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazoline (Int-35-C) (R)-(1-(((4-(tert-butoxy)-6,8-difluoroquinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-35-B) (5.2 g, 14 mmol) was dissolved in dichloromethane (70 ml) and treated with imidazole (2.8 g, 41 mmol) followed by the addition of TBDMS-Cl (2.7 g, 18 mmol) in three equal portions at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was diluted with DCM (300 mL) and washed with sodium bicarbonate (3×100 mL). The combined organic layers were concentrated in vacuo. The resulting mixture was purified by silica gel column chromatography (gradient of ethyl acetate in hexanes). The product-containing fractions were concentrated in vacuo to give the title compound (Int-35-C). MS(ESI): MS(ESI): m / z (M+Na)+511. 1 H NMR (methanol-d4)δ:7.55-7.42(m,2H),4.62(s,2H),3.98(d,J=10.8Hz,1H),3.83(d ,J=10.9Hz,1H),1.68-1.59(m,1H),1.52-1.43(m,1H),0.87(s,9H),0.05(s,6H).
[0258] Step D: 4-(tert-butoxy)-2-(((S)-1-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazoline (Int-35-D) (S)-4-(tert-butoxy)-2-((1-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazoline (Int-35-C) (19 ml, 5.1 mmol) in THF was added to dis(2,2,6,6-tetramethylpiperidinyl)zinc-LiCl-MgCl2 in THF / toluene (19 ml, 6.1 mmol). The reaction mixture was stirred for 1 h at room temperature. A separate mixture of CPhos Pd G4 (0.63 g, 0.77 mmol), 1-bromo-8-chloro-3-(methoxymethoxy)naphthalene (3.1 g, 10. mmol) and dioxane (25 ml) was prepared under sonication and gently heated until homogeneous before being added to the zincate mixture. The reaction mixture was purged with argon and then heated to 100° C. overnight. The reaction mixture was diluted with EtOAc (200 mL) and washed with ammonium chloride (3×100 mL). The combined organics were concentrated in vacuo. The resulting mixture was purified by silica gel column chromatography (gradient of ethyl acetate in hexanes). The product-containing fractions were concentrated in vacuo to give the title compound (Int-35-D). The atropisomers were separated by chiral SFC (column F, 15% MeOH with 0.1% NH4OH).(Int-35-D-1, peak 1)-MS(ESI):m / z(M+H-tBu)+653.1H NMR(499MHz,DMSO-d6)δ 8.03-7.96(m,1H),7.76(d,J=2.2Hz,1H),7.63(d,J=8.5Hz,1H),7.53-7.48(m,2H),7.36( d,J=2.3Hz,1H),5.40(s,2H),4.64(d,J=11.3Hz,1H),4.46(d,J=11.4Hz,1H),3.87(d,J=1 0.9Hz,1H),3.77(d,J=10.9Hz,1H),3.45(s,3H),1.87-1.78(m,1H),1.74(s,9H),1.67-1. 55(m,1H),0.79(s,9H),-0.01(s,6H).(Int-35-D-2, peak 2-MS(ESI):m / z(M+H-tBu)+653.1H NMR(499MHz,DMSO-d6)δ 8.04-7.94(m,1H),7.76(d,J=2.0Hz,1H),7.63(d,J=8.5Hz,1H),7.53-7.48(m,2H ),7.35(d,J=2.1Hz,1H),5.40(s,2H),4.57(d,J=11.5Hz,1H),4.53(d,J=11.5Hz, 1H),3.88(d,J=10.8Hz,1H),3.75(d,J=10.9Hz,1H),3.45(s,3H),1.82(d,J=8.5H z,1H),1.74(s,9H),1.70-1.58(m,1H),0.79(s,9H),-0.01(s,3H),-0.01(s,3H).
[0259] Step E: 7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-(((R)-2,2-difluoro-1-(hydroxymethyl)cyclopropyl)methoxy)-6,8-difluoroquinazolin-4-ol (Int-35) 4-(tert-butoxy)-2-(((S)-1-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazoline (Int-35-D-1) (100.mg, 0.141mmol, peak 1) was dissolved in acetonitrile (1100μL), water (282μL) and subsequently treated with TFA (28μL). The reaction mixture was stirred overnight and then quenched with sodium bicarbonate (sat. aq. solution). The product was extracted with DCM and concentrated in vacuo to give the title compound (Int-35). MS(ESI): m / z(M+H)+539.
[0260] Intermediate 36: 2-(((R)-2,2-difluoro-1-(hydroxymethyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-4-ol (Int-36) [ka]
[0261] Step A: ((1R)-1-(((4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-36-A) TBAF (700 μl, 0.700 mmol, 1M in THF) was added to a stirred solution of 4-(tert-butoxy)-2-(((S)-1-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazoline (Int-35-D-1) (250 mg, 0.352 mmol) in THF (1760 μl) at ambient temperature. The reaction mixture was stirred for 2 h. Ammonium chloride was added (1 mL, aqueous saturated) and stirred for 1 h. The product was extracted with EtOAc (3×10 mL) and the combined organics were concentrated in vacuo. The product was purified by column chromatography on silica (0 to 100% EtOAc in hexanes). The product-containing fractions were concentrated in vacuo to give the title compound (Int-36-A). MS (ESI): m / z (M+H-tBu)+539.
[0262] Step B: ((1R)-1-(((4-(tert-butoxy)-6,8-difluoro-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-36-B) ((1R)-1-(((4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-36-A) (196 mg, 0.329 mmol) was dissolved in DMF (3294 μL). N,N-Dicyclohexylmethylamine (350 μL, 1.6 mmol) and (triisopropylsilyl)acetylene (739 μL, 3.29 mmol) were added successively. The reaction mixture was degassed with argon and methanesulfonato(2-dicyclohexylphosphino-2',4',6'-tri-I-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (56 mg, 0.066 mmol) was added. Argon was bubbled through the reaction mixture, which was then sealed and stirred at 80° C. overnight. The reaction mixture was diluted with water (6 mL), extracted with EtOAc (3×10 mL) and the organics were concentrated in vacuo. The product was purified by silica gel column chromatography (0 to 100% EtOAc in hexanes). The product-containing fractions were concentrated in vacuo to give the title compound (Int-36-B). MS (ESI): m / z (M+H-tBu) + 685.
[0263] Step C: ((1R)-1-(((4-(tert-butoxy)-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-36-C) TBAF (240 μl, 0.24 mmol, in THF) was added to a solution of ((1R)-1-(((4-(tert-butoxy)-6,8-difluoro-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-36-B) (90 mg, 0.12 mmol) in THF (1 ml) at ambient temperature. The reaction mixture was stirred for 1 h and then treated with ammonium chloride (aqueous saturated 1 mL). The product was extracted with EtOAc (3×1 mL). The organic layers were combined and then concentrated in vacuo. The product was purified by silica gel column chromatography (0 to 100% EtOAc in hexanes). The product-containing fractions were concentrated in vacuo to give the title compound (Int-36-C). MS(ESI):m / z(M+H-tBu) + 529.
[0264] Step D: 2-(((R)-2,2-difluoro-1-(hydroxymethyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-4-ol (Int-36) TFA (15 μl) was added to a stirred mixture of ((1R)-1-(((4-(tert-butoxy)-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)methanol (Int-36-C) (45 mg, 0.077 mmol) and acetonitrile (600 μl) / water (154 μl). The reaction mixture was stirred at room temperature for 4 h, then concentrated in vacuo and lyophilized to give the title compound (Int-36). MS (ESI): m / z (M+H)+529.
[0265] Intermediate 37: 7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-37) [ka]
[0266] Step A: 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazoline (Int-37-A) A mixture of 4-(tert-butoxy)-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (0.50 g, 0.81 mmol) (Int-34-D-2) and DMF (5.4 mL) was added with ethynyltriisopropylsilane (1.8 mL, 8.1 mmol), N-cyclohexyl-N-methylcyclohexanamine (0.52 mL, 2.4 mmol) and (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (Xphos Pd G3) (0.34 g, 0.41 mmol) was added under nitrogen atmosphere. The mixture was heated to 80° C. for 3 h. After 3 h, the mixture was allowed to cool to room temperature, diluted with ethyl acetate, and then washed with water (3×8 mL). The organic layer was then dried over magnesium sulfate, filtered, and then concentrated under reduced pressure. The resulting mixture was purified by silica gel column chromatography (gradient of 0 to 30% ethyl acetate in hexanes) to give 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazoline (Int-37-A). MS (ESI): m / z (M+H) + 762.
[0267] Step B: 7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-37) To a flask containing 4-(tert-butoxy)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazoline (Int-37-A) (0.37 g, 0.49 mmol) and THF (9.7 mL) was added TBAF (1.0 M in THF, 1.2 mL, 1.2 mmol). The mixture was stirred at room temperature for 30 minutes. After 30 minutes, the mixture was diluted with ethyl acetate and saturated ammonium chloride. The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting mixture was purified by silica gel column chromatography (0 to 100% (3:1 ethyl acetate:ethanol) gradient in hexanes) to give a mixture of 4-(tert-butoxy)-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline and 7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-37). To this mixture was added acetonitrile (3.2 mL), water (0.81 mL) and TFA (0.81 mL). The mixture was stirred for 2 hours at ambient temperature. After 2 hours, the mixture was diluted with ethyl acetate and aqueous saturated sodium bicarbonate. The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting mixture was purified by silica gel column chromatography (gradient of 0 to 100% (3:1 ethyl acetate:ethanol) in hexanes) to give 7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-37). MS(ESI):MS(ESI):m / z(M+H) + 550. 1H NMR(499MHz,DMSO-d6)δ 8.02(d,J=8.2Hz,1H),7.70(d,J=2.0Hz,1H),7.61-7.56(m,2H),7.52(dd ,J=7.7Hz,1H),7.31(d,J=2.1Hz,1H),5.39(s,2H),5.37-5.22(m,1H),4.1 6(d,J=10.3Hz,1H),4.07(d,J=10.3Hz,1H),3.78(s,1H),3.45(s,3H),3. 20-2.97(m,4H),2.87-2.79(m,1H),2.20-1.99(m,3H),1.87-1.76(m,3H).
[0268] Intermediate 38: Triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) [ka]
[0269] Step A: 8-((triisopropylsilyl)ethynyl)naphthalene-1,3-diol (Int-38-A) To a solution of naphthalene-1,3-diol (16.0 g, 100 mmol) in dioxane (160 mL) was added (bromoethynyl)triisopropylsilane (31.3 g, 120 mmol), potassium acetate (19.6 g, 200 mmol) and dichloro(p-cymene)ruthenium(II) dimer (6.12 g, 9.99 mmol) at 25° C. under N2 atmosphere and the mixture was stirred at 110° C. for 16 h. The reaction mixture was diluted with DCM (200 mL) and the resulting mixture was filtered. The filtrate was concentrated under vacuum and the residue was purified by flash silica gel chromatography eluting with ethyl acetate / hexanes) to give 8-((triisopropylsilyl)ethynyl)naphthalene-1,3-diol (Int-38-A). 1H NMR(400MHz,CDCl3)δ 9.26(s,1H),7.60(d,J=8.3Hz,1H),7.44(d,J=7.1Hz,1H),7.26-7.30(m,1H),6.72(s,1H),6.60(s,1H),4.90(br s,1H),1.14-1.18(m,21H).
[0270] Step B: 3-(Methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-ol (Int-38-B) To a solution of 8-((triisopropylsilyl)ethynyl)naphthalene-1,3-diol (Int-38-A) (13.0 g, 38.2 mmol) in DCM (130 mL) was added DIEA (20 mL, 115 mmol) and MOM-Cl (8.44 g, 7.96 mL, 105 mmol) at 0 °C, and the mixture was stirred at 0 °C for 10 min. The reaction mixture was diluted with DCM (200 mL) and washed with brine (30 mL × 2). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by flash silica gel chromatography (eluted with ethyl acetate / hexane) to give 3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalene-1-ol (Int-38-B). 1 H NMR(400MHz,MeOD)δ 7.63-7.71(m,1H),7.44(dd,J=1.0,7.1Hz,1H),7.24-7.34(m,1H),6.93(d,J=2 .4Hz,1H),6.62(d,J=2.2Hz,1H),5.23(s,2H),3.46(s,3H),1.10-1.23(m,21H).
[0271] Step C: 3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl trifluoromethanesulfonate (Int-38-C) To a solution of 3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-ol (Int-38-B) (9.00 g, 23.40 mmol) in DCM (100 mL) was added DIEA (12.26 mL, 70.2 mmol) and TfO (5.9 mL, 35.1 mmol) at −40° C., and the mixture was stirred at −40° C. for 2 min. The reaction mixture was concentrated under vacuum, and the residue was purified by flash silica gel chromatography (eluting with ethyl acetate / hexanes) to give 3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl trifluoromethanesulfonate (Int-38-C). 1 H NMR(400MHz,CHLOROFORM-d)δ=7.71(t,J=7.6Hz,2H),7.45-7.38(m,2H),7.29(d,J=2.0Hz,1H),5.27(s,2H),3.54-3.46(m,3H),1.18-1.10(m,21H).
[0272] Step D: Triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) To a solution of 3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl trifluoromethanesulfonate (Int-38-C) (9.00 g, 17.42 mmol) and bis(pinacolato)diboron (8.85 g, 34.8 mmol) in toluene (180 mL) was added potassium acetate (5.98 g, 61.0 mmol) and PdCl2(dppf) (1.275 g, 1.742 mmol) at 20 °C, and the solution was stirred at 110 °C for 15 h under N2 atmosphere. The reaction mixture was diluted with EtOAc (500 mL) and the resulting mixture was filtered. The filtrate was concentrated in vacuo and the residue was purified by flash silica gel chromatography (eluting with EtOAc / hexanes) to give triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38). 1H NMR(400MHz,CDCl3)δ 7.69(dd,J=2.8,7.7Hz,2H),7.47(d,J=2.4Hz,1H),7.31-7.40(m,2H),5.27-5.31(m,2H),3.47-3.52(m,3H),1.44(s,12H),1.12-1.21(m,21H).
[0273] Intermediate 39: 6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-ol (Int-39) [ka]
[0274] Step A: 7-Bromo-4-(tert-butoxy)-2,6-dichloro-8-fluoroquinazoline (Int-39-A) To a solution of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (Int-22) (5 g, 15.13 mmol) in THF (50 mL) was added lithium 2-methylpropan-2-olate (7 mL, 15.40 mmol, 2.2 M in THF) at 25° C. under N2 atmosphere. The mixture was stirred at 25° C. for 1 h. LCMS showed that the starting material was consumed and the desired peak was formed. TLC (SiO2; petroleum ether:ethyl acetate=20:1) showed that the starting material was consumed and a new spot was observed. The mixture was quenched with H2O (20 mL), extracted with EtOAc (2×60 mL), dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by flash silica gel chromatography (basified with TEA and eluted with EtOAc / hexanes) to give 7-bromo-4-(tert-butoxy)-2,6-dichloro-8-fluoroquinazoline (Int-39-A). MS(ESI): MS(ESI): m / z (M+H-tBu). + 311.3,313.3. 1H NMR(400MHz, CDCl3)δ 7.98(d,J=1.7Hz,1H),1.77(s,9H).
[0275] Step B: 7-Bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-39-B) To a solution of 7-bromo-4-(tert-butoxy)-2,6-dichloro-8-fluoroquinazoline (Int-39-A) (4 g, 10.87 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) (2.60 g, 16.30 mmol) in dioxane (60 mL) was added Cs2CO3 (7.08 g, 21.74 mmol) and RuPhos Pd G2 (0.844 g, 1.087 mmol). The solution was stirred at 80 °C for 15 h under N2 atmosphere. LCMS showed the starting material was consumed and the desired MS was observed. The reaction mixture was quenched with water (10 mL) and the resulting mixture was extracted with EtOAc (150 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluted with EtOAc / hexanes) to give 7-bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-39-B). MS (ESI): m / z (M+H) + 489.8,491.8.
[0276] Step C: 4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazoline (Int-39-C) A mixture of 7-bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-39-B) (2 g, 4.08 mmol) and triisopropyl ((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaboro))- To a solution of (naphthalen-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) (3.02 g, 6.11 mmol), potassium phosphate, tribasic acid (2.60 g, 12.23 mmol), rRac-BI-DIME (0.404 g, 1.223 mmol) and Pd(OAc)2 (0.137 g, 0.611 mmol) were added under N2 and the solution was stirred at 60 °C for 15 h under N2 atmosphere. The reaction mixture was diluted with EtOAc (100 mL) and washed with water (10 mL) and brine (10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (elution with EtOAc / hexanes) to give 4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazoline (Int-39-C). MS (ESI): m / z (M+H). + 778.4.
[0277] Step D: 6-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-ol (12) (Int-39) A mixture of 4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazoline (Int-39-C) (250 mg, 0.225 mmol) with MeCN (4 mL), water (1 mL) and TFA (0.25 mL) was stirred at 25° C. for 2 h. LCMS showed the starting material was consumed and the desired MS was formed. The reaction mixture was concentrated under vacuum at 25° C. The residue was purified by preparative HPLC (column: Boston Green ODS, ACN / water, containing 0.1% TFA) to give 6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-ol (Int-39). MS(ESI): m / z(M+H) + 722.3.
[0278] Intermediate 40: 7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-40) [ka]
[0279] Step A: 7-Bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-A) To a solution of 7-bromo-4-(tert-butoxy)-2,6-dichloro-8-fluoroquinazoline (Int-39-A) (10 g, 27.2 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (Int-8) (6.49 g, 40.8 mmol) in dioxane (150 mL) was added Cs2CO3 (17.71 g, 54.3 mmol) and RuPhos Pd G2 (2.111 g, 2.72 mmol). The solution was stirred at 80 °C for 15 h under N2 atmosphere. The reaction mixture was quenched with water (50 mL) and the resulting mixture was extracted with EtOAc (300 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (elution with ethyl acetate / hexanes) to give 7-bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-A). MS(ESI)[M+H] + m / z:490.
[0280] Step B: 4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-B) To a stirred solution of 7-bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-A) (8.7 g, 18 mmol) in THF (100 mL) was added nBuLi (10.64 mL, 26.6 mmol) (2.5 M in hexanes) at -78 °C, and the resulting mixture was stirred at -78 °C for 2 h. The reaction was quenched with water (10 mL), and the resulting mixture was extracted with EtOAc (200 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (elution with a gradient of 0 to 100% ethyl acetate in hexanes) to give 4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-B). MS(ESI)[M+H] + m / z: 412.
[0281] Step C: 4-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(2,4-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (Int-40-C) A solution of 4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-B) (5.7 g, 13.84 mmol) in (TMP)2Zn·2MgCl2·2LiCl (180 mL, 59.5 mmol, 0.33 M in THF) was stirred at 50 °C for 5 h. 4-Bromo-N-(2,4-dimethoxybenzyl)-N-(3,5-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (13.30 g, 24.22 mmol) and CPhos Pd G3 (2.232 g, 2.77 mmol) in THF (24 mL) were added to the reaction solution in a glove box at 25° C., and the reaction mixture was then stirred for 15 h at 50° C. The reaction was diluted with EtOAc (500 mL) and saturated aqueous NaHCO3 (150 mL), and the resulting mixture was filtered. The filtrate was concentrated in vacuo and the residue was purified by flash silica gel chromatography (eluting with a gradient of 0 to 100% EtOAc in hexanes) to give 4-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(2,4-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (Int-40-C). MS(ESI)[M+H] + m / z:880.
[0282] Step D: 4-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(2,4-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (Int-40-D-1) The atropisomeric mixture of 4-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(2,4-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (Int-40-C) (6.5 g, 7.38 mmol) was separated using preparative SFC (column H; 0.1% NH3H2O in 45% EtOH) to give 4-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(2,4-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (Int-40-D-1, first eluting isomer). MS(ESI)[M+H] + m / z:880.
[0283] Step E: 7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-40) A mixture of 4-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(2,4-dimethoxybenzyl)-5,7-difluorobenzo[d]oxazol-2-amine (Int-40-D-1) (2.5 g, 2.8 mmol) with MeCN (20 mL), water (5 mL) and TFA (1 mL) was stirred at 25 °C for 4 h. The reaction mixture was concentrated in vacuo and the residue was basified with aqueous NH3·H2O (1 mL). The mixture was purified by preparative HPLC (ACN / water with C18 (0.04% NH3H2O + 10 mM NH4HCO3)) to give 7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-40). MS(ESI)[M+H] + m / z:824.
[0284] Intermediate 41: 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-41) [ka]
[0285] Step A: 6-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (Int-41-A) To a solution of 7-bromo-4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazoline (Int-40-A) (235 mg, 0.479 mmol) in THF (2 mL) was added isopropylmagnesium chloride-lithium chloride complex (0.774 mL, 1.006 mmol) (1.3 M in THF) at 0° C. under N2 atmosphere and the mixture was stirred at 0° C. for 20 min. Zinc chloride (0.766 mL, 0.766 mmol, 1 M in THF) was added to the reaction solution at 0° C. and the mixture was stirred at 25° C. for 10 min. 6-Chloro-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (216 mg, 0.479 mmol) and CPhos Pd G3 (39 mg, 0.048 mmol) were added to the reaction solution at 25° C. in a glove box; then the reaction mixture was stirred at 50° C. for 15 h. The mixture was cooled, quenched with H2O (1 mL), extracted with EtOAc (2×3 mL), dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by flash silica gel chromatography (basified with TEA and eluted with ethyl acetate / hexanes) to give 6-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (Int-41-A). MS(ESI)[M+H] + :m / z 826.
[0286] Step B: 6-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (Int-41-B-1) Racemic 6-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (Int-41-A) (90 mg, 0.109 mmol) was purified by SFC (column: G; 0.1% NH3·HO) 25% ethanol) to give 6-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (Int-41-B-1), the first eluting isomer by SFC. MS(ESI)[M+H] + :m / z 826.
[0287] Step C: 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-41) 6-(4-(tert-butoxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (Int-41-B-1) (42 mg, 0.051 mmol, from step D) was added to a solution of MeCN (4 mL), water (1 mL) and TFA (0.05 mL) at 20° C. The mixture was stirred at 20° C. for 1 h. LCMS showed the starting material was consumed and the desired peak was formed. The solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by reverse phase preparative HPLC (C18 ACN / water with 0.225% TFA) to give 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-41). MS(ESI)[M+H] + : m / z 770.
[0288] [Example 1]: (3R)-1-(6-chloro-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.1) [ka]
[0289] Step A: (3R)-1-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of 6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-ol (Int-39) (80 mg, 0.11 mmol) in MeCN (1 mL) was added ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate (V) (74 mg, 0.17 mmol) at 25° C. The mixture was stirred at 25° C. for 30 min. N-Ethyl-N-isopropylpropan-2-amine (72 mg, 0.55 mmol) and (R)-3-methylpiperidin-3-ol (19 mg, 0.167 mmol) were added to the reaction solution; then the mixture was stirred at 80° C. for 2 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by preparative TLC plate (silica, hexane / EtOAc=0 / 1) to give (3R)-1-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol as a yellow oil. MS(ESI): m / z(M+H) +819.4. The mixture of atropisomers (3R)-1-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol was separated by preparative SFC (column G; 35% IPA with 0.1% NH3H2O) to give (3R)-1-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3 -(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Pk1, first eluting isomer) was obtained as a yellow solid, and (3R)-1-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Pk2, second eluting isomer) was obtained as a yellow solid. MS (ESI): m / z (M+H) + 819.4.
[0290] Step B: (3R)-1-(6-chloro-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (3R)-1-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Pk1 from step A, 38 mg, 0.046 mmol) in THF (0.5 mL) was added TBAF (0.070 mL, 0.070 mmol) (1 M in THF) at 25° C. The mixture was stirred at 25° C. for 30 min. The reaction solution was concentrated under reduced pressure, and the residue was purified by preparative TLC plate (silica, DCM / MeOH=10 / 1) to give (3R)-1-(6-chloro-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol as a yellow oil. LCMS (ESI): m / z (M+H) + 663.2.
[0291] Step C: (3R)-1-(6-chloro-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.1) To a solution of (3R)-1-(6-chloro-7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (from step B, 22 mg, 0.033 mmol) in 2-propanol (0.25 mL) was added HCl / dioxane (8.29 μl, 0.033 mmol) (4 M in dioxane) at 25° C. The mixture was stirred at 25° C. for 30 min. LCMS showed the starting material was consumed and the desired MS was formed. The reaction solution was concentrated under vacuum and the residue was purified by preparative HPLC (C18, 0 to 100% ACN / water, containing 0.1% TFA) to give (3R)-1-(6-chloro-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.1). LCMS (ESI): m / z (M+H) + 619.2. 1 H NMR (400MHz, MeOD) δ 8.09-8.22(m,1H),7.84(d,J=8.2Hz,1H),7.51(d,J=7.2Hz,1H),7.38-7.44( m,1H),7.35(d,J=2.4Hz,1H),7.06(d,J=2.5Hz,1H),5.39-5.69(m,1H),4.56- 4.78(m,3H),4.25-4.41(m,1H),3.81-4.06(m,3H),3.57-3.67(m,1H),3.35-3 .52(m,2H),3.10-3.18(m,1H),2.56-2.80(m,2H),2.30-2.49(m,3H),2.19(br d,J=11.1Hz,2H),1.75-1.91(m,3H),1.30(s,3H).
[0292] [Example 2]: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.2) [ka]
[0293] Step A: (R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23-A) (273 mg, 0.870 mmol) and (R)-(1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methanol hydrochloride (Int-10) (193 mg, 0.957 mmol) in DMF (9.0 mL) was added cesium carbonate (851 mg, 2.61 mmol), 1,4-diazabicyclo[2.2.2]octane (19.5 mg, 0.174 mmol) and N,N-diisopropylethylamine (0.152 mL, 0.870 mmol) at room temperature. The mixture was stirred at room temperature for 17 h, after which the reaction mixture was heated to 60 °C for 9 h. The reaction mixture was quenched with H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash NH-silica gel chromatography (gradient of 20 to 50% EtOAc in hexanes) to give (R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 443.
[0294] Step B: 1-((R)-1-(((6,8-difluoro-4-((R)-3-methyl-3-((trimethylsilyl)oxy)piperidin-1-yl)quinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)-N,N-dimethylmethanamine To a solution of (R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (261 mg, 0.590 mmol) in DMF (6.0 mL) was added imidazole (201 mg, 2.95 mmol) and chlorotrimethylsilane (0.150 mL, 1.18 mmol) at room temperature. After the mixture was stirred at room temperature for 15 h, the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 0 to 50% EtOAc in hexanes) to give 1-((R)-1-(((6,8-difluoro-4-((R)-3-methyl-3-((trimethylsilyl)oxy)piperidin-1-yl)quinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)-N,N-dimethylmethanamine. ESI-MS m / z[M+H] + 515.
[0295] Step C: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.2) To a 12 wt.% solution of (TMP)2Zn·xMgCl2·xLiCl in THF / toluene (4.27 mL, 0.583 mmol) was added 1-((R)-1-(((6,8-difluoro-4-((R)-3-methyl-3-((trimethylsilyl)oxy)piperidin-1-yl)quinazolin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)-N,N-dimethylmethanamine (100 mg, 0.194 mmol). After stirring the mixture at 50 °C for 1 h, a solution of 1-bromo-8-chloro-3-(methoxymethoxy)naphthalene (70.3 mg, 0.233 mmol) and CPhos Pd G3 (15.7 mg, 0.0194 mmol) in 1,4-dioxane (1.0 mL) was added to the reaction mixture. After the mixture was stirred at 50° C. for 18 h, the reaction was quenched by the addition of aqueous saturated NaHCO3 and EtOAc, and the mixture was filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (gradient of 0 to 100% EtOAc in hexanes) to give the coupling compound.
[0296] To a solution of the coupling compound in dichloromethane (4.0 mL) was added 4.0 M 1,4-dioxane HCl solution (2.0 mL). After stirring the mixture at room temperature for 30 min, the reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (C18, 0 to 100% MeCN / water, with 0.1% formic acid) to give (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.2). ESI-MS m / z[M+H] + 619,621. 1H NMR(400MHz,DMSO-d6)δ 10.31(s,0.5H),10.30(s,0.5H),7.88-7.82(m,1.5H),7.76(d,J=9.3Hz,0.5H),7.44-7.34(m,3H), 7.13-7.09(m,1H),4.79(s,0.5H),4.65(s,0.5H),4.45(d,J=11.0Hz,1H),4.38(d,J=11.2Hz,1H),4. 13-3.99(m,1H),3.85(d,J=13.2Hz,1H),3.46-3.33(m,1H),3.30-3.19(m,1H),2.65-2.57(m,1H),2 .38-2.29(m,1H),2.15(s,6H),2.09-1.94(m,1H),1.84-1.54(m,4H),1.51-1.42(m,1H),1.17(s,1.5 H),1.14(s,1.5H).
[0297] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.2, making the appropriate substitutions of starting materials, intermediates and reagents, where the appropriate substitutions are either commercially available, synthesized as described in the literature, synthesized using methods available to one skilled in the art, or synthesized as described herein. [Table 8]
[0298] [Example 5]: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.5) [ka]
[0299] Step A: (R)-1-(6,8-difluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-23-A) (300 mg, 0.956 mmol), cyclopropane-1,1-diyldimethanol (195 mg, 1.91 mmol) and RuPhos Pd G3 (24.0 mg, 0.0287 mmol) in 1,4-dioxane (5.0 mL) was added cesium carbonate (935 mg, 2.87 mmol) at room temperature. After stirring the mixture at 100° C. for 2 h, the reaction mixture was cooled to room temperature, quenched with H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (gradient of 50 to 100% EtOAc in hexanes) to give (R)-1-(6,8-difluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 380.
[0300] Step B: (R)-1-(6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(6,8-difluoro-2-((1-(hydroxymethyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (150 mg, 0.395 mmol) in N,N-dimethylacetamide (2.0 mL) was added ethanesulfonyl chloride (0.0719 mL, 0.791 mmol) and triethylamine (0.278 mL, 1.98 mmol) at 5° C. After the mixture was stirred at 5° C. for 30 min, the reaction mixture was treated with 4-methoxypiperidine (0.245 mL, 1.98 mmol). After the mixture was stirred at 75° C. for 2 h, the reaction mixture was cooled to room temperature, quenched with H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash NH-silica gel chromatography (gradient of 20 to 100% EtOAc in hexanes) to give (R)-1-(6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 477.
[0301] Step C: (R)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)-4-(3-methyl-3-((trimethylsilyl)oxy)piperidin-1-yl)quinazoline To a solution of (R)-1-(6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (161 mg, 0.338 mmol) in DMF (3.4 mL) was added imidazole (115 mg, 1.69 mmol) and chlorotrimethylsilane (0.129 mL, 1.01 mmol) at room temperature. After the mixture was stirred at room temperature for 2 h, the reaction was quenched by the addition of water. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash NH-silica gel chromatography (gradient of 0 to 30% EtOAc in hexanes) to give (R)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)-4-(3-methyl-3-((trimethylsilyl)oxy)piperidin-1-yl)quinazoline. ESI-MS m / z[M+H] + 549.
[0302] Step D: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.5) To a 12 wt.% solution of (TMP)2Zn·xMgCl2·xLiCl in THF / toluene (4.33 mL, 0.590 mmol) was added (R)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)-4-(3-methyl-3-((trimethylsilyl)oxy)piperidin-1-yl)quinazoline (108 mg, 0.197 mmol). After stirring the mixture at 50 °C for 1.5 h, a solution of 1-bromo-8-chloro-3-(methoxymethoxy)naphthalene (71.2 mg, 0.236 mmol) and CPhos Pd G3 (15.9 mg, 0.0197 mmol) in 1,4-dioxane (1.0 mL) was added to the reaction mixture. After the mixture was stirred at 50° C. for 15 h, the reaction was quenched by the addition of aqueous saturated NaHCO3 and EtOAc, and the mixture was filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 20 to 100% EtOAc in hexanes). The fractions containing the intermediate were concentrated in vacuo. The residue was redissolved in dichloromethane (2.0 mL) and treated with 4.0 M HCl solution in 1,4-dioxane (1.0 mL). After the mixture was stirred at room temperature for 30 min, the reaction mixture was concentrated in vacuo. The residue was purified by reverse phase HPLC (MeCN / water, with 0.1% formic acid) to give (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.5). ESI-MS m / z [M+H] + 653,655. 1H NMR(400MHz,DMSO-d6)δ 10.31(s,0.5H),10.30(s,0.5H),7.87-7.79(m,1.5H),7.74(d,J=10.1Hz,0.5H),7.44-7.35(m,3H),7.12-7.09( m,1H),4.79(s,0.5H),4.65(s,0.5H),4.26-4.18(m,2H),4.09-3.95(m,1H),3.80(d,J=13.0Hz,1H),3.40(d,J=1 2.7Hz,0.5H),3.31-3.20(m,1.5H),3.18(s,3H),3.14-3.05(m,1H),2.79-2.65(m,2H),2.34-2.20(m,2H),2.10- 1.94(m,3H),1.82-1.55(m,5H),1.41-1.28(m,2H),1.16(s,1.5H),1.14(s,1.5H),0.61(brs,2H),0.37(brs,2H).
[0303] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.5, making the appropriate substitutions of starting materials, intermediates and reagents, where the appropriate substitutions are either commercially available, synthesized as described in the literature, synthesized using methods available to one skilled in the art, or synthesized as described herein. [Table 9]
[0304] [Example 7]: (3R)-1-(7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.7) [ka]
[0305] To a solution of (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.5) (25.6 mg, 0.0392 mmol), triisopropylsilylacetylene (87.2 μL, 0.392 mmol) and XPhos Pd G3 (16.6 mg, 0.0196 mmol) in DMF (0.4 mL) was added N-cyclohexyl-N-methylcyclohexanamine (0.0420 mL, 0.196 mmol). The vessel was evacuated and backfilled with nitrogen and the mixture was stirred at 100 °C for 12 h. The mixture was diluted with EtOAc, the diluted mixture was washed with aqueous saturated NaHCO3, and the mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (MeCN / water, with 0.1% formic acid) to give the coupling product (peak 1, first eluting). To a solution of the coupling product (peak 1, first eluting) in THF (1 mL) was added tetrabutylammonium fluoride (0.100 mL, 0.100 mmol, 1 M in tetrahydrofuran) and the mixture was stirred at room temperature for 3 h. The mixture was diluted with ethyl acetate, the diluted mixture was washed with water, and the mixture was concentrated under reduced pressure. The residue was purified by flash NH2-silica gel chromatography (gradient of 0 to 10% MeOH in EtOAc) to give (3R)-1-(7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-((1-((4-methoxypiperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex. 7). ESI-MS m / z [M+H] + 643. 1H NMR(400MHz,DMSO-d6)δ 10.17(s,1H),7.89(dd,J=8.2,1.4Hz,1H),7.65(d,J=10.1Hz,1H),7.49-7.39(m,2H),7.35(d,J=2.6Hz,1H),7.10(d,J=2 .6Hz,1H),4.67(s,1H),4.24(d,J=10.8Hz,1H),4.17(d,J=10.8Hz,1H),4.05(d,J=13.5Hz,1H),3.84(d,J=13.1Hz,1H),3 .57(s,1H),3.38-3.32(m,1H),3.26-3.20(m,1H),3.18(s,3H),3.15-3.06(m,1H),2.79-2.66(m,2H),2.34-2.21(m,2H), 2.11-1.95(m,3H),1.82-1.73(m,2H),1.73-1.55(m,3H),1.42-1.29(m,2H),1.14(s,3H),0.61(brs,2H),0.37(brs,2H).
[0306] [Example 8]: 1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-6,8-difluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.8) [ka]
[0307] Step A: 1-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of 7-bromo-2,4-dichloro-6,8-difluoroquinazoline (500 mg, 1.59 mmol) and 3-methylpiperidin-3-ol hydrochloride (266 mg, 1.75 mmol) in DMSO (3 mL) was added N,N-diisopropylethylamine (1.10 mL, 6.37 mmol) at room temperature. After the mixture was stirred at room temperature for 30 min, the reaction was quenched by the addition of water. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 20 to 50% EtOAc in hexanes) to give 1-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 392,394,396.
[0308] Step B: 1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of 1-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (560 mg, 1.43 mmol) and (1-((dimethylamino)methyl)cyclopropyl)methanol (203 mg, 1.57 mmol) in DMF (14 mL) was added cesium carbonate (929 mg, 2.85 mmol) and 1,4-diazabicyclo[2.2.2]octane (32.0 mg, 0.285 mmol) at room temperature. After the mixture was stirred at room temperature for 63 h, the reaction was quenched by the addition of water. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash NH2-silica gel chromatography (gradient of 0 to 20% MeOH in EtOAc) to give 1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 485,487.
[0309] Step C: 1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-6,8-difluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of 1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (25.0 mg, 0.0515 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol (18.1 mg, 0.0670 mmol) and tetrakis(triphenylphosphine)palladium(0) (6.0 mg, 5.2 μmol) in 1,4-dioxane (0.5 mL) was added 2.0 M aqueous Na2CO3 (51.5 μL, 0.103 mmol) at room temperature. The mixture was stirred at 100 °C for 16 h, after which the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC (0 to 100% MeCN / water, with 0.1% formic acid) to give 1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-6,8-difluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.8). ESI-MS m / z [M+H] + 549. 1H NMR(400MHz,DMSO-d6)δ 10.02-10.00(m,1H),7.89(d,J=10.3Hz,1H),7.81(d,J=8.3Hz,1H),7.48-7.41(m,1H),7 .35-7.21(m,3H),7.16-7.12(m,1H),4.69-4.68(m,1H),4.24-4.16(m,2H),4.14-4.04(m, 1H),3.91-3.82(m,1H),3.42-3.33(m,1H),3.29-3.20(m,1H),2.22(brs,2H),2.15(s,6H) ,2.09-1.95(m,1H),1.76-1.56(m,3H),1.16-1.14(m,3H),0.62(brs,2H),0.39(brs,2H).
[0310] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.8, making appropriate substitutions of starting materials, intermediates and / or reagents. Suitable replacement materials are either commercially available, synthesized as described in the literature, synthesized using methods available to one skilled in the art, or synthesized as described herein. [Table 10]
[0311] [Example 10]: (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.10) [ka]
[0312] Step A: (R)-1-(7-bromo-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-25) (300 mg, 0.764 mmol) and (R)-(1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methanol hydrochloride (Int-10) (169 mg, 0.840 mmol) in DMF (7.5 mL) was added cesium carbonate (747 mg, 2.29 mmol), 1,4-diazabicyclo[2.2.2]octane (17.1 mg, 0.153 mmol) and N,N-diisopropylethylamine (0.399 mL, 2.29 mmol) at room temperature. The mixture was stirred at room temperature for 87 h, after which the reaction was quenched by the addition of HO. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 20 to 100% EtOAc in hexanes) to give (R)-1-(7-bromo-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.10-A). ESI-MS m / z[M+H] + 521,523. 1 H NMR(400MHz,CDCl3)δ 8.02(dd,J=9.8,2.0Hz,1H),4.66(s,1H),4.23(d,J=13.0Hz,1H),3.93(d,J=13.3Hz,1H),3. 42(d,J=13.4Hz,1H),3.24-3.13(m,1H),2.05-1.89(m,1H),1.72-1.54(m,3H),1.11(s,3H).
[0313] Step B: (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(7-bromo-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (182 mg, 0.349 mmol), triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) (259 mg, 0.524 mmol) and cataCXium® A Pd G3 (50.8 mg, 0.0698 mmol) in THF (3.5 mL) was added a 1.0 M aqueous solution of K3PO4 (1.05 mL, 1.05 mmol) at room temperature. After the mixture was stirred at 65° C. for 16 h, the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash NH2-silica gel chromatography (gradient of 20 to 50% EtOAc in hexanes) to give the coupling product. To a solution of this coupling product in dichloromethane (4.0 mL) was added 4.0 M HCl solution in 1,4-dioxane (2.0 mL). After the mixture was stirred at room temperature for 1 h, the reaction mixture was concentrated in vacuo. The residue was purified by reverse-phase HPLC (MeCN / water, with 0.1% formic acid) to give the naphthol product (peak 1, first elution). To a solution of this naphthol product (peak 1, first elution) in THF (3.5 mL) was added tetrabutylammonium fluoride (0.350 mL, 0.350 mmol, 1 M in tetrahydrofuran) and the mixture was stirred at room temperature for 15 h. The mixture was diluted with ethyl acetate, the diluted mixture was washed with water, and the mixture was concentrated under reduced pressure. The residue was purified by flash NH-silica gel chromatography (gradient of 0 to 10% MeOH in EtOAc) to give (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.10). ESI-MS m / z[M+H] +609. 1 H NMR(400MHz,DMSO-d6)δ 10.18(s,1H),7.89(dd,J=8.2,1.4Hz,1H),7.68(d,J=9.7Hz,1H),7.50-7.39(m,2H),7.37(d,J=2.6Hz,1H ),7.11(d,J=2.6Hz,1H),4.68(s,1H),4.43(d,J=11.2Hz,1H),4.38(d,J=10.9Hz,1H),4.08(d,J=13.6Hz, 1H),3.87(d,J=13.3Hz,1H),3.58(s,1H),3.39-3.33(m,1H),3.27-3.17(m,1H),2.60(d,J=12.0Hz,1H),2 .35(d,J=12.8Hz,1H),2.15(s,6H),2.09-1.96(m,1H),1.82-1.56(m,4H),1.52-1.42(m,1H),1.14(s,3H).
[0314] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.10, with appropriate substitutions of starting materials, intermediates and / or reagents, and optionally, after completion of the indicated step using the indicated conditions, stereoisomers were resolved and the indicated peak was carried forward. The appropriate substitutions are commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein. [Table 11]
[0315] [Example 13]: (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.13) [ka]
[0316] To a solution of (R)-1-(7-bromo-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.10-A) (30.0 mg, 0.0575 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol (20.2 mg, 0.0748 mmol) and tetrakis(triphenylphosphine)palladium(0) (6.7 mg, 5.8 μmol) in 1,4-dioxane (0.6 mL) was added 2.0 M aqueous solution of Na2CO3 (57.5 μL, 0.115 mmol) at room temperature. The mixture was stirred at 100 °C for 14 h, after which the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC (MeCN / water, with 0.1% formic acid) to give (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.13). ESI-MS m / z[M+H] + 585. ESI-MS m / z[M+H] + 621,623. 1H NMR(400MHz,DMSO-d6)δ 10.02-10.00(m,1H),7.91(d,J=10.3Hz,1H),7.81(d,J=8.1Hz,1H),7.48-7.41(m,1H),7.36-7.21(m,3H) ),7.17-7.13(m,1H),4.70-4.68(m,1H),4.45(d,J=11.2Hz,1H),4.39(d,J=11.2Hz,1H),4.11(d,J=13.0 Hz,1H),3.95-3.85(m,1H),3.40(d,J=13.2Hz,1H),3.30-3.20(m,1H),2.61(d,J=13.2Hz,1H),2.35(d,J =13.0Hz,1H),2.15(s,6H),2.09-1.95(m,1H),1.84-1.56(m,4H),1.52-1.42(m,1H),1.17-1.16(m,3H).
[0317] [Example 14]: (3R)-1-(7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.14) [ka]
[0318] To a solution of (R)-1-(7-bromo-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.10-A) (30.0 mg, 0.0575 mmol), 2-(8-chloro-7-fluoronaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (35.3 mg, 0.115 mmol) and XPhos Pd G2 (4.5 mg, 5.8 μmol) in 1,4-dioxane (0.6 mL) was added a 2.0 M aqueous solution of Na2CO3 (57.5 mL, 0.115 mmol) at room temperature. The mixture was stirred at 100 °C for 6 h, after which the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC (0 to 100% MeCN / water, with 0.1% formic acid) to give (3R)-1-(7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.14). ESI-MS m / z[M+H] + 621,623. 1 H NMR(400MHz,DMSO-d6)δ 8.28-8.19(m,2H),7.88(d,J=9.0Hz,0.5H),7.79(d,J=9.4Hz,0.5H),7.77-7.65(m,3H),4.7 9-4.65(m,1H),4.45(d,J=10.9Hz,1H),4.38(d,J=11.4Hz,1H),4.15-4.00(m,1H),3.86(d,J =12.8Hz,1H),3.45-3.33(m,1H),3.30-3.20(m,1H),2.61(d,J=13.2Hz,1H),2.38-2.30(m,1 H),2.15(s,6H),2.09-1.92(m,1H),1.84-1.55(m,4H),1.52-1.42(m,1H),1.16-1.14(m,3H).
[0319] [Example 15]: (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.15) [ka]
[0320] To a solution of (3R)-1-(7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.14) (7.2 mg, 12 μmol), triisopropylsilylacetylene (25.8 μL, 0.116 mmol) and XPhos Pd G3 (4.9 mg, 5.8 μmol) in DMF (0.25 mL) was added N-cyclohexyl-N-methylcyclohexanamine (12.4 μL, 58.0 μmol). The vessel was evacuated and backfilled with nitrogen and the mixture was stirred at 100° C. for 15 h. The mixture was diluted with EtOAc, the diluted mixture was washed with aqueous saturated NaHCO3 and the mixture was concentrated under reduced pressure to give the coupling product. The residue was purified by flash NH2-silica gel chromatography (gradient of 20 to 50% EtOAc in hexanes) to give the coupled product.
[0321] To a solution of the above coupling product in THF (0.2 mL) was added tetrabutylammonium fluoride (0.0200 mL, 0.0200 mmol, 1M in tetrahydrofuran) and the mixture was stirred at room temperature for 30 min. The mixture was diluted with ethyl acetate, the diluted mixture was washed with water, and the mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (MeCN / water, with 0.1% formic acid) to give (3R)-1-(2-(((R)-1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.15). ESI-MS m / z [M+H] + 611. 1 H NMR(400MHz,DMSO-d6)δ 8.27-8.14(m,2H),7.81-7.58(m,4H),4.72-4.69(m,1H),4.48-4.33( m,2H),4.15-4.00(m,2H),3.95-3.78(m,1H),3.45-3.35(m,1H),3.28- 3.15(m,1H),2.65-2.56(m,1H),2.40-2.31(m,1H),2.15(s,6H),2.09- 1.95(m,1H),1.84-1.55(m,4H),1.52-1.42(m,1H),1.16-1.14(m,3H).
[0322] [Example 16]: (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.16) [ka]
[0323] To a solution of (R)-1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-18) (123 mg, 0.263 mmol), triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) (156 mg, 0.316 mmol) and cataCXium® A Pd G3 (38.3 mg, 0.0526 mmol) in THF (2.6 mL) was added a 1.0 M aqueous solution of K3PO4 (0.790 mL, 0.790 mmol) at room temperature. After the mixture was stirred at 65° C. for 15 h, the reaction was quenched by the addition of H2O. The reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 0 to 30% MeOH in EtOAc) to give the coupling intermediate, which was redissolved in DCM (4 mL). The reaction mixture was treated with 4.0 M HCl solution in 1,4-dioxane (2.0 mL). After the mixture was stirred at room temperature for 30 min, the reaction mixture was concentrated in vacuo. The residue was purified by reverse phase HPLC (0 to 100% MeCN / water, with 0.1% formic acid) to give the deprotected naphthol intermediate, which was redissolved in THF (4 mL). The reaction mixture was treated with tetrabutylammonium fluoride (0.800 mL, 0.800 mmol, 1 M in tetrahydrofuran), and the mixture was stirred at room temperature for 20 h. The mixture was diluted with ethyl acetate, the diluted mixture was washed with water, and the mixture was concentrated under reduced pressure. The residue was purified by flash NH2-silica gel chromatography (gradient of 0 to 10% MeOH in EtOAc) to give (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.16). ESI-MS m / z [M+H] + 555. 1H NMR(400MHz,DMSO-d6)δ 10.09(s,1H),7.89-7.75(m,2H),7.47-7.37(m,2H),7.29(d,J=2.5Hz,1H),7.21-7.1 4(m,1H),7.-7.00(m,1H),4.65-4.60(m,1H),4.23-4.14(m,2H),4.10-3.92(m,1H),3. 90-3.72(m,1H),3.50-3.36(m,2H),3.29-3.22(m,1H),2.22(brs,2H),2.15(s,6H),2. 10-1.94(m,1H),1.74-1.56(m,3H),1.15-1.14(m,3H),0.62(brs,2H),0.38(brs,2H).
[0324] [Example 17]: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)azepan-4-ol (Ex. 17) [ka]
[0325] To a mixture of 1-(7-bromo-6-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)azepan-4-ol (Int-19) (25 mg, 0.050 mmol), [2-(tert-butoxycarbonylamino)-7-fluoro-1,3-benzothiazol-4-yl]boronic acid (20 mg, 0.065 mmol) and tetrakis(triphenylphosphine)palladium(0) (5.8 mg, 5.0 μmol) in 1,4-dioxane (2 mL) was added sodium carbonate (0.050 mL, 2 M aqueous solution) and the mixture was stirred at 100° C. for 16 hours. The mixture was diluted with ethyl acetate and the diluted mixture was concentrated under reduced pressure. To the residue was added hydrochloride salt (3 mL, 4 M in 1,4-dioxane) and the mixture was stirred at 50° C. for 1 hour. After concentration under reduced pressure, the residue was purified by reverse phase HPLC (MeCN / water, containing 0.1% formic acid) to give 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-4-yl)azepan-4-ol (Ex. 17). ESI-MS m / z[M+H]+589,591. 1 H NMR(400MHz,DMSO-d6)δ 7.99-7.90(m,3H),7.26-7.21(m,1H),7.09-7.03(m,1H),4.65-4.63(m,1H),4.25-4.17(m,2H),4.00-3.75(m,6) H),2.55(s,2H),2.30-2.05(m,7H),1.94-1.69(m,3H),1.63-1.53(m,1H),0.65-0.59(m,2H),0.43-0.37(m,2H).
[0326] [Example 18]: 2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-4-(4-hydroxyazepan-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile (Ex.18) [ka]
[0327] To a solution of 1-(7-bromo-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol (Int-21) (30.0 mg, 0.0564 mmol), (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinane-2-yl)-7-fluorobenzo[b]thiophen-2-yl)tert-butyl carbamate (Int-15) (34.2 mg, 0.0846 mmol) and dichlorobis(diphenylphosphinophenyl)etherpalladium(II) (6.1 mg, 8.5 μmol) in toluene (1.5 mL) was added cesium carbonate (45.9 mg, 0.141 mmol). After the mixture was stirred at 100° C. for 13 h, the reaction mixture was cooled to room temperature, quenched with H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (gradient of 0 to 50% MeOH in EtOAc) to give the coupling intermediate, which was redissolved in DCM (0.5 mL). The reaction mixture was treated with HCl (0.5 mL, 4.0 M in 1,4-dioxane). After the mixture was stirred at room temperature for 6 h, the reaction mixture was concentrated in vacuo. The residue was purified by flash NH-silica gel chromatography (gradient of 0 to 10% MeOH in EtOAc) to give 2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-4-(4-hydroxyazepan-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile (Ex. 18). ESI-MS m / z[M+H] + 643,645. 1H NMR(400MHz,DMSO-d6)δ 8.09(s,2H),7.95(s,1H),7.26-7.21(m,1H),7.17-7.10(m,1H),5.33-5.20(m,1H),4.66-4.61(m,1H),4.12-4.05(m, 1H),4.02-3.70(m,6H),3.13-2.96(m,3H),2.87-2.75(m,1H),2.15-1.67(m,9H),1.61-150(m,1H),1.26-1.19(m,2H).
[0328] [Example 19]: (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)pyrido[3,2-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex.19) [ka]
[0329] To a solution of (R)-1-(7-bromo-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-20) (60 mg, 0.13 mmol), triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) (79 mg, 0.16 mmol) and cataCXium® A Pd G3 (19 mg, 0.027 mmol) in THF (3.0 mL) was added a 1.0 M aqueous solution of K3PO4 (0.40 mL, 0.40 mmol) at room temperature. The mixture was stirred at 60 °C for 4 h, after which the reaction was quenched by the addition of HO. The reaction mixture was extracted with EtOAc, washed with water, and the mixture was concentrated under reduced pressure. To the residue was added hydrochloride (0.3 mL, 4M in 1,4-dioxane), and the mixture was stirred at room temperature for 1 h. After concentration, tetrabutylammonium fluoride (0.3 mL, 1M in THF) was added to the residue, and the mixture was stirred at room temperature for 1 h. The mixture was diluted with ethyl acetate, the diluted mixture was washed with water, and the mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (MeCN / water, with 0.1% formic acid) to give (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)pyrido[3,2-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex.19). ESI-MS m / z [M+H] + 538. 1H NMR(400MHz,DMSO-d6)δ 10.17(br s,1H),8.48(dd,J=4.4,2.4Hz,1H),7.91-7.88(m,1H),7.72(dd,J=12.8,2Hz,1H),7.51-7.40 (m,2H),7.31(d,J=2.8Hz,1H),7.07(dd,J=17.4,2.4Hz,1H),4.57-4.49(m,1H)4.38-4.15(m,3 H),4.10-3.90(m,1H),3.74-3.68(m,1H),2.29-2.21(m,2H),2.18(s,6H),2.01-1.86(m,2H),1 .71-1.50(m,3H),1.25-1.22(m,1H),1.15-1.07(m,3H),0.65-0.61(m,2H),0.43-0.38(m,2H).
[0330] [Example 20]: (R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex.20) [ka]
[0331] Step A: (R)-1-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(7-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (30 mg, 0.071 mmol), 2-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (30 mg, 0.085 mmol) and potassium carbonate (48.9 mg, 0.354 mmol) in 1,4-dioxane (3.0 ml) / water (0.6 ml) was added tetrakis(triphenylphosphine)palladium(0) (16 mg, 0.014 mmol) at room temperature. The mixture was degassed under reduced pressure and purged with nitrogen several times. The mixture was stirred at 85° C. for 24 h under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash NH2-silica chromatography (eluent 12 to 100% EtOAc in hexanes) and reverse-phase HPLC (MeCN / water with 0.1% formic acid) to give (R)-1-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 610,612. 1 H NMR(400MHz,CDCl3)δ 9.12-9.22(m,1H),7.32-7.84(m,5H),5.30-5.35(m,2H),4.28-4.45(m,4H),3.44-3.75(m,5H),3.26-3.34(m,1H),3.14(br s,1H),2.31-2.62(m,8H),1.43-2.10(m,4H),1.23-1.36(m,3H),0.72(br s,2H),0.51(br s,2H).
[0332] Step B: (R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex. 20) To a solution of (R)-1-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (7.6 mg, 0.013 mmol) in 1,4-dioxane (1.0 mL) was added 4M HCl in 1,4-dioxane (93.4 μL, 0.374 mmol) at room temperature under nitrogen atmosphere. The mixture was stirred at room temperature for 1 h under nitrogen atmosphere. The reaction mixture was concentrated in vacuo. The residue was purified by reverse phase HPLC (0 to 100% MeCN / water, containing 0.1% formic acid) to give (R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex. 20). ESI-MS m / z[M+H] + 566,568. 1 H NMR(400MHz,CDCl3)δ 9.00-9.19(m,1 H),7.51-7.76(m,1H),7.18-7.25(m,2H),6.37-7.08(m,2H),3.94-4.49(m,5H),3.15-3.23(m,1H),2. 91-3.00(m,1H),2.53-2.66(m,2H),2.42-2.46(m,6H),1.29-1.88(m,4H),1.24-1.26(m,3H),0.73(br s,2H),0.55(br s,2H).
[0333] [Example 21]: (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex.21) [ka]
[0334] Step A: (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(7-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Int-17) (100 mg, 0.236 mmol), triisopropyl((6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)silane (Int-38) (140 mg, 0.283 mmol) and cataCXium® A Pd G3 (34 mg, 0.047 mmol) in THF (2.0 mL) was added potassium phosphate, tribasic (150 mg, 0.708 mmol) at room temperature. The mixture was degassed under reduced pressure and purged with nitrogen several times. The mixture was stirred at 60° C. for 16 h under nitrogen atmosphere. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash NH-silica chromatography (eluent 12-100% EtOAc in hexanes) and reverse-phase HPLC (C18, 0-100% MeCN / water with 0.1% formic acid) to give (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z [M+H] + 756. 1H NMR(400MHz,CDCl3)δ 9.15-9.18(m,1H),7.80-7.82(m,1H),7.66-7.70(m,1H),7.51-7.52(m,1H),7.38-7.43(m,1H),7.30-7.33(m,1H),5.29-5.34(m,2H), 4.31-4.48(m,4H),2.85-3.75(m,6H),2.27-2.43(m,8H),1.60-2.17(m,4H),1.22-1.35(m,3H),0.85-0.89(m,18H),0.48-0.74(m,7H).
[0335] Step B: (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-7-(3-hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol To a solution of (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-7-(3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (78 mg, 0.10 mmol) in 1,4-dioxane (1.0 mL) was added 4 M HCl in 1,4-dioxane (0.129 mL, 0.516 mmol) at room temperature under nitrogen atmosphere. The mixture was stirred at room temperature for 1 h under nitrogen atmosphere. The reaction mixture was concentrated in vacuo. The residue was purified by reverse phase HPLC (C18, 0-100% MeCN / water with 0.1% formic acid) to give (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-7-(3-hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol. ESI-MS m / z[M+H] + 712. 1H NMR(400MHz,CDCl3)δ 9.12-9.01(m,1H),7.59-7.68(m,1H),7.48-7.53(m,1H),7.48-7.50(m,1H),7.24-7.32(m,1H),6.90-6.97 (m,1H),6.14-6.67(m,1H),3.94-4.90(m,5H),2.18-3.22(m,10H),1.21-1.74(m,7H),0.44-0.81(m,25H).
[0336] Step C: (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex.21) To a solution of (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-7-(3-hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (62 mg, 0.087 mmol) in THF (1.0 mL) was added 1 M tetrabutylammonium fluoride in THF (0.26 mL, 0.26 mmol) at room temperature under nitrogen atmosphere. The mixture was stirred at room temperature for 3 h under nitrogen atmosphere. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC (MeCN / water, containing 0.1% formic acid) to give (R)-1-(2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Ex.21). ESI-MS m / z[M+H] + 556. 1H NMR(400MHz,CDCl3)δ 8.90-9.07(m,1H),7.58-7.65(m,1H),7.36-7.45(m,1H),7.19-7.30(m,1H),6.56-7.02(m,2H),4.00-4.49(m,5H),3.72(q,2H,J=7.0Hz ),3.01-3.19(m,2H),2.48-2.62(m,3H),2.34-2.39(m,6H),1.37-1.89(m,4H),1.20-1.28(m,3H),0.66-0.74(m,2H),0.50-0.54(m,2H).
[0337] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.21, making appropriate substitutions of starting materials, intermediates and / or reagents. Suitable replacement materials are either commercially available, synthesized as described in the literature, synthesized using methods available to one skilled in the art, or synthesized as described herein. [Table 12]
[0338] [Example 25]: 1-(7-(2-amino-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol (Ex.25) [ka]
[0339] Step A: 1-(7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol To a solution of 7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-40) (50 mg, 0.061 mmol) in MeCN (1 mL) was added BOP (40.2 mg, 0.091 mmol) at 25° C. The mixture was stirred at 25° C. for 30 min. Azepan-4-ol hydrochloride (13.80 mg, 0.091 mmol) and DIEA (0.053 mL, 0.303 mmol) were added to the reaction solution; then the mixture was stirred at 80° C. for 15 h. LCMS showed that the starting material was consumed and the desired MS was formed. TLC (SiO2; DCM:MeOH=15:1) showed that the starting material was consumed and a new spot was observed. After cooling to room temperature, the reaction solution was concentrated under reduced pressure and the residue was purified by preparative TLC plate (SiO2, DCM / MeOH=15 / 1) to give 1-(7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol. MS(ESI)[M+H] + m / z:921.
[0340] Step B: 1-(7-(2-amino-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol A solution of 1-(7-(2-(bis(2,4-dimethoxybenzyl)amino)-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol (35 mg, 0.038 mmol) in TFA (1 mL) was stirred at 50° C. for 30 min. The reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (1 mL). K2CO3 (26.2 mg, 0.190 mmol) was added to the mixture and the mixture was stirred at 25° C. for 3 h. The reaction mixture was filtered and the filtrate was purified by preparative HPLC (C18, 0 to 100% ACN / water, containing 0.1% TFA) followed by preparative HPLC (C18, ACN / water, containing 10 mM NH4HCO3) to give 1-(7-(2-amino-5,7-difluorobenzo[d]oxazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)azepan-4-ol (Ex.25). MS(ESI)[M+H] + m / z:621 1 H NMR(400MHz,MeOD)δ 8.04(s,1H),6.85(t,J=10.3Hz,1H),5.38-5.18(m,1H),4.32-4.24(m,1H),4.23-4.16(m,1H),4.14-3.8 4(m,5H),3.28-3.09(m,3H),3.05-2.94(m,1H),2.38-2.08(m,5H),2.06-1.79(m,6H),1.78-1.61(m,1H).
[0341] [Example 26]: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.26) [ka]
[0342] Step A: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-41, 100 mg, 0.130 mmol) in MeCN (1 mL) was added BOP (86 mg, 0.195 mmol) at 20° C. The mixture was stirred at 20° C. for 30 min. TEA (0.09 mL, 0.646 mmol) and 3-methylpiperidin-3-ol, HCl (30 mg, 0.198 mmol) were added to the reaction solution; the mixture was stirred at 80° C. for 2 h. LCMS showed the starting material was consumed and the desired peak was formed. TLC (SiO2; petroleum ether:ethyl acetate=1:1) showed the starting material was consumed and a new spot was observed. The reaction solution was purified by preparative TLC (SiO2, petroleum ether:ethyl acetate=1:1) to give 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol. MS(ESI)[M+H] + : m / z 867.
[0343] Step B: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol A solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (113 mg, 0.130 mmol) in TFA (2 mL, 26.0 mmol) was stirred at 50° C. for 15 h. LCMS showed the starting material was consumed and the desired peak was formed. TLC (SiO2; DCM:MeOH=10:1) showed the starting material was consumed and a new spot was observed. The mixture was cooled and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by preparative TLC (SiO2, DCM:MeOH=10:1) to give 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol. MS(ESI)[M+H] + : m / z 627.
[0344] Step C: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol Racemic 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (80 mg, 0.128 mmol) was purified by SFC (column D, containing 0.1% NH4OH). 40% MeOH) to give 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.26) (the first isomer eluted by SFC). 1 H NMR(400MHz,MeOD)δ 8.09(d,J=1.6Hz,1H),6.61(s,1H),5.54-5.39(m,1H),4.58-4.51(m,1H),4.49-4.42(m,1H),4.30 -4.27(m,1H),4.09-4.06(m,1H),3.83-3.69(m,1H),3.66-3.62(m,2H),3.51(d,J=13.3Hz,1H),3. 45-3.32(m,2H),3.30-3.25(m,1H),2.63-2.49(m,1H),2.46-2.42(m,3H),2.35-2.28(m,1H),2.22 -2.18(m,2H),2.15-2.01(m,2H),1.88-1.80(m,1H),1.80-1.70(m,2H),1.26(s,3H).MS(ESI)[M+H] + : m / z 627.
[0345] [Example 27]: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidin-3-ol (Ex.27) [ka]
[0346] Step A: (3R)-1-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidin-3-ol 7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-34) (0.0140 g, 0.0250 mmol) was dissolved in acetonitrile (0.250 mL), ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate (V) (0.0170 g, 0.0380 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.0160 g, 0.125 mmol) were added, and the mixture was stirred at 18 ° C. for 1 hour. (R)-piperidin-3-ol (0.00505 g, 0.0500 mmol) was added to the reaction solution, and the mixture was stirred at 18° C. for 16 hours. The mixture was concentrated, and the resulting mixture was diluted with EtOAc (2 mL * 2) and washed with HO (1 mL). The organic layers were then combined and concentrated under reduced pressure to give (3R)-1-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidin-3-ol. MS (ESI) [M+H] + m / z 643.
[0347] Step B: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidin-3-ol (Ex.27) (3R)-1-(7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidin-3-ol (0.0128 g, 0.0200 mmol) was dissolved in dioxane (0.500 mL). HCl / dioxane (0.4 M, 0.50 mL) was added and the reaction was shaken at 40° C. for 1 h. The mixture was evaporated under vacuum and purified by HPLC (C18, 0-100% ACN / water, with 0.1% TFA) to give (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidin-3-ol (Ex.27). MS(ESI)[M+H] + : m / z 599.
[0348] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.27, with appropriate substitutions of starting materials, intermediates and / or reagents. The stereoisomers of the examples were optionally: 1) completed at the indicated step using the indicated conditions, then resolved and the indicated peak carried forward; 2) synthesized by using the indicated intermediate(s) that were optionally resolved as described herein; 3) optionally synthesized using commercially available chirally pure reagents; or 4) synthesized using the indicated intermediate(s) that were resolved and then resolved. The appropriate replacement materials are commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein.
[0349] [Table 13]
[0350] TIFF2024543879000089.tif184165
[0351] TIFF2024543879000090.tif179165
[0352] TIFF2024543879000091.tif184164
[0353] TIFF2024543879000092.tif80163
[0354] [Example 42]: (3R)-1-(7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.42) [ka]
[0355] To a flask containing 7-(8-ethynyl-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-ol (Int-37) (92 mg, 0.17 mmol) and acetonitrile (1.0 mL) was added BOP (0.11 g, 0.25 mmol), followed by Hunig's base (0.15 mL, 0.84 mmol) and then (3R)-3-methyl-piperidin-3-ol hydrochloride (25 mg, 0.17 mmol). The mixture was heated to 80° C. for 1 h. After 1 h, the mixture was allowed to cool to room temperature. HCl (4.0 M in dioxane, 0.43 mL, 1.7 mmol) was added and the mixture was heated to 40° C. for 1 h. After 1 h, the mixture was allowed to cool to room temperature. DMSO (0.50 mL) was added and the mixture was purified by reverse phase HPLC (MeCN / water, with 0.1% TFA modifier) to give impure product. This impure product was further purified by SFC (column V; 30% MeOH with 0.1% NH4OH) to give (3R)-1-(7-(8-ethynyl-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.42). MS (ESI): m / z (M+H) + 603. 1H NMR(499MHz,DMSO-d6)δ 7.90(d,J=8.2Hz,1H),7.68(d,J=9.8Hz,1H),7.49(d,J=7.1Hz,1H),7.46-7.41(m,1H),7.37(d,J=2.5Hz,1 H),7.12(d,J=2.5Hz,1H),5.29(d,J=53.9Hz,1H),4.70(s,1H),4.13-4.05(m,2H),4.02-3.96(m,1H),3.90 -3.82(m,1H),3.58(s,1H),3.39-3.36(m,1H),3.27-3.21(m,1H),3.14-3.08(m,2H),3.08-3.00(m,2H),2. 87-2.80(m,1H),2.16-2.11(m,1H),2.11-2.00(m,3H),1.88-1.76(m,3H),1.72-1.61(m,3H),1.16(s,3H).
[0356] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.42, making appropriate substitutions of starting materials, intermediates and / or reagents, where the appropriate substitutions are either commercially available, synthesized as described in the literature, synthesized using methods available to one skilled in the art, or synthesized as described herein. [Table 14]
[0357] [Example 45]: Dimethylcarbamate ((3S,7aS)-7a-(((7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoro-4-((R)-3-hydroxy-3-methylpiperidin-1-yl)quinazolin-2-yl)oxy)methyl)hexahydro-1H-pyrrolidin-3-yl)methyl (Ex. 45) [ka]
[0358] Step A: (3R)-1-(7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoro-2-(((3S,7aS)-3-(hydroxymethyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (3R)-1-(2-(((3S,7aS)-3-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-6,8-difluoro-7-(7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-30) (105 mg, 0.104 mmol) in THF (0.7 mL) was added TBAF (0.311 mL, 0.311 mmol). The mixture was stirred at 20° C. for 1 h. LCMS showed that a major peak of the desired product mass was observed. The mixture was concentrated and the residue was purified by preparative TLC (CH2Cl2 / NH3 (7M in MeOH) = 100:3) to give (3R)-1-(7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoro-2-(((3S,7aS)-3-(hydroxymethyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol. MS (ESI) [M+H] + m / z 617.
[0359] Step B: Dimethylcarbamate ((3S,7aS)-7a-(((7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoro-4-((R)-3-hydroxy-3-methylpiperidin-1-yl)quinazolin-2-yl)oxy)methyl)hexahydro-1H-pyrrolidin-3-yl)methyl (Ex. 45) To a solution of (3R)-1-(7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoro-2-(((3S,7aS)-3-(hydroxymethyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (40 mg, 0.065 mmol) in THF (0.5 mL) was added sodium hydride (6.23 mg, 0.259 mmol) at 0° C. The mixture was stirred at 0° C. for 0.5 h. Dimethylcarbamic acid chloride (10.46 mg, 0.097 mmol) in THF (0.5 mL) was then added. The mixture was stirred at 20° C. for 15 h under nitrogen. LCMS showed that a major peak of the desired product mass was observed. The mixture was quenched with HO (3 mL) and EtOAc (3 mL * 3), the organic layer was dried over Na2SO4, filtered, concentrated and the residue was purified by preparative HPLC (C18, 0 to 100% ACN / water, with 0.225% formic acid) to give dimethylcarbamate ((3S,7aS)-7a-(((7-(8-ethynyl-7-fluoronaphthalen-1-yl)-6,8-difluoro-4-((R)-3-hydroxy-3-methylpiperidin-1-yl)quinazolin-2-yl)oxy)methyl)hexahydro-1H-pyrrolidin-3-yl)methyl (Ex. 45). MS (ESI) [M+H] + m / z 688. 1 H NMR(400MHz,MeOD)δ 8.06-8.16(m,2 H),7.72(d,J=9.6Hz,1 H),7.61-7.69(m,1 H),7.58(d,J=7.2Hz,1 H),7.45(t,J=8.8Hz,1 H),4.54-4.65(m,2 H),4.46-4.53(m,1 H),4.28-4.45(m,3 H),4.00-4.20(m,2 H),3.45-3.52(m,2 H),3.34-3.45(m,2 H),2.86(d,J=17.2Hz,6 H),2.38(d,J=6.4Hz,1 H),1.95-2.24(m,8 H),1.71-1.88(m,3 H),1.26(s,3 H).
[0360] [Example 46]: (3S)-1-(7-(8-ethynylnaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.46) [ka]
[0361] Step A: (3S)-1-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol To a solution of (3S)-1-(7-(8-chloronaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Int-31) (100 mg, 0.167 mmol) in DMF (2000 μL) was added N-cyclohexyl-N-methylcyclohexanamine (359 μL, 1.675 mmol), ethynyltriisopropylsilane (751 μL, 3.35 mmol) and XPHOs Pd G3 (128 mg, 0.151 mmol). The reaction mixture was degassed three times using nitrogen and vacuum and heated at 100° C. overnight. The reaction mixture was cooled to room temperature, diluted with EtOAc and quenched with saturated NH4Cl solution. The organic layer was separated, washed with brine and concentrated to give (3S)-1-(6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-7-(8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4-yl)-3-methylpiperidin-3-ol. MS (ESI): m / z [M+H] + 743
[0362] Step B: (3S)-1-(7-(8-ethynylnaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex. 46) The crude mixture from step A was placed in THF (2000 μL) and tetrabutylammonium fluoride (335 μL, 0.335 mmol) was added. The mixture was stirred for 30 min, diluted with EtOAc, washed twice with saturated NaHCO3 solution, with brine and concentrated. The product was purified using silica gel chromatography with 0 to 25% methanol in DCM to give a racemic mixture which was separated by chiral SFC (column U, 30% MeOH with 0.1% NH4OH) to give (3S)-1-(7-(8-ethynylnaphthalen-1-yl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol (Ex.46). MS (ESI): m / z [M+H] + 587. 1 H NMR(499MHz,DMSO-d6)δ 8.17(dd,J=12.6,8.3Hz,2H),7.78-7.68(m,3H),7.60(p,J=8.0Hz,2H),5.28(d,J=53.9Hz,1H),4.71(s,1H),4.03(dd,J=48.4,10.3Hz, 4H),3.85(t,J=13.1Hz,1H),3.66(s,1H),3.14-2.97(m,4H),2.84(t,J=8.2Hz,1H),2.23-1.91(m,5H),1.91-1.49(m,7H),1.16(s,3H).
[0363] The compounds in the following table were synthesized using procedures similar to those described in the synthesis of Ex.46, with appropriate substitutions of starting materials, intermediates and / or reagents, and optionally completing the indicated steps using the conditions indicated, resolving stereoisomers and carrying forward the indicated peaks. The appropriate substitutions are commercially available, synthesized as described in the literature, synthesized using methods available to one of skill in the art, or synthesized as described herein.
[0364] [Table 15]
[0365] [Example 49]: (3R)-1-(7-(8-chloro-3-hydroxynaphthalen-1-yl)-6,8-difluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperidin-3-ol trifluroacetate salt (Ex. 49) [ka]
[0366] A mixture of (3R)-1-(2-chloro-7-(8-chloro-3-(methoxymethoxy)naphthalen-1-yl)-6,8-difluoroquinazolin-4-yl)-3-methylpiperidin-3-ol (Int-29-2) (30 mg, 0.056 mmol), N-methyl-L-prolinol (19.4 mg, 0.17 mmol), and cesium carbonate (58.5 mg, 0.18 mmol) in dioxane (0.5 mL) in a 2 dram vial was sparged underwater with nitrogen for 2 minutes and treated with chloro(triphenylphosphine)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (PPh3-Pd-G2, 6.43 mg, 0.011 mmol). The vial was capped and heated at 95° C. for 6 hours, cooled to room temperature, diluted with ethyl acetate (3 ml), filtered through a pad of Florisil on Celite, rinsing the pad with ethyl acetate (2×10 ml) and the combined filtrates were concentrated. The residue was dissolved in 2-propanol (2 ml) and treated with 4M HCl in dioxane (0.5 ml) at room temperature. The mixture was stirred at room temperature for 20 hours, concentrated and the residue was purified by preparative HPLC (C18, 0-100% ACN / water, with 0.1% TFA) to give the title compound (Ex. 49). MS (ESI): m / z [M+H] + 569.1H NMR(500MHz,DMSO-d6)δ 10.38(s,1H),10.04(bs,1H),7.92(d,J=10.3Hz,1H),7.87(d,J=8.1Hz,1H),7.48-7.35(m,3H), 7.14(s,1H),4.71(dd,J=12.3,3.3Hz,1H),4.61(dd,J=12.4,6.7Hz,1H),4.11(d,J=13.0Hz,1H), 3.92(d,J=13.1Hz,1H),3.87-3.79(m,1H),3.69-3.54(m,2H),3.33-3.24(m,2H),3.22-3.06(m,1 H),2.96(d,J=4.7Hz,3H),2.34-2.21(m,1H),2.13-1.83(m,4H),1.82-1.57(m,3H),1.19(s,3H).
[0367] Assay Procedure for SOS-catalyzed guanine nucleotide exchange (GNE) assay of KRAS-G12C / D / V, HRAS and NRAS recombinant proteins Recombinant KRAS-G12C (SEQ ID NO:1), which contains an additional triple mutation (C51S / C80L / C118S) in this assay, KRAS-G12D (SEQ ID NO:2), KRAS-G12V (SEQ ID NO:3), HRAS (SEQ ID NO:4) and NRAS (SEQ ID NO:5) proteins are used in this assay. Specifically, the SOS-catalyzed nucleotide exchange assay uses preformed time-resolved fluorescence resonance energy transfer (TR-FRET) complexes containing specific biotinylated RAS proteins (KRAS-G12C / V / D, HRAS, NRAS; as described above) with BODIPY-GDP and terbium-streptavidin. Test compounds are preincubated with this complex for 60 minutes. The exchange reaction is then initiated by the addition of recombinant human SOS protein (SEQ ID NO:6) and unlabeled GTP. Small molecule inhibitors stabilize the BODIPY-GDP complex, while unprocessed protein rapidly exchanges BODIPY-GDP for unlabeled GTP, resulting in a reduction in the TR-FRET signal and allowing measurement of the inhibitory activity of test compounds.
[0368] To make preformed TR-FRET complexes, each biotinylated RAS protein is diluted to 2 μM in EDTA buffer (20 mM HEPES, 50 mM sodium chloride, 10 mM EDTA, and 0.01% Tween) and incubated at room temperature for 1 h. This mixture is then further diluted to 90 nM in assay buffer (20 mM HEPES, 150 mM sodium chloride, 10 mM magnesium chloride, and 0.005% Tween) containing 15 nM terbium-streptavidin (Invitrogen, Cat. No. PV3577) and 900 nM BODIPY-GDP (Invitrogen, Cat. No. G22360) and incubated at room temperature for 6 h. Note that this preformed TR-FRET complex of each RAS protein was made in advance, aliquoted, and stored at -80°C until the day of the experiment.
[0369] Each test compound (10 mM stock in DMSO) is diluted in DMSO in a 384-well low dead volume microplate (Labcyte, Cat. No. LP-0200) to make ten 3-fold dilutions. Once titrations are performed, 10 nL of diluted compound is acoustically dispensed into a 384-well assay plate (Corning, Cat. No. 3820) using an Echo 550 (Labcyte). Each well of the assay plate then receives 3 μL of the specific 3× RAS preformed TR-FRET complex and 3 μL of assay buffer and is incubated at room temperature for 60 minutes (pre-incubation time). Each well then receives 3 μL of 3× recombinant human SOS protein and GTP (Sigma, G8877) (in assay buffer) and is incubated at room temperature for 60 minutes or for KRAS-G12V, 90 minutes. The 9 μL final reaction in each well consisted of 3 mM GTP and the specific RAS and SOS proteins at the following concentrations: KRAS-G12C / SOS=3 nM / 40 nM, KRAS-G12D / SOS=1 nM / 40 nM, KRAS-G12V / SOS=1.25 nM / 160 nM, HRAS / SOS=1.25 nM / 40 nM and NRAS / SOS=1.25 nM / 40 nM.
[0370] The TR-FRET signal is measured on an Envision (PerkinElmer) plate reader: excitation filter = 340 nm; emission 1 = 495 nm; emission 2 = 520 nm; dichroic mirror = D400 / D505; delay time = 100 ms. The signal in each well is measured as the ratio of emission at 520 nm to emission at 495 nm. The percent effect in each well is determined after normalization to control wells containing DMSO (no effect) or a saturating concentration of inhibitor (maximal effect). The apparent effect as a function of compound concentration was fitted to a four-parameter logistic equation and the IC was calculated using Spotfire software. 50 The results of this assay for each RAS type are shown in the table below under headings containing "GNE."
[0371] Procedure for the intracellular phospho-ERK assay, G12C NCI-H358 cells (ATCC® CRL-5807™) containing homozygous KRAS-G12C activating mutation were cultured in T150 flasks in growth medium (RPMI medium 1640-GlutaMAX™-I (ThermoFisher Scientific 61870) containing 10% fetal bovine serum (ThermoFisher Scientific 10091148). Cells in growth medium after TrypLE (ThermoFisher scientific 12604021) digestion were harvested and seeded at a density of 15,000 cells / well in 384-well collagen-coated cell culture plates (Corning 356702) and incubated overnight at 37°C and 5% CO2. Compound dose-response titrations (30 μM final concentration and 1:3 dilution, 10-step dose response) were prepared, and appropriate amounts of test compounds were dispensed into 384-well intermediate plates using an Echo 550 liquid handler. RPMI medium 1640-GlutaMAX™-I was added to the intermediate plates, and the contents of the intermediate plates were then transferred to 384-well collagen-coated cell culture plates, which were incubated at 37° C. and 5% CO2 for 2 hours. After removing the medium from the collagen-coated cell culture plates, the cells were lysed in the lysis buffer of Alpha SureFire® Ultra™ Multiplex p-ERK and Total ERK Assay Kit (PerkinElmer MPSU-PTERK) containing Halt™ protease and phosphatase inhibitor cocktail (ThermoFisher Scientific 78446) at room temperature for 30 minutes under constant shaking at 300 rpm. The cell lysates were then transferred to OptiPlate-384 plates (PerkinElmer 6005620) and ERK phosphorylation (p-ERK) and total ERK levels were detected by Alpha SureFire® Ultra™ Multiplex p-ERK kit and total ERK assay kit (PerkinElmer MPSU-PTERK) according to the manufacturer's protocol.Assay plates were read on an EnVision Multimode Plate Reader (PerkinElmer) and the ratio of p-ERK to total ERK in each well was used as the collected readout. Dose-response curves were analyzed using a four-parameter logistic model and IC was calculated using Spotfire software. 50 The results of this assay are shown in the table below under the heading "G12C H358."
[0372] Procedure for the intracellular phospho-ERK assay, G12D AsPC-1 cells (ATCC® CRL-1682™) containing homozygous KRAS-G12D activating mutation were cultured in T150 flasks in growth medium (RPMI medium 1640-GlutaMAX™-I (ThermoFisher Scientific 61870) containing 10% fetal bovine serum (ThermoFisher Scientific 10091148). Cells in growth medium after TrypLE (ThermoFisher scientific 12604021) digestion were harvested and seeded at a density of 15,000 cells / well in 384-well collagen-coated cell culture plates (Corning 356702) and incubated overnight at 37°C and 5% CO2. Compound dose-response titrations (30 μM final concentration and 1:3 dilution, 10-step dose response) were prepared, and appropriate amounts of test compounds were dispensed into 384-well intermediate plates using an Echo 550 liquid handler. RPMI medium 1640-GlutaMAX™-I was added to the intermediate plates, and the contents of the intermediate plates were then transferred to 384-well collagen-coated cell culture plates, which were incubated at 37° C. and 5% CO2 for 2 hours. After removing the medium from the collagen-coated cell culture plates, the cells were lysed in the lysis buffer of Alpha SureFire® Ultra™ Multiplex p-ERK and Total ERK Assay Kit (PerkinElmer MPSU-PTERK) containing Halt™ protease and phosphatase inhibitor cocktail (ThermoFisher Scientific 78446) at room temperature for 30 minutes under constant shaking at 300 rpm. The cell lysates were then transferred to OptiPlate-384 plates (PerkinElmer 6005620) and ERK phosphorylation (p-ERK) and total ERK levels were detected by Alpha SureFire® Ultra™ Multiplex p-ERK kit and total ERK assay kit (PerkinElmer MPSU-PTERK) according to the manufacturer's protocol.Assay plates were read on an EnVision Multimode Plate Reader (PerkinElmer) and the ratio of p-ERK to total ERK in each well was used as the collected readout. Dose-response curves were analyzed using a four-parameter logistic model and IC was calculated using Spotfire software. 50 Values were calculated. The results of this assay are shown in the table below under the heading "G12D ASPC-1."
[0373] [Table 16]
[0374] TIFF2024543879000100.tif77151
[0375] array SEQ ID NO:1 - recombinant KRAS G12C TIFF2024543879000101.tif39150
[0376] SEQ ID NO:2-Recombinant KRAS G12D TIFF2024543879000102.tif38151
[0377] SEQ ID NO:3-Recombinant KRAS G12V TIFF2024543879000103.tif39151
[0378] SEQ ID NO:4-HRAS TIFF2024543879000104.tif39151
[0379] SEQ ID NO:5-NRAS TIFF2024543879000105.tif39151
[0380] SEQ ID NO:6 - Recombinant human SOS protein TIFF2024543879000106.tif122150
Claims
1. Formula (I) 【Chemistry 1】 During the ceremony 【Chemistry 2】 part is: 【Chemistry 3】 selected from the group consisting of: R for each occurrence B are independently halo, cyano, C 1 ~C 3 Alkyl, C 1 ~C 3 Fluoroalkyl, cyclopropyl and C 1 ~C 4 cyanoalkyl; Ring X is: (i) 5-9 membered monocyclic or fused bicyclic or bridged bicyclic heterocycloalkyl, wherein said heterocycloalkyl is saturated and, in addition to the depicted N atom, can contain N, S, S(O), S(O) 2 and O; (ii) 8-10 membered spiroheterocycloalkyl, wherein the spiroheterocycloalkyl is saturated and, in addition to the depicted N atom, can contain N, S, S(O), S(O) 2 and O, selected from the group consisting of: wherein ring X is unsubstituted or independently selected from fluoro, cyano, hydroxy, C 1 ~C 6 Alkyl, C 1 ~C 6 Fluoroalkyl, C 1 ~C 3 hydroxyalkyl, —N(H)C(O)heteroaryl, where heteroaryl is C 1 ~C 3 and each R is selected from the group consisting of 1 to 3 R X2 is substituted by a substituent; R X1 is H, C 1 ~C 6 Alkyl, C 1 ~C 6 Fluoroalkyl, C 1 ~C 6 Hydroxyalkyl and C 1 ~C 4 cyanoalkyl; Ring Y is: (i) an 8-10 membered bicyclic ring system, wherein said 8-10 membered bicyclic ring system is partially unsaturated or aromatic and said 8-10 membered bicyclic ring system contains 0-3 heteroatoms selected from the group consisting of N, S and O; (ii) a 13-14 membered tricyclic ring system, wherein said 13-14 membered tricyclic ring system is partially unsaturated or aromatic and said 13-14 membered tricyclic ring system contains 0-3 heteroatoms selected from the group consisting of N, S and O; and (iii) phenyl; and (iv) a 6-membered heteroaryl ring containing 1 to 2 N atoms selected from the group consisting of: wherein ring Y is unsubstituted or independently selected from halo, hydroxy, amino, oxo, C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Fluoroalkoxy, C 2 ~C 3 Alkynyl, C 2 ~C 3 Fluoroalkynyl, C 1 ~C 3 Fluoroalkyl, C 1 ~C 3 Cyanoalkyl, C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cyclofluoroalkyl 、 C 3 ~C 6 Cycloalkoxy 、 C 3 ~C 6 Cyclofluoroalkoxy 、 C 2 ~C 3 Alkenyl, C 2 ~C 3 1 to 4 R selected from the group consisting of fluoroalkenyl and cyano; Y is substituted by a substituent; Ring Z is: (i) a 5-8 membered monocyclic or bicyclic heterocycloalkyl, wherein said heterocycloalkyl is saturated and contains 1-3 heteroatoms independently selected from the group consisting of N, S and O, and said heterocycloalkyl is unsubstituted or is selected from halo, hydroxy, C 1 ~C 3 Alkyl, C 1 ~C 3 Hydroxyalkyl, -C(H)(OH)CF 2 H, —O—CH 2 -O-(C 1 ~C 3 fluoroalkyl) and methylene (C 1 ~C 3 Alkyl) (C 1 ~C 3 one to two substituents R selected from the group consisting of alkyl) carbamates; ZHC is replaced by; (ii) 【Chemistry 4】 and where M is hydroxy, C 1 ~C 3 Dialkylamino and C 1 ~C 4 alkylamino, wherein the cyclopropyl group is unsubstituted or independently substituted with up to two halo groups; (iii) 【Chemistry 5】 and wherein P is a 5-8 membered monocyclic or fused bicyclic or bridged bicyclic heterocycloalkyl, said heterocycloalkyl being saturated and containing 1-2 heteroatoms selected from the group consisting of N and O, said heterocycloalkyl being unsubstituted or substituted with halo, hydroxy, C 1 ~C 3 Hydroxyalkyl, C 1 ~C 3 Cyanoalkyl, carbamoyl, C 1 ~C 3 Alkoxy, cyano and -NHC(O)C 1 ~C 3 one R selected from the group consisting of alkyl P substituted with substituents, wherein the cyclopropyl group is unsubstituted or substituted, independently, with up to two halo groups; and (iv) 4-8 membered monocyclic or bicyclic cycloalkyl, wherein said cycloalkyl is saturated and unsubstituted or independently selected from halo, hydroxy, C 1 ~C 3 Alkyl, C 1 ~C 3 Fluoroalkyl, C 1 ~C 3 Hydroxyalkyl, C 1 ~C 3 Hydroxyfluoroalkyl, C 3 ~C 4 Cycloalkyl, C 3 ~C 4 Cyclofluoroalkyl, C 3 ~C 4 Hydroxycycloalkyl and C 3 ~C 4 1 to 3 substituents R selected from the group consisting of hydroxycyclofluoroalkyl ZC has been replaced with selected from the group consisting of: The subscript n is 1 or 2; The subscript q is 0, 1, or 2 or a pharma- ceutically acceptable salt thereof.
2. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein ring X is a 5-8 membered monocyclic heterocycloalkyl, said heterocycloalkyl being saturated and containing, in addition to the depicted N atom, 0-1 heteroatoms selected from the group consisting of N, S and O. 【Request 3】 【Chemical 6】 The base is: 【Chemistry 7】 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof. 【Request 4】 【Chemical 8】 The base is: 【Chemistry 9】 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof. 【Request 5】 【Chemical 10】 The part 【Chemistry 11】 2. The compound of claim 1, wherein:
6. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein ring Y is selected from the group consisting of naphthyl, phenyl, pyridyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, pyridopyrazolyl, and benzothiophenyl.
7. Ring Y is: 【Chemistry 12】 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof. 【Request 8】 【Chemical 13】 The base is: 【Chemistry 14】 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
9. 【Chemical 15】 The base is: 【Chemistry 16】 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
10. 2. The compound according to claim 1, selected from Examples 1 to 49, or a pharma- ceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof, a further anti-cancer agent and a pharma- ceutically acceptable carrier.
13. A method for inhibiting KRAS-G12D protein, comprising contacting KRAS-G12D protein with a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof to inhibit the activity of said KRAS-G12D protein.
14. A method for inhibiting KRAS-G12C protein, comprising contacting KRAS-G12C protein with a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof to inhibit the activity of said KRAS-G12C protein.
15. KRAS-G12V protein with a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof to inhibit the activity of the KRAS-G12V protein.
16. 13. A method for treating cancer, comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, to a subject in need of such treatment.
17. 17. The method of claim 16, further comprising administering to the subject an additional active agent.
18. 11. A compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, for use in therapy, or the use of a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, in therapy.
19. A compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, for use in the treatment of cancer, or the use of a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, for treating cancer.
20. A compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment of cancer, or use of a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment of cancer.
21. 11. A compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof and a further anti-cancer agent for use in the treatment of cancer, or use of a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof and said further anti-cancer agent for treating cancer.
22. 11. Use of a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof and a further anti-cancer agent for the preparation of a medicament for the treatment of cancer, or a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof and said further anti-cancer agent for the preparation of a medicament for the treatment of cancer.
23. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof for use in the treatment of cancer, or use of a pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof for treating cancer.
24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof and a further anti-cancer agent for use in the treatment of cancer, or use of a pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof and said further anti-cancer agent for treating cancer.
Citation Information
Patent Citations
Substituted quinazoline compounds and methods of use
US20190127336A1
KRAS g12d inhibitors
WO2021041671A1
A compound having inhibitory activity against KRAS g12d mutation
WO2021107160A1
Azaquinazoline pan-kras inhibitors
WO2022132200A1
Heterocyclic compounds and uses thereof
WO2022173870A1
